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 Hemophilia is a congenital bleeding disorder caused by a deficiency of clotting factor 
VIII (FVIII; hemophilia A) or IX (FIX; hemophilia B). Severe hemophilia patients have less than 
1% (or 1 IU dL-1) of normal factor activity, and often experience spontaneous bleeding episodes. 
These frequently occur in the joints, causing debilitating arthropathy later in life. The only 
proven method for preventing joint damage is the prophylactic administration of the appropriate 
clotting factor from a young age. However, prophylaxis with both FVIII and FIX is complicated 
by considerable between-subject variability in pharmacokinetic (PK) response. While a 
traditional PK study can be difficult to implement in routine care, a population pharmacokinetic 
(PopPK) approach – which reduces sampling burden and allows patients to forego a washout 
period – represents a more feasible method of dose tailoring for both patients and treatment 
providers. Nonetheless, PopPK can be challenging to implement due to a significant data 
requirement and a complicated process for model development and evaluation. 
 To overcome these barriers, the Web Accessible Population Pharmacokinetic Service for 
Hemophilia (WAPPS-Hemo) was launched in 2015. This service provides individual estimates 
of clinically relevant PK parameters (e.g. half-life, time to 1%, factor level at 72 hours post-
infusion) from sparse patient samples and demographic data using Bayesian forecasting, with 
PopPK models serving as prior information. In order to meet its goals, the WAPPS-Hemo project 
requires PopPK models that are valid for Bayesian estimation for as many of the currently 
available factor concentrates as possible. In order to standardize the model building process, a 
data analysis protocol, outlining the steps of model development and evaluation and the criteria 
for decision-making, was established. This protocol was put into practice in the development of 
generic models for two classes of factor concentrate (standard half-life FVIII and standard half-
v 
 
life recombinant FIX). To date, the models described in this dissertation have been used to 
process over 2,000 PK requests on the WAPPS-Hemo platform. 
 In addition to developing models for use on the WAPPS-Hemo platform, the clinical 
factors impacting model performance were investigated. Since Bayesian forecasting relies on 
only a few samples from the individual patient, the timing of these samples is of considerable 
importance. Limited sampling analyses were conducted to confirm that accurate estimates of 
relevant PK parameters can be obtained from a variety of limited sampling schemes. When 
sampling is extremely limited (e.g. collected during a single clinic visit), estimation can be 
improved by incorporating knowledge of prior doses, and by conducting the PK study when 
samples are likely to be within assay quantification limits. Model performance is also dependent 
on the patient’s endogenous (baseline) factor production. In severe hemophilia patients, baseline 
factor activity may range from truly zero up to 1 IU dL-1; however, baseline is often unknown as 
1 IU dL-1 is typically the lower limit of quantification for both the one-stage clotting and 
chromogenic assays, forcing an assumption to be made. The consequences of these assumptions 
are highly variable; while baseline has little influence on the estimation of half-life, it makes a 
substantial difference when estimating time to 1% activity.  
 The models developed for this project have the potential for high impact with respect to 
the patient, who benefits from an individualized dosing regimen rather than a trial and error 
approach, resulting in fewer adverse events and, in many cases, more cost-effective use of factor 
concentrates. The work presented in this dissertation also explores a variety of factors that 
impact model performance; this knowledge can be used by treatment providers to ensure they 
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Chapter 1: Background 
 
The Clotting Cascade 
When the body suffers an injury to the vascular system, the physiological response is to 
minimize blood loss at the site of damage and restore hemostasis. The coagulation cascade is one 
of the mechanisms triggered by vascular trauma, and the end product of this pathway is a cross-
linked fibrin scaffolding for aggregated platelets to form a clot. The components of the cascade 
are inactive enzyme precursors, or zymogens, known as coagulation factors. The coagulation 
cascade consists of two distinct pathways, each of which is prompted by a different event and 
plays a unique role in achieving hemostasis. 
 The extrinsic pathway is initiated when damaged endothelial cells release tissue factor, 
which binds and activates coagulation factor VII [1]. The resulting complex activates factor X, 
which joins with factor V to form the prothrombinase complex. Prothrombinase activates 
prothrombin to thrombin, which not only converts inactive fibrinogen into clot-forming fibrin, 
but also activates several components of the intrinsic pathway of the coagulation cascade 
including factors XIII, V and VIII [2]. The main function of the extrinsic pathway is to generate 
an initial burst of thrombin; it is quickly inhibited by tissue factor pathway inhibitor, at which 
point the more kinetically efficient intrinsic pathway takes responsibility for the growth and 
maintenance of the fibrin clot [3]. The intrinsic pathway begins by activation of clotting factor 
XII upon binding to collagen. Factor XII proteolytically cleaves factor XI, which then activates 
factor IX (FIX). Finally, FIX joins with co-factor VIII (FVIII) to form a complex that also 
activates factor X. The rate of factor X activation by this intrinsic tenase complex is estimated to 




thrombin is produced by this pathway [4,5]. Without sufficient production of the intrinsic tenase 
complex, an inadequate amount of activated Factor X is generated and the propagation phase of 
vascular repair is ineffective. 
 
Hemophilia A and B 
Hemophilia is an inherited bleeding disorder caused by a deficiency in one of the clotting 
factors that forms the intrinsic tenase complex (hemophilia A: FVIII; hemophilia B: FIX). This 
results in bleeding episodes, often in the joints, and eventual arthropathy. In the most severe 
hemophilia patients (those with less than 1 IU dL-1 [i.e. 1% of normal] of the respective clotting 
factor activity), these bleeds may occur spontaneously. A recent study estimates the prevalence 
of hemophilia A and B to be roughly 17 and 4 cases per 100,000 males, respectively, of which 
roughly 30% are the severe form. This amounts to an expected 1,125,000 hemophilia patients 
worldwide [6].  
 
Current Hemophilia Therapy 
Although strides are being made in the development of alternative therapies (e.g. 
monoclonal antibodies, gene therapy), the mainstay of hemophilia treatment is prophylactic 
intravenous administration of the deficient clotting factor. Prophylactic treatment aims to convert 
severe hemophilia patients to a moderate phenotype by regularly administering clotting factor 
concentrates, and the strategy is based on several clinical observations. The first is a 1965 study, 
which found that the joint scores of moderate hemophilia A patients (i.e. those with FVIII levels 
between 1 and 3 IU dL-1) were markedly improved compared to severe patients [7]. The second, 
described by Nilsson and colleagues, is the observation that patients on prophylaxis who spent 




study by Manco-Johnson et al demonstrated reduced incidence of joint bleeds, life-threatening 
bleeds, and lowered risk of joint damage following prophylaxis in young hemophilia A patients 
[9]. Finally, Collins et al observed an association between time spent below 1 IU dL-1 per week 
and occurrence of bleeding events [10].   
Despite global consensus regarding the initiation of prophylaxis at a young age [11–13], 
the implementation of this approach is highly variable [14]. While part of this variation may be 
attributed to the cost or availability of factor concentrates [15], the considerable between-subject 
variability in the pharmacokinetic (PK) handling of both FVIII and FIX is the major obstacle to 
the determination of an effective ‘one-size-fits-all’ dosing regimen.   
 
Pharmacokinetics of Clotting Factor Concentrates  
The pharmacokinetics of FVIII are well characterized, and are discussed in detail in 
Chapter 2, which contains a comprehensive review of FVIII PK studies conducted in recent 
years with a focus on variability and the sources thereof.  
The pharmacokinetics of FIX, on the other hand, are not as well understood. A 
comprehensive review, analogous to the one presented in Chapter 2 for FVIII, was performed to 
identify original PK studies for factor IX products in hemophilia B patients; the details and 
results from the 34 eligible studies are presented in Table 1. 
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Table 1. Studies on the pharmacokinetics of plasma-derived and recombinant FIX. PK parameters are presented as mean ± SD (%CV) 
unless otherwise noted; n. g. denotes values that were not reported in the studies. 









Clearance                    
(mL h-1 kg-1) 
Volume of 






8 19-65 74 h 11 
29.7 ± 4.3  
(14%)       
4.25 ± 0.64 
(15%) 
n. g. n. g. 
[17] 
pdFIX-SD 
11 12-60 72 h 12 
34.2 ± 3.5  
(10%) 
7.4 ± 0.8 
(11%) 




33.3 ± 3.8  
(11%) 
6.9 ± 1.2 
(17%) 




72 h 12 
20 ± 4.3  
(21%) 
10.4 ± 2.2 
(22%) 




20 ± 4.1  
(21%) 
8.3 ± 2.3 
(28%) 
210 ± 7 
(3%) 
12 20-29 
19 ± 4.9  
(26%) 
8.5 ± 1.2 
(14%) 
220 ± 6  
(3%) 
12 30-39 
20 ± 6.5  
(33%) 
7.2 ± 1.4 
(19%) 
190 ± 4 
 (2%) 
7 40-49 
19 ± 4.2  
(22%) 
7.6 ± 1.7 
(22%) 
200 ± 5 
(3%) 
3 50-56 
17 ± 7.1  
(42%) 
7.5 ± 0.3  
(3%) 
180 ± 8  
(4%) 
[19] rFIX 
19 <15  
                          
15-40   
                                                
>40 
72 h 12 








19.4 h ± 5.5 
(28%) 
9 




38 7-75 48 h 7 
14.9 h  
(7.2-33.7) 
















Clearance                    
(mL h-1 kg-1) 
Volume of 
Distribution                    
(mL kg-1) 
Analysis Method 










15 ≥12 48 h 7 
12.9 4.2 61 Nonlinear 
regression BeneFIX® 13.7 7.1 118 
[23]a unspecified 13 13-70 
retrospective analysis; 
details not provided 
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[24] Aimafix DI 
12 
12-36 50 h 12 
23.5 h ± 12.3 
(52%)      
6.5 ± 1.4 
(22%) 




17.6 h ± 3.5 
(20%) 
5.3 ± 1.6 
(30%) 
131.1 ± 25.6 
(20%) 
[25] BeneFIX® 10 24.7 (8.6) 72 h 11 
24.4 ± 6.4  
(26%) 
4.84 ± 1.03 
(21%) 





[26] BeneFIX® 24 12-61 72 h 12 
22.4 ± 6.4  
(26%) 
n.g. n.g. n. g. 




25 23.1 (8.83)   74 h 11 
26.7 ± 3.8  
(14%) 








26.8 ± 3.7 
 (14%) 
4.1 ± 1.2 
(29%) 
[29] BeneFIX® 20 0.6-4 24h 4 
10.9 ± 2.3 
 (21%) 





[30] AlphaNine® 25 25.8 (8.68)  74 h 10 to 12 


















Clearance                    
(mL h-1 kg-1) 
Volume of 
Distribution                    
(mL kg-1) 
Analysis Method 
[31] Nonafact®  13 19-58 48 h 10 
18.7 ± 2.0  
(11%) 









168 h 13 
82.94 ± 18.15 
(22%) 
0.76 ± 0.08 
(10%) 
90.13 ± 13.24 
(15%) 
NCA   
5 
96.25 ± 41.85 
(43%) 
0.74 ± 0.21 
(28%) 
99.50 ± 47.42 
(48%) 
5 
110.45 ± 17.48 
(16%) 





48 h 9 
19.34 6.99 194.98 
pdFIX 8 17.79 5.48 140.58 
[33] 
IB1001 
32 15-64 72 h 12 
29.7 h ± 18.2 
(61%)  
5.0 ± 2.0 
(40%) 







33.4 h ± 21.2 
(63%)  
5.0 ± 1.0 
(20%)  
180 ± 70 
(39%) 
[34] 
rIX-FP (albumin) 13 
15-58 
336 h 11 
91.57 ± 20.74 
(23%) 
0.75 ± 0.19 
(25%) 





32-48 h 6 
14.59 ± 1.73 
(12%) 
4.76 ± 1.08 
(23%) 
98.7 ± 14.9 
(15%) 
rFIX 8 
17.23 ± 2.28 
(13%) 
5.24 ± 0.85 
(16%) 
130.6 ± 29.9 
(23%) 
[35] Haemonine® 13 13-45 72 h 12 
27.6 ± 4.5  
(16%) 
205.4 n. g. PCModfit 
[36] rFIXFc 11 18-76 240 h 14 
56.7 ± 10.4 
(18%)   
3.18 ± 0.745 
(23%) 






27.0 (9.7)   74 h 11 
32.7 ± 7.4  
(23%)                 
4.2 ± 1.0 
(24%) 




method BeneFIX® 22 
36.0 ± 12.8 
(36%) 
4.6 ± 1.0 
(22%) 








n. g. n. g. n. g. 













Clearance                    
(mL h-1 kg-1) 
Volume of 





9 15-73 48 h 10 
16.6  
(13.2-20.9) 
n. g. n. g. n. g. 
BeneFIX® 
17.5  
(14.8-25.6)                    
[40] BAX326 25 12-65 72 h 12 
25.4 ± 6.9 
 (27%) 
6.0 ± 1.5 
(24%) 
179 ± 45 
(25%) 
  




[42] BeneFIX® 7 n.g. 48-72 h 5-9 
36 ± 8.3  
(23%)   
3.8 ±  0.4 






168 h 6 
69.6 0.758 76.1 non-
compartmental 






































[45] BeneFIX® 17 12-59 72 h 12 23.7 ± 5.6 (24%)   
7.5 ± 1.8 
(24%) 
216 ± 66 
(30%) 
SAS 




          













Clearance                    
(mL h-1 kg-1) 
Volume of 























48 h 6 
18.2 (15.5-21.3) n. g. n. g. 





168 h 7 
73.0  





















32 14.8-64.5 72 12 
24.2 ± 6.9  
(28%)                                       
5.1 ± 1.3 
(25%)




26.4 ± 13.6 
(52%) 
5.0 ± 1.2 
(24%) 
181 ± 57 
(31%) 
aResults presented as median (range)  
bResults presented as mean (range) 
cResults presented as median (IQR)
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Relative to FVIII, standard half-life FIX has a larger volume of distribution, higher 
clearance, and longer half-life; typical values for these parameters are roughly 150 mL kg-1, 4.0 
mL h-1 kg-1, and 30 h, respectively [50], compared to 48 mL kg-1, 3.0 mL h-1 kg-1, and 14 h for 
FVIII [51]. The increased volume of distribution of FIX is attributed to its smaller size (57 kDa, 
compared to 300 kDa for FVIII) which allows for extensive distribution into the extravascular 
space. The inter-individual variation in FIX PK parameters is high, with a three to fourfold range 
between the most extreme values, though the PK within an individual is quite stable over time 
[52]. Few covariates have been found to explain this variability. Clearance and volume of 
distribution are correlated to body weight, but increasing age (beyond adolescence, when body 
weight is no longer changing appreciably) has no noticeable effect on PK parameters. 
Considerable differences have been observed between plasma-derived and recombinant FIX, 
although the terminal half-life was found to be similar in comparison studies [20,53,54]. 
In recent years, considerable success has been found in the extension of FIX half-life 
through a variety of techniques. Three new concentrates are currently available; one pegylated 
product and two rFIX fusion proteins (albumin, and the Fc fragment of IgG1). All three products 
achieve significant extensions of half-life (80–100 h), allowing for less frequent infusions, 






Role of Pharmacokinetics in Hemophilia Treatment 
Hemophilia patients are typically dosed by total body weight, but evidence suggests that 
this approach is suboptimal, resulting in either overdosing (and excessive use of expensive 
clotting factor concentrate) or underdosing (and ineffective or unsafe treatment). To improve 
both patient outcomes and cost-effectiveness, PK-based individualization of dosing regimens has 
been proposed [51,56]. However, a classic PK study for FVIII or FIX requires rigorous sampling 
(ten samples over the course of two to three days, as recommended by the International Society 
on Thrombosis and Haemostasis). Furthermore, this type of study requires the patient to undergo 
a potentially hazardous washout period. For these reasons, the classical PK approach can be 
difficult to apply in clinical settings. 
Population Pharmacokinetics 
The population PK (PopPK) approach can be used to address some of these hurdles. The 
primary advantage of PopPK is a significantly reduced sampling burden; accurate PK parameter 
estimates can be obtained from as few as two to three well-timed samples [57]. This is achieved 
by leveraging information from a large patient population in the form of a PopPK model, which 
is in turn comprised of three sub-models: a structural model (defining the shape of the factor 
activity vs. time profile), a covariate model (describing the relationships between PK parameters 
and patient characteristics), and a statistical model (describing the variability). The total 
variability around a given parameter may be partitioned into predictable variability, which can be 
attributed to demographic, environmental, or genetic covariates, and unpredictable variability. 
The unpredictable component of the variability may be further divided into between-subject 
variability (BSV, 𝜂) and within-subject variability (WSV, 𝜌; also referred to as inter-occasion 
variability [IOV]). Finally, the remaining discrepancy between predicted and observed factor 




1-compartment model (parameterized by clearance [CL] and volume [V]), with BSV on CL, a 










𝐶𝐿𝑗 = 𝜃𝐶𝐿 ∙ 𝑒
𝜂𝑗 






𝐶𝑖𝑗 = ?̂?𝑖𝑗 + 𝜀𝑖𝑗 
The parameters denoted with 𝜃 are known as fixed effects, which are constant across 
individuals; these include the typical values of PK parameters within the population as well as 
the covariate effects on those parameters. Random effects (𝜂, 𝜀, and, if applicable, 𝜌) describe 
the unpredictable variability, and are specific to the individual. Further details regarding PopPK 





Figure 1. Partitioning of variability in pharmacokinetic response 
 
 The magnitude of these different variabilities plays a role in determining the appropriate 
dosing strategy for a therapy [58]. If a drug has low BSV and low WSV, along with a relatively 
wide therapeutic window, a generic population dose will maintain safe and effective 
concentrations in most patients. Conversely, when a drug that displays WSV that is wider than 
the therapeutic window, it becomes impossible to identify a safe and effective dose for a patient. 
In the case of clotting factor concentrates, BSV is quite high, but WSV is relatively low; that is, 
patients vary considerably from one another, but each patient’s individual PK is reasonably 
stable over time. In this scenario, an individualized approach to dosing, which takes the patient’s 















The WAPPS-Hemo Project 
Despite its many advantages, PopPK is not without its own challenges. The development 
of a PopPK model requires a significant amount of data (a considerable obstacle in a rare disease 
setting), as well as proficiency in model building and evaluation. In the hemophilia community, a 
lack of confidence in model performance, as well as skepticism surrounding specific therapeutic 
targets (especially in the case of FIX), have also traditionally hampered the uptake of the PopPK 
approach. To facilitate its incorporation into routine care, a number of tools have been 
developed. Björkman evaluated the free Bayesian computer program TCIWorks for estimation of 
individual FVIII PK [59] but found that its efficient use required a level of expertise beyond that 
of the typical target user. myPKFiT, an industry-sponsored, brand-specific PopPK calculator 
recently received class II medical device approval from the US Food and Drug Administration. 
However, its application is currently limited in the United States to the on-label use of a single 
FVIII product (Advate), leaving a substantial portion of the hemophilia population unserved 
[60].  
The Web Accessible Population Pharmacokinetic Service – Hemophilia (WAPPS-Hemo, 
Figure 2) program is an online service developed at McMaster University that is designed to help 
clinicians overcome the barriers typically associated with PK-tailoring of clotting factor 
regimens. Hemophilia treatment providers submit patient demographic information (e.g. age, 
weight, height) and 2–4 blood samples on the WAPPS-Hemo website (www.wapps-hemo.org). 
Using Bayesian forecasting, estimates of individual PK parameters are obtained and validated 
before being returned to the clinician. The patient report includes a graphical representation of 
the predicted concentration-time profile (with observed factor levels overlaid), as well as 




expected factor activity at key post-infusion times (e.g. 24, 48, and 72 hours) along with 
confidence intervals.  
After the PK request has been completed, clinicians can enter the clinical calculator 
module, which allows for the exploration of alternative dosing regimens. There are three 
foundational components to a hemophilia regimen: dose, frequency of administration, and the 
target trough factor activity level. The user defines two of these three variables and the third is 
calculated using the patient’s individual PK. Finally, the clinician can activate myWAPPS, a 
patient-facing app that allows patients to record their infusions and see predicted current or 






Figure 2. Schematic of the WAPPS-Hemo service, including PK estimation, clinical calculator 
module, and patient app 
 
First launched in 2015, the WAPPS-Hemo network has been enthusiastically welcomed by the 
community as a useful tool in support of individualized dosing, and has grown rapidly in the last 
several years, as detailed in Chapter 7. At the time of writing, the network currently boasts over 
400 centres in more than 50 countries, representing a truly global effort to provide hemophilia 





Figure 3. The global WAPPS-Hemo network, where the colour of each country indicates the 






Overarching Thesis Objective 
To develop clotting factor PopPK models that are fit for the purpose of Bayesian forecasting for 
use in dosing regimen design in hemophilia A and B 
Objectives & Hypotheses 
1. Propose a data analysis protocol for the development and evaluation of PopPK models 
for all brands of clotting factors VIII and IX for use on the WAPPS-Hemo platform 
Hypothesis: A systematic approach to model development and evaluation will result in 
robust models that are fit for Bayesian forecasting 
 
2. Apply the data analysis protocol to develop and evaluate generic models for brands of 
factor concentrate lacking brand-specific models on WAPPS-Hemo service 
Hypothesis: Factor VIII products are pharmacokinetically similar enough to that data 
from multiple brands can be combined to build a generic PopPK model to handle PK 
requests on WAPPS-Hemo for brands lacking a dedicated model; the same hypothesis 
applies to recombinant factor IX products 
 
 
3. Develop an understanding of clinical factors that influence model performance and 
identify conditions that improve PK parameter estimation   
Hypothesis: Clinical factors such as timing of samples, information relating to prior 
doses, and knowledge of endogenous factor production level affect estimates of relevant 




Chapter 2: The use of pharmacokinetics in dose individualization of factor 
VIII in the treatment of hemophilia A 
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Introduction 
Hemophilia A is an inherited bleeding disorder caused by a deficiency in clotting factor 
VIII (FVIII) and resulting in spontaneous, often recurring, joint bleeds and eventual arthropathy. 
As an X-linked condition, hemophilia A affects approximately 1 in 5,000 males [61] but reported 
prevalence varies considerably between countries, with many cases going undiagnosed in lower 
income countries [62].  Although evidence of hemophilia can be found in ancient Egyptian and 
Hebrew texts, modern replacement therapy did not begin until the 1960s [63,64]. With the 




disorder rather than a catastrophic diagnosis. While a gene therapy cure remains elusive, 
considerable progress in the treatment of hemophilia patients has been made. When it was 
discovered that viruses such as hepatitis B, hepatitis C and HIV could be transmitted through 
these products, more rigorous safety measures were introduced, including stricter donor 
screening and the implementation of viral inactivation processes [65]. Advances in DNA 
technologies and lingering concerns about the safety of plasma-derived concentrates propelled 
the development of recombinant coagulation factors in the early 1990s [66,67].  
  Two main treatment strategies exist for the management of hemophilia A: on-demand, or 
episodic, and prophylactic. The concept of prophylaxis, initiated by Nilsson and colleagues in the 
1970s [7,68], is derived from the clinical observation that patients with moderate hemophilia 
(those whose factor levels are >1% of normal) are less prone to the arthropathy and spontaneous 
bleeds seen in those with severe hemophilia [69]. Today, there is global unanimity that 
prophylaxis should be initiated in young children before joint disease is apparent [11–13], but the 
implementation of this approach varies widely between countries [14]. The cost and availability 
of factor concentrates are major barriers to its widespread adoption, as is the challenge of patient 
compliance [15]. Prophylaxis is the only known method for preventing joint damage in 
hemophilia patients, as episodic treatment has been shown to be ineffective for the prevention of 
arthropathy [9,12]. However, an optimal dosing strategy has yet to be determined; instead, 
evidence suggests that treatment with FVIII should be individualized for best results, both from a 
therapeutic and economic perspective [51,56]. Typically, patients are dosed by weight but a 
tailored treatment plan must take into account individual variation in pharmacokinetic (PK) 
parameters, beyond what can be predicted by age and weight [70,71]. [17]  However, a classical 




elimination phase (3–48 h) – as outlined by recommendations from the International Society on 
Thrombosis and Haemostasis [72], making it a difficult approach to apply in a clinical setting.  
For this reason, population pharmacokinetic (PopPK) models are desirable. In addition to 
the rich sampling schedules, classical PK studies are also typically carried out in a homogeneous 
group of subjects, usually healthy, young males. PopPK studies, on the other hand, use sparse 
sampling in a more heterogeneous group of subjects to gain understanding of variability. Since 
fewer samples are required, populations that are unable to undergo the rigid sampling of classical 
PK studies (e.g. paediatrics, elderly, critical care patients) can be included [73]. Often, subjects 
that appear similar exhibit different PK behaviour due to unpredictable variability. For example, 
Collins et al. examined the variability in time to reach 1 IU dL-1 and found significant variation 
not only between children and adults, but within each group as well, with times ranging from 44 
to 78 h in children and 46 to 103 h in adults [74]. Total variability in population parameter values 
can be split into predictable and unpredictable variability. Predictable variability can be ascribed 
to covariates that influence PK. These covariates may be demographic (body weight, age), 
behavioural (smoking status, diet), genetic (phenotypes affecting drug clearance), or physiologic 
(pregnancy, disease state) in nature, and the identification of meaningful covariates can help 
recognise subpopulations that are at risk of over- or under-dosing if the standard weight-based 
strategy is employed [75].  
Unpredictable variability may be between patients or within a patient, and a main goal of 
PopPK is to estimate the magnitude of this unexplained variability. When unexplained variability 
is high, the chances of reaching drug concentrations outside the target range increase and issues 
of safety and efficacy can occur [76]. The target concentration window of the drug can be used to 




safe and effective. By comparing each element of variability to this threshold, a suitable dosing 
regimen can be chosen. If the therapeutic window is large, variability is not an issue and a 
generic population dose is acceptable; if the within subject variability is greater than the 
permissible variability, it is not possible to define a safe and effective dose for an individual. 
However, if the variability threshold lies between the total unpredictable variability and the 
unpredictable within subject variability, individualized dosing is beneficial [58]. Since within 
subject variability is small relative to intersubject variability in the case of FVIII PK parameters 
[70], individualizing dose by incorporating subject-specific PK behaviour is the appropriate 
method.   
This approach is used in the therapeutic monitoring of several other conditions [77–79], 
and a 2010 study by Björkman et al. indicated that a limited sampling strategy could be as useful 
for prediction as a full study [57]. However, adoption of this approach has been hampered 
recently due to the complexity of the models involved and a relative shortage of PK data due to 
the rarity of the disease. To contribute overcoming these barriers, we have reviewed the available 
pharmacokinetic data for FVIII in the treatment of hemophilia patients with the aim of 
facilitating their uptake and use in the development of PopPK models for dose individualization.  
 
Pharmacokinetics of FVIII 
 Studies on the PK of plasma-derived factor VIII were reviewed comprehensively by 
Björkman and Carlsson in 1997 [50]. A similar review in conducted here for studies published in 
the years 1998 through 2015 for both plasma-derived and recombinant products. Mean values of 
the PK parameters and associated variabilities were assessed across included studies. In the 




systematic. The search was completed using PubMed with the following search criteria: 
(‘hemophilia’ [all fields] or ‘hemophilia a’ [MeSH terms] or ‘hemophilia a’ [all fields] or 
‘haemophilia’ [all fields]) and (‘pharmacokinetics’ [subheading] or ‘pharmacokinetics’ [all 
fields] or ‘pharmacokinetics’ [MeSH terms]). Further selection was made for only those original 
studies presenting new PK data in hemophilia A patients.   
An issue faced at the time of the Björkman review was inadequate sampling time (<48 h), 
resulting in an underestimated half-life and overestimated clearance. Since highlighting the effect 
of inadequate sampling on estimation of PK parameters, studies have generally extended 
sampling time to at least 48 h, hopefully eliminating one source of variability in estimated PK. 
On the other hand, the recent introduction of concentrates with extended half-life (EHL) has 
made the optimal length of sampling time a new matter of discussion, which in general needs to 
be reconciled with the general PK recommendation that sampling time should cover at least five 
half-lives [80]. The study details and calculated PK parameters for each reference is presented in 
Table 2. Patients included in each of the studies were in stable condition (i.e. not presenting any 
recent bleed) and in absence of any inhibitors.  
 The pharmacokinetics of FVIII are generally well characterised, with the exception of 
EHL products. Typical values for clearance (0.3 dL h-1 kg-1), volume of distribution at steady 
state (Vss, 48 mL kg
-1, or slightly larger than plasma volume) and half-life (14 h) are known [51], 
and the average parameter values for the studies in Table 2 are quite similar (12.94 h, 0.32 dL h-1 
kg-1, and 56 mL kg-1, respectively). The half-lives for the EHL products ranged from 18.2 to 
19.04 h and this extension is due to reduced clearance (0.3 vs. 0.18 dL h-1 kg-1) rather than more 
extensive distribution, since Vss is unchanged. As seen in Table 2, the PK parameters obtained 




± 12.94 h in adult patients. Furthermore, the variability within each study is considerable as well; 
many studies report a coefficient of variation greater than 30% for estimates of half-life, 
clearance and Vss. Though this may encompass both patient-related variability and experimental 
error, it reinforces the idea that individual dose adjustments would be of great clinical benefit, to 
limit both overdosing (associated with wastage of resources) and underdosing (associated with 
ineffective and unsafe treatment) [30].  
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Table 2. Studies on the pharmacokinetics of plasma-derived and recombinant FVIII. PK parameters are presented as mean ± SD 
(%CV); n. g. denotes values that were not reported in the studies. 












t1/2                                  
(h) 
CL                              
(mL h-1 kg) 







OS 10 27-41 48 h 14 
15.5 ± 2.8 (18%)          
14.9 ± 2.9 (19%) 
2.76 ± 0.61 (21%)             
4.02 ± 0.044 (10%) 
77.1 ± 13.9 (18%)         
95.0 ± 21.9 (23%) 
NCA 
[82] Recombinate®  
OS 
CH 
30 ≥12 24 h 8 
13.1 ± 2.4 (18%) 
13.1 ± 1.9 (14%) 
1.9 ± 0.3 (16%) 
1.52 ± 0.21 (14%) 
60.3 ± 5.8 (10%) 
49.1 ± 6.9 (14%) 
NCA 
[83] Emoclot® OS 14 18-44 36 h 12 12.51 ± 0.54 (4%) 5.06 ± 3.167 (63%) n. g. n. g. 
[84] KOGENATE®  OS 20 12-60 48 h 11 
13.8 ± 2.2 (16%) 
14.6 ± 3.1 (21%) 
12.6 ± 0.1 (8%) 




OS 18 14-46 48 h n. g. 
16 ± 3 (19%) 
16 ± 5 (31%) 
n. g. n. g. NCA 
[86] BDDrFVIII CH 113 ≥7 24 h n. g. 10.5 ± 2.6 (25%) n. g. n. g. n. g. 
[87] BDDrFVIII CH 39 0-5 n. g. n. g. 7.5 ± 2.7 (36%) n. g. n. g. n. g. 
[88] KOGENATE®  OS 15 12-59 48 h 11 14.4 ± 2.7 (19%) n. g. n. g. n. g. 




18 ≥12 48 h 9 
17.37 ± 12.94 (74%) 
11.69 ± 5.21 (44%) 
3.80 ± 1.32 (35%) 
3.83 ± 1.22 (32%) 
78.50 ± 25.60 (33%) 
58.13 ± 17.11 (29%) 
n. g. 



















t1/2                                  
(h) 
CL                              
(mL h-1 kg) 







OS 30 10-65 48 h 11 
11.2 ± 2.5 (22%) 
12.0 ± 4.3 (36%) 
3.0 ± 1.0 (33%) 
3.0 ± 1.0 (33%) 
46 ± 10 (22%) 




[93] Haemoctin® SDH n. g. 13 11-16 30 h 12 11.8 ± 4.2 (36%) 1.52 ± 0.5 (33%) n. g. NCA 
[94] 
BDDrFVIII-A 
BDDrFVIII-B           
Hemofil®  
CH 18 18-44 48 h 12 
15.4 ± 5.4 (35%) 
14.8 ± 5.6 (38%)     
13.7 ± 3.7 (27%) 




ReFacto®       
Advate® 
CH 17 19-72 48 h 11 
13.0 ± 3.1 (24%)       
13.6 ± 3.8 (28%) 
3.85 ± 1.36 (35%)   
3.97 ± 1.40 (35%) 
58.6 ± 13.7 (23%)          
61.7 ± 18.6 (30%) 
NCA 
[96] 
BAY 79-4980  
 Recombinate® 
OS+CH 24 12-60 168 h 13 
11.4 ± 2.49 (22%)     
11.6 ± 2.55 (22%) 
3.13 ± 0.81 (26%)   
3.07 ± 0.72 (23%) 
50.0 ± 9.5 (19%)           
49.4 ± 9.6 (19%) 
NCA 




13 21-69 32 h 9 
12.95 ± 4.73 (36%) 
7.70 ± 4.26 (55%) 
3.5 ± 0.7 (20%) 
4.2 ± 1.4 (33%) 
46.6 ± 12.1 (26%) 
36.2 ± 7.5 (21%) 
NCA 









N8                   
   Advate® 
OS 20 13-54 48 h 9 
10.83 ± 4.95 (46%)     
11.19 ± 3.51 (31%) 
4.11 ± 1.06 (26%)       
4.17 ± 1.20 (29%) 
59.8 ± 11.7 (20%)        
61.3 ± 7.9 (13%) 
NCA 
[102] Advate® n. g. 71 7-59 48 h 10 13.95 ± 5.30 (38%) 3.91 ± 1.18 (30%) n. g. n. g. 
[103] NovoEight® OS 
14                                
14                               
48 
0-5              
6-11           
≥12 
48 h 14 
7.7 ± 1.8 (23%)        
8.0 ± 1.9 (24%)          
11.2 ± 4.2 (38%) 
6.2 ± 3.7 (60%)   5.0 
± 1.7 (34%)   3.5 ± 
1.1 (29%) 
56.7 ± 26.4 (47%)      
46.8 ± 10.6 (23%)       

















t1/2                                  
(h) 
CL                              
(mL h-1 kg) 










48 h n. g. 
11.91 ± 5.36 (45%) 
13.08 ± 2.59 (20%) 
5.41 ± 2.32 (43%) 
4.05 ± 0.92 (23%) 
68.29 ± 10.42(15%) 







9.49 ± 3.32 (35%) 
9.99 ± 1.88 (19%) 
5.40 ± 2.37 (44%) 
4.33 ± 1.21 (28%) 
55.32 ± 7.09 (13%) 






12-61 48 h 10 
13.8 ± 3.5 (25%) 
14.3 ± 3.8 (26%) 
3.8 ± 1.4 (37%) 
2.8 ± 1.0 (36%) 
67 ± 16 (24%) 






12.6 ± 3.0 (24%) 
12.4 ± 3.2 (26%) 
4.6 ± 1.7 (37%) 
3.4 ± 1.3 (38%) 
71 ± 21 (30%) 
55 ± 23 (42%) 
NCA 








12.2 2.49 43.9 1-compartment 




CH 7 18-65 168 h 13 
12.9 ± 6.95 (54%) 
18.2 ± 9.72 (53%) 
2.3 ± 2.1 (92%) 
1.6 ± 0.74 (46%) 
42 ± 24 (57%) 
43 ± 10 (23%) 
NCA 
[108] 
Efraloctocog Alfa  
Advate®  
OS 28 ≥12 120 h 6 
19.0 2.0 ± 0.67 (34%) 
n. g. 
Compartmental 
analysis 12.4 3.0 ± 0.94 (31%) 
[109] N8-GP  CH 26 2-60 168 h 14 19.04 ± 5.53 (29%) 1.79 ± 0.92 (51%) 45.3 ± 17.8 (39%) NCA 








12.67 ± 3.52 (28%) 
14.88 ± 8.22 (55%) 
3.60 ± 1.15 (32%) 
2.78 ± 0.98 (35%) 
58.58 ± 9.02 (15%) 
52.13 ± 19.54 (37%) 
n. g. 
*OS = one-stage assay; CH = chromogenic assay.  
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Covariates Affecting Pharmacokinetic Parameters 
 The process of model selection for a PopPK model includes both definition of the 
structural model as well as incorporation of possible covariates. Covariate modelling helps to 
describe the variability in PK response by establishing relationships between patient 
characteristics and model parameters. To facilitate the development of PopPK models for FVIII, 
any covariates that have been already shown to affect FVIII PK were identified. 
 A 2010 study by Björkman et al [111] gathered PK data from children (aged 1-6 years) 
and adolescents/adults (aged 10-65 years). Between these two groups, children exhibited lower 
in vivo recovery (1.84 vs 2.42 IU dL-1/IU kg-1), higher weight-adjusted clearance (4.34 vs. 3.26 
mL h-1 kg) and a shorter half-life (9.4 vs 11.2 h); weight-adjusted Vss was not different between 
groups. Within patient variance was also great among children, though still considerably less 
significant than between patient variance. Within the paediatric group, half-life increased with 
age. Within the adult group, weight-adjusted clearance and weight-adjusted Vss decreased with 
both age and weight (expressed as a ratio of actual weight to ideal body weight); no effect was 
observed for half-life. However, it is important to note that the r2 values for these predictors are 
quite low for both the paediatric (<0.31) and adult (<0.13) models, suggesting that the within 
patient variability cannot be adequately described by these factors. A more recent study 
conducted by Jiménez-Yuste [103] comparing three age groups (0-5, 6-11 and ≥12 years) found 
similar trends for half-life, clearance, Vss and IVR (Table 1).  
 Another characteristic that has been investigated in association with FVIII PK is blood 
type. Several studies have found that the half-life of FVIII is considerably shorter among patients 
with O-type blood compared to other blood types [112–115], likely due to the lower plasma 




Willebrand factor (vWF) have been shown to be positively correlated with half-life 
[114,116,117] as binding to vWF serves to stabilize the FVIII molecule and prevent degradation 
[118]. These levels tend to increase with age [119,120], and may help to explain the shorter 
FVIII half-life observed in children compared to adults.  
 As mentioned previously, typical dosing for hemophilia treatment is adjusted according 
to body weight. However, ideal body weight should be used in place of actual body weight or 
body mass index when calculating dose for under- or overweight patients. This is because the 
body proportion of fat does not affect the distribution and elimination of coagulation factors 
[121]. As mentioned, the typical Vss for FVIII is approximately plasma volume. Since the 
fraction vascular of fat is low (0.005 to 0.010 [122]), a surplus (or scarcity) of fat does not 
significantly affect the volume of distribution. In summary, including appropriate weight-based 
metric and/or other intrinsic or extrinsic covariates may improve dosing in sub-populations. 
 An additional source of variability inherent in the study of the PK of clotting factors is 
associated with the measurement of plasma levels themselves. The different ways of measuring 
FVIII activity can lead to a significant discrepancy in results. Assay results depend not only on 
the assay method used (one-stage vs. chromogenic), but also on the reagents and calibrants used 
[123]. The disagreement between assays was thought to be greater among B-domain deleted 
rFVIII (BDDrFVIII) [124], but more recent and specific studies have shown that the discrepancy 
is similar to that observed for wild-type recombinant concentrates [123]. Despite the high 
variability observed with different analytical methods, no definitive recommendations have been 





A Pharmacokinetic Comparison of Recombinant and Plasma-Derived Products 
 As mentioned, the transmission of several blood-borne viruses in the 1970s and 1980s 
emphasized the need for safer treatments and ultimately led to the development of recombinant 
factor concentrates [65]. The majority of comparison studies for recombinant and plasma-derived 
FVIII focus on safety, particularly on the risk of developing inhibitors [125–127]. Some early 
studies comparing the PK of recombinant and plasma-derived products found significant 
differences in some parameters, but sampling was only performed for 24 hours rather than the 
suggested 48 hours [67,128]. A more recent study used patients (≥14 years) that were switching 
from plasma-derived to recombinant FVIII as an opportunity to compare their PK [129]. 
Differences at early timepoints following infusion precluded proper assessment of 
bioequivalence, but the half-lives for both groups were similar. There is currently insufficient 
paediatric data to accurately compare plasma-derived and recombinant products in children 
[130].  
In the study by Deitcher et al. shown in Table 1 [81], changes in FVIII PK characteristics 
with concomitant use of desmospressin acetate (DDAVP) were investigated for both plasma-
derived and recombinant products. DDAVP causes a rapid release of vWF and FVIII from 
storage sites and is used in the treatment of mild hemophilia; it is assumed to be ineffective for 
patients with severe hemophilia, since these stores of FVIII do not exist. However, typical 
replacement theory combined with DDAVP administration was hypothesized to extend half-life 
of FVIII by fostering the formation of the more stable FVIII-vWF complex. At baseline, 
clearance was higher for the recombinant group, but no significant differences were observed for 
other PK parameters. The combined therapy with desmopressin resulted in a significantly larger 
Vss and mean residence time in the plasma-derived group, but not in half-life, suggesting that 




Finally, a 2005 study compared the PK of plasma-derived and B-domain deleted 
recombinant FVIII (BDDrFVIII) [94]. This modification increases the product yield, but is not 
meant to alter the in vivo functionality of the molecule and this study confirmed bioequivalence 
between two different preparations of BDDrFVIII and a plasma-derived concentrate.  In 
summary, no differences in PK were observed between plasma-derived and recombinant FVIII 
products and source of factor is not likely an important covariate to include in PopPK modelling.   
  
Development of Extended Half-Life Products  
 Since the half-life of FVIII is relatively short, prophylactic therapy requires frequent 
infusion in order to be effective. For this reason, products with longer half-lives are desirable. 
The first EHL drug for the treatment of hemophilia A to achieve approval from the FDA was 
efraloctocog alfa, or Eloctate® in June 2014 [131]. Its half-life is approximately 50% longer than 
traditional recombinant products, allowing for infusion every four days rather than every other 
day, hopefully improving patient adherence [106]. Several other products are in the pipeline, and 
the most common strategy involves fusing the FVIII molecule to another large molecule such as 
polyethylene glycol [132], human immunoglobulin fragments [133,134]  and vWF [135]. 
Another technique involves the manipulation of the FVIII molecular structure. The native 
structure of FVIII consists of two chains held together by a metal-ion bridge, rendering the 
molecule rather unstable. By adding a covalent bond between the two chains, a more stable 
single-chain structure can be formed. The single-chain rFVIII also has greater affinity for vWF. 
Since the half-life of vWF is approximately 50% longer than that of FVIII, this may translate 
into a longer-lasting product [136]. A recent study in mice, rabbits and cynomolgus monkeys 




as compared to its full-length counterpart. The importance of vWF was also confirmed in this 
study using vWF knockout mice; terminal half-life decreased by a factor of 30 compared to the 
hemophilia A mice [137].  
 Since EHL products are relatively new, few PK studies have been conducted in humans. 
As a result, the covariates affecting their PK parameters remain largely unknown. One study 
used data from a phase 3 clinical trial to investigate potential covariate effects using PopPK 
analysis [138]. Their final model included vWF level as a major covariate on clearance and 
hematocrit as a weak covariate on volume of the central compartment. Thus, the PK parameters 
of EHL products may be influenced by different covariates than their predecessors and further 
investigation is required to ensure accurate individualized dosing for these products. 
 Long-lasting products are not only possibly beneficial from a patient adherence 
perspective; they could also deliver a major economic advantage, depending of course on costs 
per unit of factor concentrate. Factor concentrates are expensive (approximately US$1 per unit), 
and prophylaxis for a 50 kg child can cost up to $300,000 per year [139–141]. As calculated by 
Björkman [57],  an increase in half-life from 8.1 to 10.8 h means that the dose given at each 
infusion can be reduced by more than half, from 29.7 to 10.7 IU/kg; this translates to a yearly 
savings of 56,000 IU.  
 While they may appear to be the first major improvement to hemophilia care since the 
development of recombinant products, the role of EHL products is still very much unknown and 
the anticipated advantages may not come to fruition. For example, a simulation exercise 
performed by Gringeri et al suggests that the longer dosing interval proposed for EHL products 




increasing the risk of bleeding events [142]. If this is the case, then EHL products may function 
better by using a similar dosing schedule as current FVIII products and maintaining a higher 
trough level. Since clinical trials with these products have found no significant change in 
annualized bleeding rate when adopting a once or twice weekly dosing schedule [143], the role 
these products will play in the hemophilia community is still largely undefined. 
 
Conclusions 
 In summary, PK investigations offer valuable information that can subsequently be used 
in the optimization of hemophilia treatment. From these studies, one can gain a true 
understanding of the importance of between patient variability in estimation of PK parameters 
for FVIII. PK studies also afford the opportunity to identify patient characteristics that may help 
in the parameterization of PopPK models; in the case of FVIII, age, ideal body weight, and blood 
type should be considered where possible, and levels of von Willebrand factor bear potential but 
are still in need of confirmation. However, individual PK still varies considerably beyond what is 
captured by these covariates, and a heterogeneous study population is necessary to capture this 
variability. Furthermore, intermittent sampling and subsequent model updating may be required 







A substantial number of studies investigating the pharmacokinetics of FVIII products 
have been conducted in the years since this review was first completed. Using the same search 
strategy as previously, an additional 19 eligible studies were found for the period following the 
original review (2016-2019), the details of which can be found in Table 3. Many studies, most of 
them crossover designs, focused on new EHL products that have entered the market in recent 
years, and whose potential and role in hemophilia treatment were not well understood at the time 
of the initial review.  
Although the PK profile of these products is somewhat improved, there does appear to be 
a limit to the degree of half-life extension achievable for FVIII concentrates. Certain EHL FIX 
products have half-lives of 100 hours or more (a roughly 4-fold increase), allowing for dosing on 
a weekly or bi-weekly basis; half-lives of EHL FVIII products peak at 20 hours or less (1.5-fold 
increase), typically extending the dosing interval by just one day [144]. This limited half-life 
prolongation has been attributed to the complexation of FVIII and vWF. The overwhelming 
majority of FVIII is present in a complex with vWF, which stabilizes the structure of the FVIII 
molecule, protects FVIII from proteolytic degradation, and prevents cellular uptake [145]. FVIII 
is also largely cleared in the FVIII-vWF complex form [146]. As a result, half-life of vWF 
(approximately 15 h, with considerable BSV [145]) limits the potential for FVIII half-life 
extension, a hurdle that the currently utilized technologies (protein fusion, PEGylation, and 
protein sequence modification) have been unable to overcome. 
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Table 3. Studies on the pharmacokinetics of plasma-derived and recombinant FVIII identified in the 2019 update. n. g. denotes values 
that were not reported in the studies.  












t1/2                                  
(h) 
CL                               
(mL h-1 kg) 







CH 27 18-65 72 h 10 
14.0 ± 3.4 (24%) 
11.6 ± 3.6 (31%) 
2.69 ± 0.81 (30%) 
3.91 ± 1.38 (35%) 
49.6 ± 7.5 (15%) 








6 to <12 












































6 to <12 


















n. g. n. g. 
Advate 26 10.4 (2.24) 4.55 (2.17) 
[151] Moroctocog alfa OS 
3 
10 
6 to <12 
≥12 
72 h 12 
7.2 ± 1.8 (25%) 












96 h Up to 7 
13.2 
14.3 


























t1/2                                  
(h) 
CL                               
(mL h-1 kg) 











4 to <7 
7 to <12 
≥12 
48 h 5 
8.80 ± 2.45 (28%) 
10.15 ± 2.48 (24%) 
12.82 ± 2.38 (18%) 





CH 25 12-70 48 h 11 
10.9 ± 4.5 (41%) 
9.9 ± 3.2 (32%) 
3.69 ± 1.48 (40%) 
3.84 ± 1.69 (44%) 
51.1 ± 8.5 (17%) 












4.0-16.7 48 h 4 
11.16 ± 0.78 (7%) 
10.87 ± 0.65 (6%) 
3.81 ± 0.36 (9%) 
4.69 ± 0.29 (6%) 
37.22 ± 2.52 (7%) 
42.77 ± 2.04 (5%) 
NCA 


















15.0 ± 4.1 (27%) 
16.0 ± 3.5 (22%) 
17.9 ± 1.7 (9%) 
17.6 ± 4.6 (26%) 
3.14 ± 1.41 (45%) 
2.14 ± 0.41 (19%) 
1.57 ± 0.40 (25%) 
1.70 ± 0.58 (34%) 
59.5 ± 16.4 (28%) 
50.1 ± 9.5 (19%) 
39.9 ± 10.7 (27%) 


























OS 21 18-36 24 h 7 
10.55 ± 2.87 (27%) 
10.45 ± 2.55 (24%) 
2.76 ± 0.76 (28%) 
2.89 ± 0.71 (24%) 
n. g. NCA 
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(h) 
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(mL h-1 kg) 







OS 14 10-50 44-52 h 2-3 
15.4 [12.0-16.8] 
16.9 [15.3-19.1] 










































n. g. NCA 







Chapter 3: Data analysis protocol for the development and evaluation of 
population pharmacokinetic models for incorporation into the Web Accessible 
Population Pharmacokinetic Service – Hemophilia (WAPPS-Hemo) 
 
This chapter is reflective of an original manuscript prepared by the Ph.D. candidate (Alanna 
McEneny-King) for submission to JMIR Research Protocols. All pertinent dialogue in this 
chapter was written by the Ph.D. candidate. 
 
Introduction 
Hemophilia is a congenital bleeding disorder caused by a deficiency in clotting factor 
VIII (FVIII, hemophilia A) or IX (FIX, hemophilia B), resulting in bleeding episodes, often in 
the joints. Hemophilia A is considerably more common than hemophilia B, with reported 
prevalences of 8.0 and 2.4 per 100,000 males, respectively [62,165]. In more severe hemophilia 
patients (i.e. those with endogenous factor levels below 10 IU L-1), bleeds may occur 
spontaneously and can lead to irreversible damage in target joints. Treatment options include 
replacement with exogenous clotting factor concentrates, which may be administered on-demand 
when bleeds occur, or prophylactically on a regular schedule.  
Prophylactic treatment has been repeatedly shown to improve joint outcomes [9,166], but 
can be somewhat challenging to implement due to wide interpatient variability in 
pharmacokinetics (PK) handling of factor concentrates [167,168]. Evidence suggests that an 
individualized approach is optimal, from both a therapeutic and economic perspective. 
Previously, PK-based dose tailoring was hampered by the high sampling burden required to 
perform classical PK estimation. However, the International Society of Thrombosis and 




the population pharmacokinetic (PopPK) approach to improve the feasibility of PK-tailored 
dosing in routine care [169]. While this approach does reduce the number of samples needed, the 
development and evaluation of PopPK models requires specialized software, expertise, and a 
considerable amount of data. In recent years, web-based PK software such as the Web 
Accessible Population Pharmacokinetics Service – Hemophilia (WAPPS-Hemo, www.wapps-
hemo.org) have emerged to tackle this obstacle and encourage the use of the PopPK approach in 
hemophilia treatment. Housed at McMaster University in Canada, the service was launched in 
2015 and has grown into the largest repository of hemophilia PK data worldwide. Users provide 
patient demographic data and a minimal number of blood samples, and receive a report 
containing the patient’s predicted PK profile and individual estimates of PK outputs such as half-
life, time to critical factor levels (50, 20, and 10 IU L-1), and factor levels at key post-infusion 
times (24, 48, 72, and 96 hours, as appropriate).         
Population pharmacokinetic modelling uses nonlinear mixed effects modelling 
techniques with the primary goal of partitioning, quantifying, and identifying sources of 
variability in PK response. Total variability can be divided into predictable and unpredictable 
variability, where predictable variability is attributed to covariates (e.g. body weight, age, blood 
type) that are known to influence a patient’s PK; the identification of important covariates can 
also help to detect at-risk subpopulations. Unpredictable variability may occur between separate 
patients (BSV) or within a single subject on different occasions (BOV). The magnitude of these 
unpredictable variabilities determines which dosing strategy (e.g. generic population dose vs. 
individualized dose) is appropriate. PopPK models typically consist of three sub-models: (1) 
structural model, which defines curve shape (e.g. two-compartment); (2) covariate models, to 




on clearance [CL]); and (3) statistical model, which describes residual variance between and 
within individuals (e.g. 30% BSV on central volume [V1]). The PopPK model parameters (i.e. 
typical values and variances) act as informative priors and, combined with sparse blood samples 
from the patient, are used to estimate individual PK parameters through Bayesian forecasting.  
In this update to our previously published protocol [170], we present the model 
development and evaluation strategy currently being used to produce PopPK models for use in 




To date, PK data from a total of 26 brands of clotting factor concentrate have been used 
for development of both brand-specific and generic PopPK models on WAPPS-Hemo; these 
include standard and extended half-life products for both factor VIII and IX. Thus far, most 
models have been built on data measured by one-stage clotting assay; however, seven products 
also have models that are valid for chromogenic assay. While the majority of the data used for 
model development originates from industry-sponsored and investigator-driven studies, some 
model derivation datasets have also been supplemented with data collected through routine usage 
of the WAPPS-Hemo service, especially when pediatric patients were not included; in certain 





Table 4. Description of the components for a typical NONMEM dataset 
 
Variable Description Units 
CID Patient identification number Positive integer 
IID Infusion identification number Positive integer 
OCC Dose occasion Positive integer 
TIME Time of each concentration 
measurement; TIME = 0 when 
predose measurement occurs 
Hours  
TAD Time of each concentration 
measurement; TIME = 0 at start 
of infusion 
Hours 
AMT Total Dose   International unit (IU) 
RATE Rate of infusion; AMT/TIME IU/h 
DV Plasma concentration of valid 
observation 
IU/L 
DV = 0  
AGE Age  Years 
HT Height  Centimetres 
BW Weight  Kilograms 
FFM Fat-free mass, calculated from 
AGE, HT and BW 
Kilograms 
EVID Event identification variable  0 = valid observation  
1 = dose event 
3 = reset event 
4 = reset and dose event 
DOSE AMT/BW  IU/kg 
PREDOSE Plasma concentration at time of 
start of bolus  
IU/L if measured; 
-1 if not measured 
MDV Missing dependent variable  0 = valid observation 
1 = dose observation   
LLOQ Lower limit of quantification of 
the assay used 
IU/L;  
assumed 10 IU/L if not provided 
BLQ Below limit of quantification -1 for non-BLQ measurements; 
LLOQ for BLQ measurements 
BASELINE Endogenous plasma 
concentration  
IU/L if measured; 
assumed LLOQ/2 if not provided 
Optional covariates: 
VWF von Willebrand Factor Percentage  
BRAND Brand of factor concentrate 
product 
Categorical 
RACE Race  Categorical  
BTYPE Blood type  0 = non-O blood type 
1 = O blood type 
-1 = unknown 




Software and Handling of BLQs 
Population pharmacokinetic modelling and Bayesian post hoc estimation are both 
performed in NONMEM using PDx-Pop (v7.3/7.4 and v5.2, respectively; ICON Development 
Systems, Ellicott City, MD, USA). When available, the modelling dataset will consist of the 
variables outlined in Table 4. Estimation is performed using the first order conditional estimation 
with interaction (FOCEI) with the LAPLACIAN option; the ADVAN and TRANS subroutines 
for each compartmental model are shown in Table 5. Graphical analysis and streamlining of 
evaluation steps are conducted in MATLAB (R2017b, Mathworks, Natick, MA, USA). As 
mentioned above, severe hemophilia patients have an endogenous factor activity level below 10 
IU L-1. As 10 IU L-1 is also the most cited lower limit of quantification (LLOQ) for coagulation 
activity assays [refs for assay LLOQ], measurements that are below the limit of quantification 
(BLQ) are common. To handle these measurements, we employ the M3 method proposed by 
Beal [173]. In brief, this method involves using maximum likelihood estimation to fit the PK 
model to all observations (where the likelihoods for BLQ observations are the likelihoods that 
these measurements are truly BLQ). Handling BLQ observations in this manner is less biased 
than ignoring or imputing the data.  
Table 5. NONMEM subroutines used to implement kinetic equations for linear models 






Model ADVAN Subroutine TRANS Subroutine 
1-compartment ADVAN1      TRANS2: CL, V 
2-compartment ADVAN3      TRANS4: CL, V1, Q, V2  




Base Model Development 
The development of the base model consists of defining the structural model (i.e. number 
of compartments) and the statistical models (i.e. BSV, BOV [if applicable], and residual 
unexplained variability [RUV]). In the case of hemophilia, where factor activity measurements 
comprise both endogenous factor and repeatedly administered exogenous factor, measured factor 
activity is the result of three distinct contributors: 
𝐶 = 𝐶𝑒𝑥𝑜𝑔𝑒𝑛𝑜𝑢𝑠 + 𝐶𝑒𝑛𝑑𝑜𝑔𝑒𝑛𝑜𝑢𝑠 
𝐶 = 𝐶𝑐𝑢𝑟𝑟𝑒𝑛𝑡 𝑑𝑜𝑠𝑒 + 𝐶𝑟𝑒𝑠𝑖𝑑𝑢𝑎𝑙 + 𝐶𝑒𝑛𝑑𝑜𝑔𝑒𝑛𝑜𝑢𝑠 
For the example of a two-compartment model, 
𝐶(𝑡) = 𝑓(𝜃, 𝑡) + (𝐶𝑝𝑟𝑒𝑑𝑜𝑠𝑒 − 𝐶𝑒𝑛𝑑𝑜𝑔𝑒𝑛𝑜𝑢𝑠)𝑒
−𝛽𝑡 + 𝐶𝑒𝑛𝑑𝑜𝑔𝑒𝑛𝑜𝑢𝑠 
where 𝑓(𝜃, 𝑡) is function relating factor activity to the individual’s parameters (𝜃), such as PK 
parameters and covariate effects, and time (𝑡); the precise form of 𝑓 depends on the number of 
compartments and the administration route. Residual exogenous FVIII from unaccounted doses  
(𝐶𝑝𝑟𝑒𝑑𝑜𝑠𝑒 − 𝐶𝑒𝑛𝑑𝑜𝑔𝑒𝑛𝑜𝑢𝑠) decays according to the terminal rate constant (𝛼 for a one-
compartment model; 𝛾 for a three-compartment model); if no predose level was measured, it is 
assumed that there was no exogenous FVIII remaining at the time of dose administration. The 
endogenous FVIII component (𝐶𝑒𝑛𝑑𝑜𝑔𝑒𝑛𝑜𝑢𝑠) is assumed to be constant and, when unknown or 
unmeasurable, is considered to be half of the lower limit of quantification (LLOQ) of the assay. 
The selection of the structural model (i.e. 1-, 2-, or 3-compartment) is driven by the 
objective function value (OFV), a numerical measure of goodness-of-fit, and graphical 




issues, the Akaike Information Criterion (AIC) and Bayesian Information Criterion are also used 
to determine the most favourable model. 
𝐴𝐼𝐶 = 𝑂𝐹𝑉 + 2 ∙ 𝑛𝑝 
𝐵𝐼𝐶 = 𝑂𝐹𝑉 + 𝑛𝑝 ∙ ln (𝑁) 
where 𝑛𝑝 is the number of parameters in the model and 𝑁 is number of observations in the 
dataset; a decrease in AIC or BIC of at least 2 is considered positive evidence in favour of the 
model [174]. In addition to these goodness-of-fit measures, the plausibility of the parameter 
estimates and graphical techniques (described in the Model Evaluation section) are also 
considered in decision-making. Furthermore, plots of the PK curves generated from estimated 
population parameters can also be helpful to assess whether meaningful differences exist 
between structural models. 
 
Residual Unexplained Variability 
Residual unexplained variability (RUV) is the unexplained variability after accounting 
for all other sources of variability, and may arise from assay error, imprecise recording of sample 
time, model misspecification, or natural variation [174]. Commonly used functions to describe 
RUV include:  
𝐶𝑖𝑗 = ?̂?𝑖𝑗 + 𝜀𝑖𝑗 
𝐶𝑖𝑗 = ?̂?𝑖𝑗  ∙ (1 + 𝜀𝑖𝑗) 




where 𝐶𝑖𝑗 is the 𝑖
th observation for the 𝑗th individual, ?̂?𝑖𝑗 is the model prediction for the 𝑖
th 
observation for the 𝑗th individual. In each case, the 𝜀-values are assumed to be independent and 




Between Subject Variability 
Between-subject variability (BSV) is modelled according to the following equation: 
𝑃𝑗 = 𝑇𝑉(𝑃) ∙ 𝑒
𝜂𝑃−𝑗  
where 𝑃𝑗 is the individual value of PK parameter 𝑃 for the 𝑗
th individual, 𝑇𝑉(𝑃) is the typical 
value of parameter 𝑃. 𝜂𝑃−𝑗 describes individual 𝑗’s deviation from the typical parameter value, 
and  𝜂𝑃~𝑁(0,𝜔𝑃
2) such that 𝑃 is log-normally distributed and physiologic PK parameter values 
remain positive. The decision to include BSV on a given PK parameter is largely driven by 𝜂-
shrinkage values, defined as: 




where 𝜔 is the estimate of the standard deviation of 𝜂 from the population model, and 𝑆𝐷(𝜂) is 
the standard deviation of 𝜂 calculated over the population. Typically, 𝜂-shrinkage takes a value 
between 0% and 100%, with higher values indicating that individual parameter estimates are 
“shrinking” towards the population value due to a lack of informative data for that particular 
parameter (Figure 4). This lack of information results in an uncertain estimate of BSV which, 
when used in Bayesian estimation, leads to uncertainty around the individual estimates and 
inappropriate outcomes (e.g. implausible half-lives, extremely wide confidence intervals, etc.). In 




interfere with later steps of model development as many diagnostic plots, particularly those used 
to assess covariate relationships, become misleading when 𝜂-shrinkage is in to 20-30% range 
[175]. For this reason, BSV is typically removed from parameters with high 𝜂-shrinkage (we use 
35% as a cut-off value) and the model is re-assessed.   
 
Figure 4. 𝜼-distribution of a structural model parameter (e.g. CL) with low (left) and high (right) 
shrinkage. The red line indicates the expected distribution from the model assumptions, while the 
blue line shows the actual distribution of individual 𝜼-values. 
 
Considering the end use of the model, the magnitude of the BSV term was also taken into 
account, as high BSV may introduce too much flexibility into the model. The inclusion of off-
diagonal elements in the omega matrix is only tested after selection of the covariate model, so as 







not to obscure covariates effects by prematurely allowing for correlation between 𝜂-terms that 
share a common covariate. 
Between-occasion variability (BOV) is modelled similarly, when sufficient data is 
available: 
𝑃𝑗𝑘 = 𝑃𝑗 ∙ 𝑒
𝜌𝑃𝑘 
where 𝜌𝑃𝑘 is normally distributed (𝜌𝑃~𝑁(0, 𝜋𝑃
2)) and described the deviation on occasion 𝑘 for 
individual 𝑗. To diagnose the inclusion of BOV terms, BSV estimates are compared from two 
different treatments of the modelling dataset. In the first run, each new occasion is treated as a 
new subject; in the second, occasions are attributed to the original subject, but BOV is not 
explicitly modelled. Parameters with significant decreases in BSV in the second run are then 
formally assessed for BOV. 
 
Covariate Model Selection 
Possible covariate relationships are first explored by examining plots of 𝜂-values against 
each covariate (either as a scatter plot for continuous covariates or boxplot for categorical 
covariates). Next, covariates are formally tested in the model using the likelihood ratio test, 
which assumes that the difference in OFV between two nested models follows a chi-squared 
distribution with 𝑃2 − 𝑃1 degrees of freedom, where 𝑃2 and 𝑃1 are the numbers of parameters in 
the larger and smaller models, respectively. Thus, if a 5% significance level is employed, the 
addition of one parameter (i.e. one degree of freedom) must decrease the OFV by at least 3.84 




Covariates are added to the model in a stepwise manner, and are kept based on OFV 
decrease, reduction of unexplained BSV, and physiological/clinical relevance of the estimated 
covariate effect. If several covariates are highly correlated (e.g. body weight, height, and fat-free 
mass), only one is included in the final model to avoid collinearity. Typical functional forms 
used include: 






𝑇𝑉𝑃𝑖 = 𝑇𝑉(𝑃) ∙ (1 + 𝜃𝑐𝑜𝑣−𝑃 ∙ (𝑐𝑜𝑣𝑖 − 𝑐𝑜𝑣𝑚𝑒𝑑)) 




𝑇𝑉𝑃𝑖 = 𝑇𝑉(𝑃) ∙ (1 + 𝜃𝑐𝑜𝑣−𝑃 ∙ 𝐶𝐴𝑇)       𝐶𝐴𝑇 = {0,1} 
where 𝑇𝑉𝑃𝑖 is the PK parameter predicted by the model for the 𝑖
th individual with covariate 
value 𝑐𝑜𝑣𝑖, 𝑐𝑜𝑣𝑚𝑒𝑑 is the median value of the covariate, and 𝜃𝑐𝑜𝑣−𝑃 is the effect of the covariate 
on parameter 𝑃. 𝐶𝐴𝑇 represents a dichotomous categorical covariate (e.g. blood group). 
Morphometric variables (e.g. body weight, fat-free mass) are modelled using the power function, 
while age, when significant, tends to follow a linear or piecewise linear relationship depending 
on the covariate space of the dataset. Graphical representations of these functional forms, with 





Figure 5. Illustration of different functional forms (left to right: power, linear, piecewise linear, 
and categorical) for covariate relationships, with varying effect sizes 
 
 In light of the final use of these models, multiple covariate models are occasionally 
required for a single clotting factor concentrate. For example, von Willebrand factor (vWF) level 
is an excellent predictor of FVIII clearance, as this protein acts as a chaperone for FVIII and 
protects it from degradation. However, vWF levels are not available for all patients. In these 
cases, an alternative model containing only basic covariates (e.g. age, body weight) is 
simultaneously developed. 
Model Evaluation 
Model evaluation consists of both basic and advanced internal methods that are selected 




graphical techniques to assess goodness-of-fit, ensure all underlying assumptions are met, and to 
identify any model misspecification. Diagnostic plots include: 
 Population/individual predicted values vs. observed values 
 Conditional weighted residuals (CWRES) vs. predicted values 
 CWRES vs. time 
 Observed/predicted values vs. time 
 Normal QQ plots 
 CWRES histograms 
 Population covariate plots 
 𝜂 histograms 
In addition to graphical assessment, 𝜂-distributions were also numerically evaluated using 𝜂-
shrinkage.. As previously alluded to, high 𝜂-shrinkage increases uncertainty around estimates 
obtained from Bayesian forecasting and also interferes with commonly used diagnostic plots; 
preliminary covariate analysis is particularly sensitive to 𝜂-shrinkage, as both hidden and 
induced relationships have been observed at 20-30% 𝜂-shrinkage [175]. As a result, we remove 
BSV from parameters when shrinkage is in excess of 35% and the model is re-assessed When 𝜂-
shrinkage is above 20%, all covariate relationships are formally explored as the graphical 
analysis can be misleading.. 𝜀-shrinkage, defined below, is also monitored: 
𝑠ℎ𝑟𝜀 = 1 − 𝑆𝐷(𝐼𝑊𝑅𝐸𝑆) 







Thus, high 𝜀-shrinkage is indicative of overfitting. Similar to 𝜂-shrinkage, 𝜀-shrinkage 
can also reduce the power of diagnostic plots (e.g. IPRED vs. observed) to detect model 
misspecifications [176] and so this value was also considered before consulting graphical 
diagnostics. While model evaluation is typically thought of as occurring once the final model has 
been decided upon, these graphical techniques and monitoring of shrinkage are used throughout 
model development to assist in decision-making.  
 Next, bootstrap analysis is performed as a non-parametric way of assessing uncertainty in 
parameter estimates by calculating the standard errors and confidence intervals around model 
parameters. The modelling dataset is randomly sampled 1000 times with replacement (stratified 
by covariates as needed) to generate 1000 new datasets of the same size as the original. 
Parameters are estimated for each prepared dataset, with the median values corresponding to 
parameter estimates and the 2.5th and 97.5th percentiles forming the 95% confidence interval. 








where 𝐵 is the number of re-sampled datasets, 𝜃𝑏 is the estimate of 𝜃 from run 𝑏, and ?̅? is the 
mean estimate of 𝜃 from the 𝐵 datasets. 
 A prediction-corrected visual predictive check (pcVPC) is then used to assess a model’s 
predictive capacity. Traditional VPCs can be used to assess whether simulations produced by a 
candidate model are able to recreate both the central tendency and the variability of the observed 
data. A large number of simulations are performed, and the corresponding percentiles of the 




hampered by large variations in independent variables such as dose. To tackle this shortcoming, 
the observed and simulated factor activity levels in each bin are normalized by the typical 
population prediction, as shown by Bergstrand et al [177]. The pcVPC is performed with 500 
simulations, and an example of a typical pcVPC generated during model evaluation is shown in 
Figure 6. 
 
Figure 6. Example of prediction-corrected visual predictive check (pcVPC) for a SHL FVIII 
model shown on linear (top) and log (bottom) scales. Dashed red lines denote median, 5th and 
95th percentiles of observed data. Solid lines denoted the same percentiles in the simulated data, 





 As the ultimate use of the models is in Bayesian forecasting, internal and external 
evaluation techniques are used to evaluate them specifically for this purpose. First, cross-
validation (typically 10-fold) is performed to assess the model’s ability to predict PK parameters 
for individuals outside of the original modelling dataset. The original dataset is split into a 
learning subset and a validation subset; in the case of a 10-fold cross-validation, the learning 
subset comprises 90% of the data while the remaining 10% is used for evaluation. Bayesian 
forecasting is performed on the validation subset using population estimates obtained from the 
learning subset. Individual estimates of key PK parameters (e.g. half-life, clearance, central 
volume, time to 1% factor activity) are then compared to those obtained using the entire 





where ?̂?𝑖 is the estimate from the cross-validation and 𝜑𝑖 is the estimate when the full dataset is 
used for model development. This process is repeated 100 times, to prevent the bias that may 
occur from a single random split of the dataset; typical results are presented in Figure 7. 
 





 Next, a limited sampling analysis is performed to ensure that the models can estimate 
individual PK parameters accurately from only a few patient samples. In addition to assessing 
the performance of the model, this analysis can also identify which sampling times are most 
informative for estimation of a given parameter using Bayesian forecasting.  Based on the 
method describe by Brekkan et al [178], a population of 1000 individuals is generated using the 
covariate and PK parameter distributions of the initial dataset. An appropriate treatment strategy 
is simulated for each subject, depending upon the clotting factor product being modelled (Table 
6).  
Table 6. Simulation details for limited sampling analysis by product type 
Product Type Dosing Regimen 
Steady State 
Simulation Length 
Reference Sampling Design 
SHL FVIII 25 IU/kg, 3 times per week 4 weeks Predose, 1, 3, 6, 12, 24, 48, 72 h 
EHL FVIII 40 IU/kg, 2 times per week 4 weeks Predose, 1, 3, 6, 24, 48, 72, 96 h 
SHL FIX 40 IU/kg, 2 times per week 4 weeks Predose, 1, 3, 6, 24, 48, 72, 96 h 
EHL FIX 40 IU/kg, one per week 4 weeks 
Predose, 1, 24, 48, 72, 96, 120, 
168, 240, 336 h 
 
Limited sampling strategies are created from 2- or 3-sample subsets of the rich design (8+ 
samples) at clinically convenient times. Individual PK parameters are obtained through Bayesian 
forecasting from each of the designs, and estimates of relevant PK parameters from the limited 
sampling strategies are compared to those obtained from the rich sampling strategy using relative 





Figure 8. Example of results from limited sampling analysis for a SHL FVIII model, depicting 





 Finally, data collected through the WAPPS-Hemo network is used to externally evaluate 
the model, provided the WAPPS data has not already been used to supplement the original 
modelling dataset. First, histograms of age and body weight for the WAPPS data and the 
modelling dataset are compared to determine if the WAPPS data is similar to the covariate space 
on which the model was built (Figure 9A). Next, the model was used to perform Bayesian 
forecasting, and the results were evaluated using goodness-of-fit plots, histograms of individual 
estimates of PK parameters (e.g. half-life, clearance, central volume, time to 1% factor activity) 
and overlaid observed data with the activity-time profile predicted by the model for each 
individual (Figure 9B-D). Due to the sparse nature of the PK data collected through WAPPS-
Hemo, a formal evaluation comparing estimates to some ‘true’ value is not feasible; rather, this 
method ensures that the model produces reasonable results in the conditions in which it is 






Figure 9. Process of external validation using WAPPS-Hemo data.  (A) Comparison of covariate 
spaces of modelling (grey) and WAPPS-Hemo (blue) data (B) Goodness-of-fit plots (log scale) 
(C) Comparison of individual PK estimates for patients from modelling and WAPPS-Hemo 
datasets (D) Predicted individual activity-time profiles with 95% confidence intervals (shaded 




As of this update, 33 models for 26 clotting factor concentrates have been developed 
according to this protocol. In addition, a generic standard half-life FVIII model was developed to 
handle requests for products without a brand-specific model. To date, over 9,000 unique PK 
profiles from nearly 6,000 patients; roughly one third of these infusions correspond to pediatric 
(<12 years old) patients. The clinical module described in the original WAPPS-Hemo data 
analysis protocol was implemented in 2017, and has since been used over 1,300 times for dosing 
regimen design.  
 With regards to reporting, a recent paper by Hajducek provides a summary of the 






currently implemented on the WAPPS-Hemo platform. In brief, the models used on the WAPPS-
Hemo platform demonstrate good performance in the context of Bayesian forecasting. Cross-
validation reveals low bias and relative error on estimates of relevant PK parameters such as 
half-life and TAT2%. Results from LSA also showed acceptable bias and error, while also 
confirming the ability of the models to produce accurate estimates from a number of different 
sampling schemes; this flexibility in sampling times is an important feature that makes the 
Bayesian approach more feasible in a real world setting. Furthermore, the development and 
evaluation of three models (standard half-life FVIII, Fanhdi/Alphanate and Adynovate) are fully 
detailed in McEneny-King et al [179] and Chelle et al [171,172].   
 
Discussion 
We would first like to emphasize that the model development and evaluation strategies 
described in this report are highly influenced by its end purpose of Bayesian forecasting; models 
intended for other purposes may employ different decision-making criteria or evaluation 
techniques. Furthermore, this revised data analysis protocol follows from our collective 
experience developing over 25 models for clotting factor concentrates for use in Bayesian 
forecasting; we have observed, through the regular use of the WAPPS-Hemo service, which 
types of models perform well for this purpose and have incorporated this knowledge into the 
updated protocol. 
Since the publication of the original data analysis protocol for WAPPS-Hemo models in 
2016, the uptake of the PopPK approach in the hemophilia community has risen dramatically 
[180].  The WAPPS-Hemo network, currently with over 400 centres worldwide, boasts the 




space, and quality. As we continue to collect data, we aim to standardize our approach to 
updating models with data submitted to WAPPS-Hemo. This exercise poses an interesting 
question about which type of model is best suited to Bayesian forecasting: a model using data 
collected during clinical trials, or model created by merging industry and routine clinical data? 
The clean, richly sampled data from clinical trials typically enables clearer decisions regarding 
the structural model and inclusion of BSV or BOV; however, the number of patients may be low 
and the covariate space may be narrow, and especially lacking in pediatric patients. On the 
contrary, the WAPPS-Hemo data consists of over 9,000 unique PK profiles (including over 
3,000 in children under 12 years of age), but this data is not necessarily clean. To ensure that the 
inclusion of WAPPS-Hemo data improves rather than pollutes the model of interest, strict data 
cleaning procedures will be necessary for model updating. Furthermore, it may be prudent to 
restrict model updating to the re-assessment of covariate effects rather than re-selecting the 
structural model.  
Finally, a limitation – though also a strength of the project – is our constant evolution, 
necessitating regular updates to our methods, such as this report, so that the hemophilia 
community is informed of our current practices. For instance, the modelling of BOV is a more 
recent addition to our model development strategy, as more multi-occasion data became 
available; its incorporation in some models prompts further research questions regarding the 







In summary, the WAPPS-Hemo service is centred on validated PopPK models for 
clotting factor concentrates. This protocol describes the process of model development and 
evaluation that has been refined during the last three years, since the original publication of the 
data analysis plan. The WAPPS-Hemo network continues to grow, contributing to the largest 





Chapter 4: Development and evaluation of a generic population 
pharmacokinetic model for standard half-life factor VIII for use in dose 
individualization  
 
This chapter is reflective of an original manuscript published by the Ph.D. candidate (Alanna 
McEneny-King) in Journal of Pharmacokinetics and Pharmacodynamics. All pertinent dialogue 
in this chapter was written by the Ph.D. candidate. 
 
McEneny-King A, Chelle P, Foster G, Keepanasseril A, Iorio A, Edginton AN. Development 
and evaluation of a generic population pharmacokinetic model for standard half-life factor VIII 




Hemophilia A is a genetic bleeding disorder caused by a deficiency of functional clotting 
factor VIII (FVIII), affecting 1 in 6,500 male births [62]. As a result, hemophilia patients are 
unable to form clots in response to vascular injury and are thus prone to bleeding episodes. 
Among the most severe patients (i.e. those with less than 1% of normal FVIII activity), bleeds 
may occur spontaneously, particularly in joints, resulting in debilitating arthropathy. Current 
hemophilia therapy consists of regular intravenous infusions of exogenous FVIII to maintain 
FVIII levels above a certain trough at all times. Often, the selected trough is 1% (or 10 IU L-1), 
based on the observation that the rate of increase in joint score of moderate patients with 




endogenous levels below 1% [7]. Furthermore, a correlation between time spent below the 1% 
threshold and the occurrences of bleeds and hemarthroses has been demonstrated [10].  
Today, there is global consensus that prophylaxis should be initiated at a young age, 
before joint disease is apparent [11–13]. However, no optimal regimen has been determined due 
to a highly variable pharmacokinetic (PK) response between patients. High between subject 
variability (BSV) and relatively low interoccasion variability (IOV) suggests that FVIII dosing 
regimens ought to be tailored to the individual to ensure both the safety of the patient and the 
responsible use of expensive clotting factor concentrates [70,167]. The classic approach to PK-
based dose tailoring has been difficult to apply in a clinical setting, especially when trying to 
apply the approach recommended by the International Society of Thrombosis and Haemostasis 
(ISTH) for bioequivalence studies with new concentrates, which requires more than 10 samples 
taken over the course of 48 hours. More recent ISTH-issued guidelines detail the value of a 
population pharmacokinetic (PopPK) approach to PK studies oriented to dose individualization 
[169,181]. A PopPK model, which provides typical values of PK parameters (clearance [CL], 
central volume [V1]) and quantifies the variability within the population based on patient 
covariates, can act as informative prior knowledge for the Bayesian estimation of individual PK 





Table 7. Published PopPK models for standard half-life FVIII products 
Reference Product Description 
Abrantes [182] ReFacto AF/Xyntha 
2-compartment; combined RUV model; BSV on CL, F and 
baseline; IOV on CL and V2; body weight on V1 and V2; 
age, inhibitor status, and study effect on CL; race on V2; 
assay on F and RUV 
Björkman [183] Advate 
2-compartment; additive RUV model; BSV on CL and V1; 
body weight on CL, V1, and V2; age on CL 
Nestorov [184] Advate 
2-compartment; combined RUV model; BSV on CL and 
V1; body weight on V1; study on RUV and V2 
Garmann [185] Kovaltry 
2-compartment; combined RUV model; BSV on CL and 




1-compartment; combined RUV model; BSV on CL and V; 
body weight on CL and V; age on CL 
Bolon-Larger [186] 
Various recombinant and 
plasma-derived products  
2-compartment; proportional RUV model; BSV on CL, V1 
and V2; HIV status on V1 
*model for continuous infusion 
Karafoulidou [187] ReFacto 
1-compartment; proportional RUV; BSV on CL and V; 
body weight on CL and V; HIV status on V 
Hazendonk [188] 
Various recombinant and 
plasma-derived products 
2-compartment; combined RUV; BSV on CL and V1; age 
on CL and V1; blood group and major surgical procedure 
on CL; product type on F 
*some continuous infusion patients included 
 
Several PopPK models for standard half-life (SHL) FVIII products have been published 
in the literature, and are summarized in Table 7. Each of the cited models is dedicated to one 
specific brand of FVIII, and FVIII products do vary in ways that may be clinically relevant. One 
such characteristic is the source of the FVIII concentrate, which may be plasma-derived 




von Willebrand factor (vWF) content: intermediate purity (vWF:FVIII > 1), high purity 
(vWF:FVIII = 0.2–0.4), or immunopurified (vWF:FVIII < 0.1) [189]. The presence of a native 
FVIII-vWF complex in pdFVIII has been shown to impact the early phase of the PK profile, but 
does not appear to affect half-life [129]. Recombinant FVIII products can be classified according 
to their structure. In 2000, the first B-domain deleted recombinant FVIII product (BDDrFVIII) 
was released, followed by a B-domain truncated product in 2013 [190]. The purpose of this 
deletion was to improve production efficiency, with no changes to immunogenicity or 
pharmacokinetic profile. While some studies have found BDDrFVIII products to be 
bioequivalent to their full-length counterparts [94,95,97], others have found that half-lives are 
shorter after this modification [191,192]. This may be due to disrupted intermolecular 
interactions that impact the life span of FVIII [193]. Despite these differences in source and 
structure, variability seems to be greater across patients than across brands [167]. Thus, a generic 
PopPK model for SHL FVIII products can be a valuable tool, especially if one considers that 
hemophilia is a rare disorder with an abundance of similar products, all of which benefit from 





   
Figure 10. Sources and structures of the brands of SHL FVIII included in the modelling dataset 
 
The aim of this study was to develop and evaluate a generic PopPK model for SHL FVIII 
products, both plasma-derived and recombinant, using data acquired through the Web Accessible 
Population Pharmacokinetic Service – Hemophilia (WAPPS-Hemo) project. The development of 
such a model will help to determine if there are distinct PK differences between FVIII brands 
and the clinical relevance of these differences. Further, the model will be incorporated into the 
WAPPS-Hemo platform, which tackles the issue of high BSV by using PopPK models for 
Bayesian forecasting to obtain individual PK estimates from relatively few patient samples. 
Clinicians provide 2-4 factor levels, along with demographic information, and are provided with 
individual estimates of relevant PK parameters (such as half-life, time to 1% FVIII activity, or 
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permit its use for patients on brands of SHL FVIII that are not included in the modelling dataset, 




Data for recombinant and plasma-derived SHL FVIII was collected from multiple 
industry sources through the WAPPS-Hemo project. The model was developed using FVIII 
activity measurements from 310 densely sampled patients (one infusion per patient), consisting 
of between 4 and 12 factor levels (median: 10). All samples were measured using the one-stage 
clotting assay. All patients had either severe or moderate hemophilia (<1% or 1-5% of normal 
FVIII activity, respectively) and did not present detectable inhibitors at the time of PK analysis. 
The lower limit of quantification (LLOQ) varied among studies, ranging between 4 and 12.5 IU 
L-1 (median = 10 IU L-1) and samples that were below limit of quantification (BLQ) comprised 









Total Number of 
Samples 
Number of BLQ 
Samples (%) 
Number of Samples 
per Patient 
Duration of Sampling 
(h) 
310 2760 191 (6.9%) 10 (4 – 12) 48.0 (3.25 – 96.25) 
Patient Demographics 
Brand 𝑛 Age (years) Body Weight (kg) Fat-Free Mass (kg) 
Advate 79 20 (1.1 – 62) 66.9 (10.6 – 132.5) 53.5 (8.1 – 82.7) 
Emoclot 14 33 (14 – 55) 70 (40 – 93) 55 (35 – 66.9) 
Kogenate 64 19 (5 – 54) 69.15 (16.6 – 124.2) 55.4 (14.2 – 84.3) 
Kovaltry 31 31 (12 – 61) 70 (46 – 124.2) 53.2 (39.2 – 76.5) 
NovoEight 55 11 (1 – 54) 42.7 (11.7 – 107) 35.9 (10 – 71.4) 
Octanate 35 18 (3 – 54) 53 (18.5 – 89) 45.8 (14 – 67.1) 
ReFacto AF 32 24 (14 – 57) 78.5 (50.7 – 117.2) 59.35 (43.9 – 75.2) 
TOTAL 310 21 (1 – 62) 66.0 (10.6 – 132.5) 53.0 (8.1 – 84.3) 
 
Population Modelling 
PopPK model building was performed using non-linear mixed effects modelling 
techniques implemented in NONMEM and PDxPop (v7.3 and v5.2, respectively; ICON 
Development Solutions, Ellicott City, MD, USA). Graphical analysis was conducted in 
MATLAB (R2017b, Mathworks, Natick, MA, USA). Samples that were BLQ were handled 
using the M3 method [173]. 
First, the structural component of the model was developed. The model describes not 
only the exogenous dose administered, but also endogenous FVIII production and any residual 
FVIII from prior doses as trials did not necessarily include a washout period.  
𝐶(𝑡) = 𝐴𝑒−𝛼𝑡 + 𝐵𝑒−𝛽𝑡 + 𝑒𝑛𝑑𝑜𝑔𝑒𝑛𝑜𝑢𝑠 𝐹𝑉𝐼𝐼𝐼 + (𝑝𝑟𝑒𝑑𝑜𝑠𝑒 − 𝑒𝑛𝑑𝑜𝑔𝑒𝑛𝑜𝑢𝑠)𝑒−𝛽𝑡 
The endogenous FVIII component was considered to be constant; when the endogenous level 
was unknown or unmeasurable, it was assumed to be half of the LLOQ. Residual exogenous 




was assumed that there was no exogenous FVIII remaining when the dose was administered. The 
standard 1- and 2-compartment models were tested. For each, three different residual error 
models were explored: additive, proportional, and combined additive/proportional. 
Following this step, between subject variability (BSV) terms were added to PK parameters using 
an exponential form. For example: 
𝐶𝐿𝑖 = 𝐶𝐿𝑝𝑜𝑝 ∙ 𝑒
𝜂𝑗 
where 𝐶𝐿𝑖 is an individual’s clearance, 𝐶𝐿𝑝𝑜𝑝 is the population value for clearance, and 𝜂𝑗 is the 
individual’s deviation from population value. The 𝜂 values follow a normal distribution with a 
mean of zero, such that the PK parameters are log-normally distributed. Decision-making during 
these steps was driven by changes in the objective function value (ΔOFV) and shrinkage of the 
random effects.  
The inclusion of explanatory covariates helps to minimize unpredictable BSV. Only 
covariates that were consistently available for all data sources were investigated; these included 
body weight, fat-free mass (calculated from body weight, age, and height using the maturation 
model defined by Al-Sallami et al [194]), age, and brand. Preliminary covariate analysis 
consisted of examining plots of 𝜂-values versus each covariate. Covariates were then added to 
the model in a stepwise manner, and either kept or removed based on their effect on OFV, BSV, 
and parameter estimates. Body weight, fat-free mass, and age were incorporated prior to brand so 
that demographic differences between datasets were not falsely attributed to brand. Body size 
metrics were modelled using allometric functions; a variety of functions were considered to 










𝐶𝐿𝑖 = 𝐶𝐿𝑝𝑜𝑝 ∙ (1 + 𝜃𝑐𝑜𝑣−𝐶𝐿 ∙
𝑐𝑜𝑣𝑖 − 𝑐𝑜𝑣𝑚𝑒𝑑
𝑐𝑜𝑣𝑚𝑒𝑑
) ∙ 𝑒𝜂𝑖 
𝐶𝐿𝑖 = 𝐶𝐿𝑝𝑜𝑝 ∙ (1 + 𝜃𝑐𝑜𝑣−𝐶𝐿 ∙ 𝑚𝑎𝑥 (0,
𝑐𝑜𝑣𝑖 − 𝑐𝑜𝑣𝑚𝑒𝑑
𝑐𝑜𝑣𝑚𝑒𝑑
)) ∙ 𝑒𝜂𝑖 
where 𝑐𝑜𝑣𝑖 is the individual’s value for the covariate, 𝑐𝑜𝑣𝑚𝑒𝑑 is the median value for the 
covariate, and 𝜃𝑐𝑜𝑣−𝐶𝐿 is the estimated effect of the covariate on CL. 
After taking body size and age effects into account, the effect of brand was explored. Initially, 
each brand was modelled with its own covariate effect either on CL and V1.  
𝐶𝐿𝑖 = 𝐶𝐿𝑝𝑜𝑝 ∙ (1 + 𝜃𝐵𝑟𝑎𝑛𝑑1−𝐶𝐿 ∙ 𝐵𝑟𝑎𝑛𝑑1) ∙ (1 + 𝜃𝐵𝑟𝑎𝑛𝑑2−𝐶𝐿 ∙ 𝐵𝑟𝑎𝑛𝑑2)⋯
∙ (1 + 𝜃𝐵𝑟𝑎𝑛𝑑7−𝐶𝐿 ∙ 𝐵𝑟𝑎𝑛𝑑7) ∙ 𝑒
𝜂𝑖 
where 𝐵𝑟𝑎𝑛𝑑𝑖 = 1 if the individual was dosed with Brand 𝑖; otherwise, 𝐵𝑟𝑎𝑛𝑑𝑖 = 0. 
Subsequently, brands were grouped together according to results of the previous runs, or based 
on their source (e.g. plasma-derived, recombinant) and structure (e.g. full-length, B-domain 
deleted) in an effort to reduce the number of model parameters.  Grouping schemes are 
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The final SHL FVIII model was evaluated in several steps. First, graphical techniques 
were employed to assess the model’s goodness-of-fit and to assure that all model assumptions 
were met. Bootstrap analysis was also performed to assess estimated parameters and their 
associated confidence intervals. One thousand datasets consisting of 400 individuals were 
generated by randomly sampling the original dataset with replacement; to ensure all groups were 
represented in the bootstrap datasets, the original dataset was stratified according to age and 
brand. Parameter estimation was performed for each dataset and the median parameter estimates 




To evaluate the model for use in Bayesian forecasting, internal cross validation and 
limited sampling analysis were performed. A 5-fold cross validation was performed, meaning the 
dataset was randomly split into 2 subsets, one containing 80% of the data (the learning subset) 
and the other the remaining 20% (the validation subset). Relative error on individual PK 





where 𝑃𝐶𝑉 is the individual parameter estimate (CL, V1, half-life) obtained during the cross 
validation using Bayesian forecasting and 𝑃𝑓𝑢𝑙𝑙 is the “true” value estimated from the initial 
dataset. 
Limited sampling analysis can be used to determine how well the model can predict 
individual PK parameters from sparse samples. Using a method similar to that described by 
Brekkan [178], a population of 1000 virtual subjects was generated from the final SHL FVIII 
model using covariate distributions from the original dataset. For each virtual subject, a 
treatment regimen corresponding to 50 IU kg-1 on a Monday-Wednesday-Friday schedule was 
simulated for 4 weeks, with the last Friday dose being used for analysis. Different limited 
sampling schemes consisting of convenient sampling times (e.g. predose, peak, 24 hours post-
infusion) are described in detail in Table S5; a total of 34 designs were tested. Each design was 
used to obtain estimates of individual PK parameters using Bayesian forecasting, and estimates 
from the limited sampling strategies were compared to those obtained from the full sampling 








where 𝑃𝐿𝑆𝑆 is the parameter estimate from the limited sampling strategy and 𝑃𝑓𝑢𝑙𝑙 is the 
parameter estimate from the rich sampling design. 
  External evaluation was performed using data extracted from the WAPPS-Hemo 
database. Using Bayesian forecasting, PK outcomes including clearance, central volume, half-
life, and time with FVIII activity above 2% (TAT2%) were estimated using both the generic 
SHL FVIII model and a brand-specific model. The evaluation dataset was extracted on 
September 14, 2018 and contained PK for 394 patients on three brands of factor product: 
Kovaltry (full-length rFVIII), ReFacto AF (BDDrFVIII), and Fanhdi/Alphanate (intermediate 
purity pdFVIII, not included in the modelling dataset). PK data for Xyntha, a BDDrFVIII 
products produced using the same manufacturing process as ReFacto AF but calibrated using a 
different assay, was also included in the evaluation; Xyntha doses were scaled by a factor of 1.38 
to account for the difference in calibration, as done in Abrantes et al [182]. Patients ranged 
between <1 and 78 years of age and weighed between 10.6 and 138.8 kg.  
 
Results 
An abridged log of model building steps is found in Table S3. A 2-compartment structure 
with a combined residual error model and random effects on clearance (CL) and central volume 
(V1) was found to be the superior base model; random effects were not included on 
intercompartmental clearance (Q) or peripheral volume (V2) due to high shrinkage (>40%). Of 
the two body size metrics available, fat-free mass had the strongest correlation with 𝜂𝐶𝐿 and 
𝜂𝑉1(0.558 and 0.808, respectively) and provided the greatest improvement to the model in terms 




28.1%). The addition of a fat-free mass effect on V2 further reduced the OFV by 116. Based on 
covariate plots (shown in Figure S1), the effect of age on CL was explored. Power, linear, and 
piecewise linear functions for the age effect were investigated. Ultimately, a piecewise linear 
function with no age effect below the median age was selected.  
 
Figure 11. Boxplots of 𝜼-values for clearance (left) and central volume (right) across brands 






After accounting for body size and age, there still appeared to be significant differences across 
brands as shown in Figure 11. Initially, a unique effect for CL and V1 was estimated for each 
brand. In an effort to reduce the number of model parameters, brands were grouped in a number 
of ways. We began by estimating an individual effect on CL and V1 for each of the brands 
included in the dataset, using Advate as the reference brand (Table 9, Scheme 1). Based on the 
results of this run, effects were either removed (when effect sizes were below 10%) or combined 
(when effect sizes were within 10% of one another). The brand-specific effects of Kovaltry on 
CL and of Kogenate and Octanate on V1 were removed (Table 9, Scheme 2). We also explored a 
grouping scheme based on the source and structure (Table 9, Schemes 3 and 4, respectively) of 
the factor products. While grouping scheme 2 produced the lowest OFV (25325), grouping 
scheme 4 was ultimately selected for the final model. This decision was driven by the objective 
of building a model that can be used for all SHL FVIII products. Since grouping scheme 4 is 
based on the source and structure of the product, choosing a group for a product not included in 
the model dataset is intuitive. Although OFV is somewhat increased for this scheme (ΔOFV = 
+64), parameter estimates (including BSV) were relatively unchanged. The final model is 












∙ (1 + 𝜃𝐴𝐺𝐸−𝐶𝐿 ∙ 𝑚𝑎𝑥 (0,
𝐴𝐺𝐸 − 21.0
21.0
)) ∙ (1 + 𝜃𝑃𝐷−𝐶𝐿 ∙ 𝑃𝐷) ∙ (1 + 𝜃𝐵𝐷𝐷−𝐶𝐿 ∙ 𝐵𝐷𝐷) ∙ 𝑒
𝜂𝐶𝐿





∙ (1 + 𝜃𝑃𝐷−𝑉1 ∙ 𝑃𝐷) ∙ (1 + 𝜃𝐵𝐷𝐷−𝑉1 ∙ 𝐵𝐷𝐷) ∙ 𝑒
𝜂𝑉1
𝑄 = 𝑄𝑝𝑜𝑝













where 𝑃𝐷 = 1 for plasma-derived products and 𝐵𝐷𝐷 = 1 for B-domain deleted products. Final 




Table 10. Parameter estimates for the final SHL FVIII model 
Parameter Estimate %RSE 
95% Confidence 
Interval 
Clearance, CL (L h-1) 0.238 3.6% (0.221, 0.254) 
   FFM effect on CL (𝜃𝐹𝐹𝑀−𝐶𝐿) 0.794 6.1% (0.699, 0.883) 
   Age effect on CL (𝜃𝐴𝐺𝐸−𝐶𝐿) -0.205 14.5% (-0.259, -0.145) 
Central volume, V1 (L) 3.01 2.5% (2.85, 3.14) 
   FFM effect on V1 (𝜃𝐹𝐹𝑀−𝑉1) 1.02 4.2% (0.940, 1.11) 
Intercompartmental clearance, Q (L h-1) 0.142 14.4% (0.107, 0.186) 
Peripheral volume, V2 (L) 0.525 7.0% (0.457, 0.600) 
   FFM effect on V2 (𝜃𝐹𝐹𝑀−𝑉2) 0.787 16.5% (0.557, 1.07) 
Plasma-derived on CL (𝜃𝑃𝐷−𝐶𝐿) -0.126 54.0% (-0.232, 0.023) 
Plasma-derived on V1 (𝜃𝑃𝐷−𝑉1) -0.104 52.2% (-0.195, 0.017) 
BDD on CL (𝜃𝐵𝐷𝐷−𝐶𝐿) 0.309 23.3% (0.175, 0.461) 
BDD on V1 (𝜃𝐵𝐷𝐷−𝑉1) 0.159 32.4% (0.060, 0.262) 
BSV on CL (%) 41.1% 4.9% (37.3%, 44.9%) 
BSV on V1 (%) 32.4% 7.0% (28.3%, 37.2%) 
CL-V1 Correlation 0.703 5.2% (0.624, 0.765) 
Proportional error (%) 17.4% 4.8% (16.0%, 19.3%) 
 
Goodness-of-fit plots indicate that the model described the data well, with R2 values of 
0.748 and 0.945 for the population and individual predictions, respectively (Figure 12).  Plots of 
the residual errors suggest that all assumptions of normality are followed, and the pcVPC 
demonstrates an adequate description of both median values and variability across all time points 
(Figure 13). Bootstrap analysis demonstrated the model’s stability; RSE% was ≤35% for all 
parameters except those associated with the PD brand group (RSE% ≈50%; Table 10, Figure S2, 
Figure S3) and the additive error component (≥90%), which was subsequently removed. Internal 
cross-validation was performed to evaluate the model’s utility for Bayesian forecasting. The 
results summarized in Table S4 and Figure S4 show low errors (95th percentile of error <2%) on 
all parameters of interest (CL, V1, half-life, and TAT2%). Optimal sampling analysis further 
evaluated the model’s ability to accurately estimate PK parameters from sparsely sampled data. 
Estimates of half-life and time to 2% (TAT2%) from sampling designs containing as few as two 




Errors appear to be largest in sampling schemes that contain only a 72h point in tail of the curve, 
as this sample is likely to be BLQ for a significant proportion of the virtual population. The full 




Figure 12. Individual predicted values from the final SHL FVIIII model versus observed values 





Figure 13. Prediction-corrected visual predictive check (pcVPC) for the final SHL FVIII model 
shown on linear (top) and log (bottom) scales. Shaded regions are the 90% confidence intervals 






Figure 14. Errors on estimates of half-life (top) and time to 2% activity (TAT2%, bottom) from 





Using data from the 394 patients collected through the WAPPS-Hemo network, we 
compared the performance of the generic SHL FVIII model to brand-specific models for brands 
of FVIII products in each of the brand groups of the final model: Kovaltry (full-length rFVIII), 
ReFacto AF/Xyntha (BDDrFVIII), and Fanhdi/Alphanate (pdFVIII). In each case, Bayesian 
forecasting produced similar estimates of clearance, central volume, half-life, and TAT2% 
(Figure 15) from both models (Kovaltry: 𝑅2 = 0.94 – 0.97; ReFacto AF/Xyntha: 𝑅2 = 0.86 – 
0.94; Fanhdi/Alphanate: 𝑅2 = 0.94 – 0.99); the correlation is slightly poorer in the ReFacto AF 





Figure 15. Comparison of PK parameter estimates generated from the SHL FVIII model and 
brand specific models for Kovaltry (blue, 𝒏 = 213), ReFacto AF/Xyntha (purple, 𝒏 = 132), and 





This study describes the development and evaluation of a generic PopPK model for SHL 
FVIII products, built on a dataset containing data measured using the one-stage assay for seven 
different brands of SHL FVIII. The estimates of population PK parameters were similar to those 
reported in published brand-specific models despite differences in modelling data, approach, and 
objective (Table 11).  
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Fat-free mass explained a significant portion of the BSV on CL and V1 and was likely 
superior to total body weight due to its better correlation to plasma volume. Age was also found 
to be a significant covariate for CL, possibly acting as a surrogate for changes in levels of vWF 
[119], an important predictor of FVIII clearance [145]. It has been shown that vWF levels 




lives among these patients. The choice of a piecewise linear function to describe this age effect 
was primarily due to high correlation between FFM and age in children and teenagers. Including 
both covariates for patients in this age range produces a falsely high estimate of the FFM effect 
on CL, which in turn results in half-life estimates decreasing when FFM increases. As in the 
brand-specific models developed for WAPPS-Hemo, the median age (21 years) was selected as 
the cut-off for the age effect; this value is physiologically plausible, as vWF levels are fairly 
stable up to this age [120] and the correlation between age and FFM is much weaker after 
puberty (Figure S5). Unfortunately, vWF could not be directly included in the model because 
patient vWF levels were not available for all brands in the modelling dataset; blood group (which 
can also act as a surrogate for vWF) was also not available consistently and therefore could not 
be included. However, published models for FVIII that include vWF or blood group as 
covariates on CL had similar unexplained BSV on CL; moreover, unexplained BSV on CL only 
decreased by 5-8% after adding vWF or blood group compared to the base or structural model 
[184,188]. For the final SHL FVIII model described here, unexplained BSV on CL and V1 
remained high (42% and 31%, respectively) in the final SHL FVIII, even after incorporation of 
explanatory covariates; one possible explanation for this observation is inter-laboratory 
variability, as the modelling dataset was compiled from numerous sources. For the one-stage 
assay, this variability has been estimated to be around 10% for peak levels, but closer to 35% at 
levels below 50 IU L-1 [195–198]. 
This model was developed with two purposes in mind. First, the model is intended for 
use in Bayesian analysis to produce accurate estimations of relevant PK parameters from sparse 
patient data. To evaluate the model for this purpose, 5-fold cross-validation and optimal 




purpose. Secondly, it was hoped that by combining data from a variety of SHL FVIII products, 
we could develop a model that performs Bayesian estimation accurately for all brands of SHL 
FVIII, including those not included in the modelling dataset. To assess this capability, we 
compared the estimates of PK parameters for 49 patients on Fanhdi/Alphanate (a plasma-derived 
SHL FVIII) produced by the generic SHL FVIII model and a dedicated Fanhdi/Alphanate model. 
Agreement between the estimates from each model was good (R2 ≥ 0.94 for 𝑦 = 𝑥 regression for 
all parameters), suggesting that the models produce similar predictions of the parameters of 
interest. Based on these results, the model seems capable of predicting PK for brands outside the 
original covariate space, and may prove to be especially valuable for brands for which there is no 
dedicated PopPK model. An additional strength of the model is the ability to leverage pediatric 
data from other products when brand-specific pediatric data is unavailable.  
 Although it performed well in all evaluations, the model does have some limitations and 
there may be some instances in which a brand-specific model is more appropriate. For example, 
the covariate model of the SHL FVIII model was limited to values that were available across all 
seven brands. It is well known that additional covariates such as vWF, blood group, and 
hematocrit can be useful for predicting the PK of FVIII; a brand-specific model may allow for 
the incorporation of these covariates, resulting in lower unexplained BSV. Additionally, the 
modelling dataset does not contain pediatric PK data for all of the included brands; NovoEight 
alone represents over 60% of the data for children under the age of 5. If estimating PK in young 
patients, a brand-specific model may be preferable, provided that the model is built on enough 
patients, with an adequate proportion of the data coming from children. On the contrary, the SHL 
FVIII model allows for the leveraging of pooled pediatric data and may prove extremely useful 





In summary, we have developed a generic PopPK model for plasma-derived and 
recombinant SHL FVIII products measured using the one-stage assay. Fat-free mass, age, and 
brand of factor product were found to significantly influence PK parameters. All evaluation steps 
suggest that the model is fit for Bayesian forecasting and capable of accurately predicting 





Chapter 5: Development of a population pharmacokinetic model for 
recombinant factor IX and its use in evaluating limited sampling strategies for 
pediatric patients 
 
This chapter is reflective of an original manuscript prepared by the Ph.D. candidate (Alanna 
McEneny-King) for submission to Journal of Thrombosis and Haemostasis. All pertinent 




Hemophilia B is an inherited bleeding disorder resulting from a deficiency of functional 
clotting factor IX (FIX). Consequently, hemophilia B patients have a lowered clotting ability and 
are thus prone to bleeding episodes, which may occur spontaneously among the most severe 
patients (i.e. those with <1 IU dL-1 or 1% of normal FIX activity). Joints are particularly prone to 
such bleeding events and irreversible joint damage can occur, severely impacting physical 
activity and quality of life. Although recent evidence suggests that hemophilia B may not be as 
severe as hemophilia A [199], several studies have demonstrated the dramatic reduction in 
overall, spontaneous, and joint bleeds achieved with prophylaxis as compared with on-demand 
treatment [49,200,201].  Thus, regular prophylaxis is considered to be the optimal approach for 
preventing bleeds and preserving joint function in hemophilia B patients. 
A common goal of hemophilia therapy is to maintain clotting factor levels above 1 IU dL-
1 throughout the week, thereby converting the patient from a severe to moderate phenotype. 
Though this target is largely based on observations in hemophilia A patients [7,10,68], there was 
no difference found in bleeding phenotype between young hemophilia A and B patients to 




recommendation that prophylaxis be initiated at a young age [11,203–207], a ‘one size fits all’ 
dosing regimen is difficult to define due to wide inter-patient variability in pharmacokinetics 
(PK) and, particularly in the case of hemophilia B, a lack of evidence in support of a specific 
therapeutic target [208]. 
The high between subject variability (BSV) and relatively low inter-occasion variability 
(IOV) observed for FIX [18,209,210] suggests that FIX dosing regimens should be tailored to the 
individual for reasons of both safety and cost-effectiveness [211]. While the classic approach to 
PK-tailoring has been hampered by intense sampling requirements, recent guidance from the 
International Society of Thrombosis and Haemostasis advocates for a population PK (PopPK) 
approach to dose individualization [169]. The PopPK technique uses Bayesian methods to 
estimate individual PK parameters, with a PopPK model providing informative prior knowledge 
of typical values of PK parameters, estimates of variability, and influential covariates.   
The first recombinant FIX (rFIX) product (nonacog alfa, BeneFIX®) was approved by 
the US Food and Drug Administration in 1997; two other standard half-life (SHL) recombinant 
products (nonacog gamma [RIXUBIS®] and trenonacog alfa [IXINITY®]) followed in 2013 and 
2015, respectively. While all three rFIX products are similar to plasma-derived FIX, small 
differences exist between the brands. IXINITY corresponds to the Thr-148 polymorph of 
plasma-derived FIX, while BeneFIX and Rixubis contain the less common Ala-148 variant 
[212]. Also, the amount of activated factor IX was found to be significantly lower for Rixubis as 
compared to BeneFIX [213]. Despite these differences, pharmacokinetic studies have 
demonstrated that both new rFIX products are bioequivalent (RIXUBIS) or non-inferior 




derived and recombinant FIX products, particularly with regards to clearance [214], suggested to 
arise from biochemical variations (e.g. under-carboxylation).  
For these reasons, we aimed to develop and evaluate a generic PopPK model for SHL 
rFIX products, using data collected through the Web Accessible Population Pharmacokinetic 
Service – Hemophilia (WAPPS-Hemo) project. A second aim of the study was to use the model 
to perform a limited sampling analysis, the results of which are applicable to an ongoing phase 
3/4 study (NCT03855280) to evaluate IXINITY PK in pediatric (<12 years old) patients, as 





Pharmacokinetic data for SHL rFIX was collected from both industry sources and routine 
hemophilia care through the WAPPS-Hemo project. The model was developed using FIX 
activity levels from 99 patients, measured using the one-stage assay. The median number of 
samples per infusion was 9 (range: 1 – 13). Samples that were below the limit of quantification 
(BLQ) comprised 1.5% of the dataset. A summary of the sampling characteristics and patient 






Table 12. Demographics of the patient population used to develop the generic SHL rFIX model. 
Data are presented as median (range) where appropriate. 
Sampling Information 
Total number of 
patients 
Total number of 
samples 




















BeneFIX 48 (52%) 
28.3  
(3.8 – 68.7) 
71  
(18.5 – 187) 
54.6  
(14.3 – 99.6) 
49.8  
(21.7 – 120) 
IXINITY 37 (0%) 
23.7  
(4 – 64.5) 
78  
(14 – 145) 
59.5  
(11.5 – 85.6) 
75.1  
(52.3 – 83.4) 
Rixubis 14 (100%) 
39.1  
(6.3 – 72.2) 
69  
(31 – 85) 
53.6  
(24.8 – 59.8) 
44.0  
(22.0 – 130.1) 
TOTAL 99 (39%) 
28.2  
(3.8 – 72.2) 
72  
(14 – 187) 
54.8  
(11.5 – 99.6) 
51.4  




PopPK model building, employing non-linear mixed effects modelling techniques, was 
implemented in NONMEM and PDxPop (v7.3 and v5.2, respectively; ICON Development 
Solutions, Ellicott City, MD, USA). Data and graphical analyses were conducted in MATLAB 
(R2017b, Mathworks, Natick, MA, USA). Samples that were BLQ were handled using the M3 
method [173]. 
The structural component of the model was developed first, and describes not only the 
exogenous dose, but also endogenous FIX production and residual FIX from prior doses.  
𝐶(𝑡) = 𝐴 ∙ 𝑒−𝛼𝑡 +𝐵 ∙ 𝑒−𝛽𝑡 + 𝑒𝑛𝑑𝑜𝑔𝑒𝑛𝑜𝑢𝑠 𝐹𝐼𝑋 + (𝑝𝑟𝑒𝑑𝑜𝑠𝑒 𝐹𝐼𝑋 − 𝑒𝑛𝑑𝑜𝑔𝑒𝑛𝑜𝑢𝑠 𝑟𝐹𝐼𝑋) ∙ 𝑒−𝛽𝑡  
The endogenous FIX component was assumed to be constant. When the endogenous level was 




FIX (i.e. greater than baseline FIX activity measured immediately before dose) decayed 
according to the terminal rate constant (β); if no predose measurement was available, it was 
assumed that only endogenous FIX remained at the time of dosing. The standard 1-, 2-, and 3-
compartment models were tested, with three different residual error (RUV) models (additive, 
proportional and combined) explored for each. Between subject variability (BSV) terms were 
added to PK parameters using an exponential form as follows: 
𝐶𝐿𝑖 = 𝐶𝐿𝑝𝑜𝑝 ∙ 𝑒
𝜂𝑖 
where 𝐶𝐿𝑖 is the clearance value for patient 𝑖,  𝐶𝐿𝑝𝑜𝑝 is the typical value of clearance for the 
population, and 𝜂𝑖 represents the individual’s deviation from the population value. The 𝜂-values 
for each parameter are normally distributed with a mean of zero, such that the PK parameters 
follow a log-normal distribution. Selection of the structural, BSV and RUV models was driven 
by changes in goodness-of-fit metrics (objective function value [OFV], Akaike information 
criterion [AIC], or Bayesian information criterion [BIC]), diagnostic plots, plausibility of 
parameter estimates, and shrinkage of random effects. 
 To minimize unpredictable BSV, explanatory covariates were incorporated into the 
model. All data sources provided total body weight, height, age, and brand; fat-free mass (FFM) 
was calculated from body weight, age, and height using the maturation model defined by Al-
Sallami et al [194]. Plots of 𝜂-values versus each covariate were used for preliminary analysis. 
Covariates were then added in a stepwise manner, and kept based on their effect on OFV, BSV, 
and parameter estimates. Body size metrics were modelled using power functions; age effect was 






The final SHL rFIX model was evaluated using a variety of techniques. First, diagnostic 
plots were used to assess the model’s goodness-of-fit and to ensure that that all model 
assumptions were met. A prediction-corrected visual predictive check (pcVPC) was generated to 
evaluate the model’s predictive potential. Next, bootstrap analysis was performed with 
replacement to evaluate model stability and estimate confidence intervals around PK parameters. 
Internal cross-validation and limited sampling analysis (LSA) were used to evaluate the model 
for use in Bayesian forecasting. In more detail, a 10-fold cross-validation was performed; 90% of 
the data was used to build the model (learning subset) and the remaining 10% was used for 
evaluation (validation subset). Relative error on individual PK parameters was calculated using 





where 𝜑𝐶𝑉 is the parameter estimate obtained from the cross-validation and 𝜑𝑓𝑢𝑙𝑙 is the “true” 
value estimated from the complete modelling dataset. This process was repeated with 100 
random splits of the data to avoid any biases.  
Finally, LSA was used to determine which samples are most critical for the estimation of 
various parameters by Bayesian forecasting. A population of 1000 virtual individuals was 
simulated, with the same demographic and PK parameter distributions as the original modelling 
dataset. The simulated dosing regimen consisted of a 5-minute infusion of 50 IU kg-1 (rounded to 
the nearest 250 IU to account for available vial sizes) every Monday and Thursday. The regimen 
was simulated for 4 weeks to ensure steady state was reached, and the final Thursday dose was 




12, 24, 36, 48, 72, and 96 h post-infusion) was used as the reference case. A total of 31 limited 
sampling designs containing 2-3 samples each were tested. Estimates of individual PK 
parameters from the limited sampling strategies were compared to those from the full sampling 





𝐴𝑏𝑠𝑜𝑙𝑢𝑡𝑒 𝐸𝑟𝑟𝑜𝑟 = |𝐸𝑟𝑟𝑜𝑟| 
 
where 𝜑𝑓𝑢𝑙𝑙 and 𝜑𝐿𝑆𝑆 represent the estimates of PK parameter 𝜑 estimated by the rich and 
limited sampling strategies, respectively. 
 
Limited sampling analysis for pediatric clinical trial 
 A second LSA was performed to determine if any of the planned sampling times for the 
IXINITY pediatric trial could be omitted without compromising the accuracy of the parameter 
estimates. To do so, three populations (𝑛 = 1000 each) were simulated, representing 2-, 5-, and 
11-year-old boys. Body weight and height distributions were taken from the NHANES database 
for calculation of fat-free mass [215].  The intended sampling schedule is based on guidance 
from the European Medicines Agency (EMA), and contains samples at predose, 0.25–0.5 h, 4–6 
h, 24–26 h, and 46–50 h; limited sampling designs were created by systematically removing 
these timepoints (the full set of designs is described in Table S6). Pharmacokinetic outcomes of 
interest for the trial include area under the plasma concentration-time curve (AUC), terminal 
half-life, maximum post-infusion plasma concentration (Cmax), incremental recovery (IVR), 




and time to 2% and 1% factor IX activity (TAT2% and TAT1%) were also assessed. Strategies 
were evaluated using error and absolute error. 
As model-independent methods are more commonly used for PK analysis in clinical trials 
than the PopPK approach [216], we explored how noncompartmental methods would fare in the 
same limited sampling conditions. Noncompartmental analysis (NCA) was performed using the 
SimBiology® app in MATLAB. To calculate the terminal rate constant (𝜆𝑧), a minimum of 3 
observations in the terminal phase spanning at least 2 half-lives is recommended [217]. Based on 
these guidelines, only the intended EMA-based sampling strategy and the five 4-sample subsets 
thereof were assessed using NCA. Estimates of half-life, clearance, Vss, and AUC were evaluated 




Model development and evaluation 
The final base model consisted of a 2-compartment structure with proportional RUV and random 
effects on clearance and central volume (V1). Of the body weight metrics available, fat-free mass 
had the strongest correlation with both 𝜂𝐶𝐿 and 𝜂𝑉1 (0.3415 and 0.5941, respectively) and its 
inclusion in the model significantly decreased both OFV (ΔOFV = –193) and BSV on CL (ΔωCL 
= –16%) and V1 (ΔωV1 = –23%). Addition of fat-free mass terms on Q and V2 resulted in further 
decrease of the OFV (ΔOFV = –133).The estimate of fat-free mass effect on V2 had high 
standard error but, due its physiologic relevance, was kept in the model with a fixed exponent of 




covariates. The final model is summarized by the following equation, with parameter estimates 











































Table 13. Parameter estimates for the final SHL rFIX model 
Parameter (unit) Estimate % RSE 95% Confidence Intervala 
Structural Model 
CLpop (dL h-1) 3.36 3.4% (0.314, 0.360) 
V1 pop (dL) 78.4 2.5% (7.46, 8.24) 
Qpop (dL h-1) 3.01 8.1% (0.261, 0.358) 
V2 pop (dL) 61.6 8.2% (5.36, 7.34) 
Covariate Effects 
FFM effect on CL 0.765 10.5% (0.594, 0.922) 
FFM effect on V1 0.893 8.7% (0.762, 1.06) 
FFM effect on Q 0.688 26.4% (0.303, 1.00) 
FFM effect on V2 1.00 (FIXED) 
Between Subject Variability 
𝜔𝐶𝐿 30.3% 8.5% (25.1%, 34.9%) 
𝐶𝑜𝑟𝑟𝐶𝐿−𝑉1 0.696 11.3% (0.522, 0.819) 
𝜔𝑉1 25.1% 12.2% (19.0%, 30.5%) 
Residual Unexplained Variability 
CV of proportional RUV 14.7% 9.1% (12.1%, 17.3%) 






Goodness-of-fit plots demonstrate that the model describes the data well, with 𝑅2 values of 0.904 
and 0.975 for the population and individual predictions, respectively (Figure 16), and residual 
plots confirm that all assumptions of normality are followed. The pcVPC suggests that the model 
is able to adequately describe the central tendency and the variability of the data across all time 
points (Figure 17).  
 
 





Figure 17. Population prediction-corrected visual predictive check (pcVPC) for the final SHL 
rFIX model. Shaded regions are the 90% confidence regions for the simulated percentiles. 
 
Bootstrap analysis showed estimates of all model parameters are stable; RSE% was below 15% 
for all parameters except the FFM effect on Q (Table 13). The model’s utility in Bayesian 
forecasting was evaluated using cross-validation, which resulted in low errors (median <1.5%; 
95th quantile <5.0% [Figure 18]) on all parameters explored (CL, V1, half-life, and TAT2%). Its 
ability to provide accurate estimates from sparsely sampled data was assessed using optimal 
sampling analysis, which revealed that key PK outcomes such as half-life and TAT2% can be 





Figure 18. Histograms of prediction errors on half-life, TAT2%, CL, and V1 estimates 
 
 
Limited sampling analysis for pediatric clinical trial 
 Results of the limited sampling analysis were very similar for all simulated ages; for this 
reason, only the results from the 2-year-old population are shown Table 14, Table 15, Figure 19 
and Figure 21. Full results for all nine PK outcomes from all 26 limited sampling designs can be 
found in Table S6. Compared to the 11-sample reference sampling scheme, the median [95th 
quantile (Q95)] absolute error on PK parameters estimated by the 5-sample EMA-based 
sampling scheme was below 6% [<16%], with the highest error being on trough levels and 






Omitting a single sample from EMA-based sampling 
 When only one sample is eliminated from the sampling design, the estimates for most PK 
parameters are largely unchanged compared to the reference EMA-based design (Table 14, 
Figure 19 [top]). The most crucial times to include are the predose sample (which greatly affects 
estimates of clearance, trough levels, and to a lesser degree, half-life) and the peak sample 
(which impacts central volume and, by consequence, Cmax) Omitting any one of the 6-, 24-, or 





Table 14. Error (presented as mean (range) in percent) and absolute error (presented as median 
[Q95] in percent) relative to the 10-sample design using Bayesian estimation 
Error Parameters 
Sampling Design Half-Life Clearance Vss AUC 
EMA-Based -0.2 (-15.7, 11.9) 0.1 (-10.8, 18.1) -0.4 (-14.1, 17.3) 0.2 (-15.3, 12.1) 
Pre-0.5-6-24 0.5 (-17.4, 13.8) -0.7 (-15.3, 20.5) -0.4 (-14.2, 17.2) 1.1 (-17.0, 18.0) 
Pre-0.5-6-48 0.04 (-17.1, 15.1) -0.3 (-13.7, 20.7) -0.5 (-14.6, 16.1) 0.6 (-17.2, 15.9) 
Pre-0.5-24-48 -0.3 (-15.4, 12.3) -0.1 (-15.6, 16.9) -0.7 (-20.4, 21.0) 0.4 (-14.5, 18.5) 
Pre-6-24-48 -0.4 (-18.1, 14.0) 0.1 (-14.5, 21.8) -0.3 (-24.3, 37.1) 0.3 (-17.9, 17.0) 
0.5-6-24-48 -3.4 (-22.9, 13.7) 3.9 (-12.7, 33.3) -0.8 (-14.8, 17.2) -3.3 (-25.0, 14.5) 
Pre-0.5-6 1.1 (-20.3, 18.6) -1.5 (-19.2, 29.7) -0.6 (-14.8, 16.1) 2.0 (-22.9, 23.8) 
Pre-0.5-24 0.4 (-17.4, 14.0) -1.0 (-17.1, 22.8) -0.8 (-20.5, 20.0) 1.4 (-18.6, 20.7) 
Pre-0.5-48 -0.03 (-16.8, 14.6) -0.6 (-16.4, 22.7) -0.9 (-21.2, 21.7) 0.9 (-18.5, 19.6) 
Pre-6-24  0.3 (-19.5, 15.9) -0.7 (-18.6, 31.2) -0.4 (-24.1, 36.9) 1.2 (-23.8, 22.8) 
Pre-6-48 -0.2 (-19.1, 15.7) -0.4 (-17.6, 23.2) -0.6 (-26.1, 32.4) 0.9 (-18.9, 21.3) 
Pre-24-48 -0.9 (-17.9. 11.8) -0.8 (-24.1, 28.4) -2.0 (-33.0, 29.6) 1.4 (-22.1, 31.7) 
0.5-6-24 -4.4 (-33.0 16.9) 5.7 (-18.6, 66.2) -0.9 (-15.3, 16.2) -4.4 (-39.8, 22.9) 
0.5-6-48 -3.8 (-27.8, 14.3) 4.7 (-16.5, 44.7) -0.7 (-14.9, 15.9) -3.8 (-30.9, 19.8) 
0.5-24-48 -3.4 (-23.1, 13.8) 3.9 (-13.7, 33.6) -0.8 (-20.7, 19.6) -3.3 (-25.1, 15.9) 
6-24-48 -3.5 (-23.4, 12.7) 3.9 (-14.0, 40.8) -0.7 (-24.0, 34.9) -3.2 (-29.0, 16.3) 
  
Absolute Error Parameters 
Sampling Half-Life Clearance Vss AUC 
EMA-Based 2.8 [7.8] 3.1 [9.5] 3.1 [9.5] 3.2 [9.3] 
Pre-0.5-6-24 3.4 [9.9] 4.2 [11.5] 3.1 [9.7] 4.3 [11.8] 
Pre-0.5-6-48 3.0 [8.5] 3.7 [10.0] 3.2 [9.7] 3.6 [10.5] 
Pre-0.5-24-48 2.8 [8.1] 3.5 [9.8] 3.7 [11.0] 3.5 [10.0] 
Pre-6-24-48 3.1 [8.7] 4.1 [12.5] 5.8 [17.3] 4.1 [12.0] 
0.5-6-24-48 4.2 [13.0] 4.8 [16.1] 3.1 [9.4] 4.7 [13.9] 
Pre-0.5-6 4.1 [11.4] 5.3 [13.7] 3.2 [9.7] 5.4 [14.8] 
Pre-0.5-24 3.4 [10.1] 4.6 [12.7] 3.7 [11.1] 4.7 [13.3] 
Pre-0.5-48 3.0 [8.7] 4.1 [11.3] 3.8 [11.3] 4.1 [12.0] 
Pre-6-24  3.6 [10.8] 5.0 [14.1] 5.8 [17.5] 5.0 [14.1] 
Pre-6-48 3.2 [9.0] 4.7 [13.3] 5.8 [17.7] 4.7 [13.2] 
Pre-24-48 3.3 [9.5] 5.3 [14.7] 7.7 [22.0] 5.4 [14.7] 
0.5-6-24 6.3 [17.9] 6.9 [24.4] 3.2 [9.6] 6.8 [19.8] 
0.5-6-48 4.6 [15.1] 5.7 [20.0] 3.2 [9.6] 5.6 [16.8] 
0.5-24-48 4.2 [12.9] 5.1 [16.7] 3.7 [11.1] 5.0 [14.5] 







Omitting multiple samples from EMA-based sampling 
 Several 3-sample designs perform well, particularly for the estimation of half-life (Figure 
19 [middle]) and AUC (median [Q95] absolute error ≤7% [<20%] for all 3-sample designs). The 
Predose-0.5h-48h strategy resulted in the lowest absolute errors across all outcomes of interest 
(median [Q95] <6.5% [<19%]), with the Predose-0.5-24h design producing similar results (Table 
14). Estimates of central volume, peak and trough levels, and times to critical factor levels were 
the most sensitive to sample timing, with the 95th percentile of error greater than 30% for some 
sampling schemes (Table S6). 
 A number of 2-sample strategies also produce reasonably accurate estimates of most PK 
parameters. In particular, half-life is still well-estimated (median absolute error <7%) for all 
strategies except for 0.5h-6h (Figure 19 [bottom]). Of particular note, the Pre-0.5h strategy 
produces PK parameter estimates that are similarly accurate to the optimal 3-sample design 
(median <7%; Q95 ≤20% - Table S6); however, errors on trough levels are slightly elevated (9% 








Figure 19. Half-life error relative to the rich 10-sample design for 4- (top), 3- (middle), and 2- 





 Results from the noncompartmental analysis are shown in Table 15. Relative to the rich 
11-sample design, estimates of CL, Vss, and AUC0-inf obtained from the EMA-based sampling 
design are fairly precise (median [Q95] absolute error <6% [≈20%]). However, half-life 
estimates are significantly under-predicted using this sampling strategy (mean error: –24.6%).   
 Omitting the 48-hour sample has the greatest impact on PK parameter estimates. With the 
exception of Vss, which was relatively unchanged, all other outcomes had substantially higher 
errors. Without this late sample, AUC is considerably underestimated (mean error: –44%), 
resulting in an overestimation of clearance (mean error: +27%); half-life was also severely 
underestimated, with mean error of –48%. Omission of the predose sample – which resulted in 
the largest error on most PK parameters when Bayesian methods were used – produced almost 
identical estimates to the full EMA-based sampling scheme when NCA was used. This is due to 
a difference in how the predose sample is used between the two methods. For NCA, the predose 
simply acts as a starting point (C0) while in Bayesian estimation, predose acts as a late time point 
(72–96 hours, depending on the day of the PK study) when knowledge of the previous dose is 
available, as was assumed in this study. Of the post-infusion samples, exclusion of the 6-hour 
point produced the most accurate estimate of clearance and AUC0-inf; half-life was best predicted 
from the strategy omitting the 24-hour sample, while the steady state volume of distribution was 





Table 15. Error (presented as mean (range) in percent) and absolute error (presented as median 
[Q95] in percent) relative to the 10-sample design using noncompartmental analysis 
Error Parameter 
Sampling Design Half-Life Clearance Vss AUC 
EMA-Based Sampling -24.6 (-73.3, 65.2) 4.0 (-19.2, 61.8) -3.7 (-23.9, 27.0) -3.0 (-38.2, 23.7) 
Pre-0.5-6-24 -48.3 (-80.7, 37.6) 26.7 (-22.5, 161.7) 7.5 (-18.6, 91.8) -19.4 (-61.8, 29.1) 
Pre-0.5-6-48 -29.9 (-75.2, 35.3) -8.1 (-38.5, 67.5) -19.8 (-44.1, 23.1) 10.8 (-40.3, 62.6) 
Pre-0.5-24-48 -33.2 (-76.4, 83.8) -5.2 (-40.9, 58.6) -16.5 (-47.8, 15.7) 7.2 (-36.9, 69.2) 
Pre-6-24-48 -20.7 (-73.3, 65.2) 19.6 (-9.0, 83.8) 16.1 (-6.7, 51.0) -15.6 (-45.6, 9.9) 
0.5-6-24-48 -24.6 (-73.3, 65.2) 4.0 (-19.2, 62.1) -3.6 (-23.8, 27.1) -3.1 (-38.3, 23.7) 
  
Absolute Error Parameter 
Sampling Design Half-Life Clearance Vss AUC 
EMA-Based Sampling 27.2 [56.4] 6.1 [20.5] 5.4 [14.6] 6.2 [17.3] 
Pre-0.5-6-24 49.9 [69.0] 24.4 [58.0] 7.4 [25.5] 19.6 [36.7] 
Pre-0.5-6-48 30.3 [56.6] 11.1 [27.3] 20.2 [34.1] 12.1 [35.8] 
Pre-0.5-24-48 34.0 [58.5] 9.3 [24.0] 16.7 [32.9] 9.6 [30.5] 
Pre-6-24-48 24.0 [54.4] 18.9 [38.3] 15.3 [32.5] 15.9 [27.7] 
0.5-6-24-48 27.2 [56.4] 6.2 [20.6] 5.3 [14.6] 6.2 [17.4] 
 
 
 Due to the significant bias observed in half-life estimates for all sampling strategies, we 
investigated the impact of including a later time point. If the EMA-based sampling design is 
supplemented with a 72 h or 96 h sample, the mean error on half-life improves from –24.6% to –
2.5% and +2.0%, respectively, without significantly altering the estimates of other PK 
parameters of interest (Figure 20). If the addition of another sampling time is problematic, recall 
that the omission of predose has little impact on estimates obtained using NCA. Therefore, an 
alternative strategy consisting of samples at peak (0.5 h), 6 h, 24 h, 48 h, and either 72 or 96 
hours may be more appropriate to accurately estimate all relevant PK parameters when 





Figure 20. Impact of inclusion of a late sampling tie (72 or 96 h) on PK parameter estimates 
compared to EMA-based sampling strategy when using NCA  
 
Discussion 
 We report the development and evaluation of a PopPK model for all currently available 
SHL rFIX products, built on data measured using the one-stage clotting assay and amassed from 
both industry trials and routine hemophilia care through the WAPPS-Hemo project. The 
structural and covariate models, and parameter estimates, are within the space of those reported 
in the literature [178,218–220], despite differences in both modelling objectives and approaches, 
and in the products included in the modelling datasets across the referenced studies. Inclusion of 
fat-free mass explained substantial portions of the BSV on both CL (ΔBSVCL = –16.1%) and V1 
(ΔBSVV1 = –23.0%), and resulted in a greater reduction in OFV compared to total body weight 
(ΔOFV = –193 for FFM; ΔOFV = –164 for BW). The objective function value was further 
decreased by addition of FFM terms on Q and V2 (ΔOFV = –121), but age was not found to be a 




RIXUBIS comprised only 14% of the dataset, and all RIXUBIS data was very sparsely sampled 
(mean number of samples per infusion: RIXUBIS – 3.0; BeneFIX – 8.4; IXINITY – 11.1). When 
an effect for IXINITY was included on CL and V1, the OFV did not substantially decrease, the 
magnitude of the covariate effect was small (<10% difference from the reference group), and 
unexplained BSV on CL and V1 were effectively unchanged. For these reasons, no brand effect 
is included in the final model. This may change in future updates to the model, as the WAPPS-
Hemo project continues to collect data from all three products to facilitate this comparison. 
 This model was built to tackle two objectives. The first is development of a model for 
Bayesian forecasting for use on the WAPPS-Hemo platform; this requires a model that can 
produce accurate estimations of all relevant PK parameters from sparsely sampled patient data. 
To evaluate the model in this capacity, 10-fold cross-validation and limited sampling analysis 
were performed, and the results demonstrate that the model is well-suited to this purpose. The 
second aim of the study was to determine how omission of one or two of the intended samples 
would affect the estimation of key PK outcomes in a clinical trial investigating the PK of 
IXINITY in pediatric patients. When Bayesian forecasting is used to estimate the PK parameters, 
one sample can be removed without compromising the accuracy of the outcomes of interest. In 
fact, several 3-sample designs also maintain low errors (absolute error Q95 <15%). However, 
these results do not hold when noncompartmental methods are used. In fact, even the intended 
EMA-based sampling results in considerably underestimates half-life; an additional sample at 72 
or 96 h post-infusion is needed for its accurate estimation. This is not unexpected, as it has been 
noted that FIX requires relatively long sampling to obtain sufficient data to accurately estimate 
PK [221]; many studies sampling for 48 hours report a half-life of less than 20 hours, while 




Despite this shortcoming, AUC, clearance, and Vss were estimated quite accurately using the 
EMA-based sampling strategy for NCA (Table 15). This limited sampling analysis serves to 
highlight the robustness of the Bayesian approach, and its flexibility with respect to missing 







Figure 21. Comparison of errors on estimates of half-life (blue), clearance (yellow), Vss (orange), and AUC (purple) from Bayesian estimation (left) 
and NCA (right) 






 We developed a PopPK model for rFIX and evaluated it for use in Bayesian forecasting 
on the WAPPS-Hemo platform. The model was built using data for three different brands of 
rFIX collected from both clinical trials and routine hemophilia care, and leveraged pooled 
pediatric PK data to address a practical problem when brand-specific pediatric data was 
unavailable. To this end, a limited sampling analysis was performed using the model to 
determine which sampling times can be omitted if pediatric sample volume limitations prevent 
participating centres from collecting samples at all the intended times.  When Bayesian 
forecasting is used, accurate estimates of all PK outcomes of interest can be obtained from as 
few as 3 samples; if NCA is used, there is little flexibility to omit samples while maintaining the 






Chapter 6: Limited sampling strategies for accurate determination of 
extended half-life factor VIII pharmacokinetics in severe hemophilia A 
patients 
 
This chapter is reflective of an original manuscript prepared by the Ph.D. candidate (Alanna 
McEneny-King) for submission to Haemophilia. All pertinent dialogue in this chapter was 




Hemophilia A is a rare and hereditary coagulation disorder characterized by a lack of 
functional coagulation factor VIII (FVIII). This lowered clotting ability can result in internal 
bleeding, often into the joints, resulting in debilitating arthropathy. In severe hemophilia A 
patients (i.e. those with less than 1 IU dL-1, or 1% of normal FVIII activity), these bleeds may 
occur spontaneously. It has long been noted that maintaining FVIII activity levels above 1 IU dL-
1, even modestly, can greatly improve patient outcomes. Ahlberg observed that the chronic joint 
damage observed in severe hemophilia patients was rare among those with factor activity above 
2–3  IU dL-1 [7]; Nilsson and colleagues later found that patients who spent more time with 
factor levels above 1 IU dL-1 had improved joint function [8]. More recently, bleeding rate has 
been shown to be correlated with time per week with FVIII < 1 IU dL-1 in both adults and 
children [10,222]. The concept of prophylactic factor replacement therapy is derived from these 
clinical observations, and is the only known method for the prevention of joint damage [9].  
Although the prophylactic use of clotting factor concentrates has greatly improved 




The half-life of conventional FVIII products is relatively short (approximately 12 hours [167]), 
necessitating frequent injections in order to maintain FVIII activity levels above 1 IU dL-1. This 
demanding infusion schedule often results in the need for central venous lines in young children 
and reduced adherence among adolescents [223,224].  
In an attempt to alleviate this treatment burden, a number of strategies have been 
employed to improve the pharmacokinetic (PK) profile of recombinant FVIII (rFVIII). One 
approach is the fusion of rFVIII to the Fc domain of IgG1, taking advantage of the endogenous 
IgG recycling pathway [225]. The resulting product (rFVIII Fc fusion protein [rFVIIIFc], or 
efraloctacog alfa) demonstrates, on average, a 1.5-fold increase in half-life over standard half-life 
rFVIII products [108].  This more favourable PK profile allows for a dosing interval of 3–5 days, 
compared to the 2–3 day interval for rFVIII. 
Although rFVIIIFc demonstrates an extended PK profile compared to rFVIII, it also 
exhibits the wide and unpredictable variability in PK response observed in its standard half-life 
counterparts [226].  The mean (95% confidence interval) half-life of rFVIIIFc was reported to be 
18.8 (14.3–24.5) hours for adults [106], 14.9 (12.0 – 17.8) hours for children between the ages of 
6 and 11 [110], and 12.7 (11.2 – 14.1) hours for children from 2 to <6 years of age [110]. As a 
result, dosing regimens should be tailored to the individual patient. To obtain a tailored dose 
using a classical PK approach, the International Society of Thrombosis and Hemostasis 
recommends at least 10 post-infusion samples after a washout period; this method is both 
burdensome and risky for the patient, and impractical for routine use. The population PK 
(PopPK) approach allows for the determination of individual PK parameters from fewer samples 
than traditional methods. The combination of a Bayesian PK approach, which estimates 




and a limited sampling strategy (LSS) has been shown to produce accurate estimations of 
individual activity levels for conventional FVIII [57,227,228]. Optimal sampling windows have 
been suggested for both conventional and EHL clotting factor concentrates; current 
recommendations for EHL factors suggest using the guidelines for conventional FVIII (i.e. 4–8h, 
16–28 h, and 40–60 h) and adding a sample between 60 and 84 hours post-infusion [169]. 
However, formal investigations of LSSs for EHL FVIII products are lacking.   
The aim of this study was to identify LSSs for rFVIIIFc that allow for accurate 
determination of relevant PK parameters. Furthermore, the predictions generated from the LSS 






Factor activity profile simulation and statistical analyses were performed in Matlab (R2017b, 
Mathworks, Natick, MA, USA). Individual PK estimates of the simulated populations were 
obtained using Bayesian forecasting in NONMEM (v7.3, ICON Development Systems, Ellicott 
City, MD, USA).  
 
Population pharmacokinetic model 
The PopPK model used to generate estimates of individual PK parameters was developed 
by Nestorov et al [184] using data measured with the one-stage clotting assay. For this study, we 
used the parameters from the base model, as the final model included a von Willebrand factor 
effect on clearance and a hematocrit effect on central volume. The base model describes 




volume. Further description of the model can be found in Table 16. This rFVIIIFc model was 
developed on richly sampled data from 180 previously treated severe hemophilia A patients 
between 12 and 65 years of age, weighing between 42.0 and 127.4 kg. The base model also 
included a study effect on the additive residual error component; since the population in the 
phase 3 study (𝑛 = 164) was considerably larger than the phase 1/2a study (𝑛 = 16), the additive 
error corresponding to the phase 3 study was used here.  
 
Table 16. Details of the base rFVIIIFc model developed by Nestorov et al [184] 
Parameter Estimate Covariate Effects BSV (%) IOV (%) 
Clearance, CL (dL h-1) 1.72  31.1 21.9 





 13.8 10.5 
Intercompartmental 







Peripheral volume, V2 (dL) 5.79 
  Additive error (IU dL-1) 0.264 




Simulated populations and activity profiles 
An adult population of 1000 virtual 25-year-olds was generated, with PK parameter 
distributions taken from the published PopPK model described above [184]. Endogenous FVIII 
activity was assumed to be 0.25 IU dL-1 as all patients were reported to be severe and the assay’s 
lower limit of quantification (LLOQ) was reported to be 0.5 IU dL-1. For each individual, a 
treatment regimen of 50 IU kg-1 (rounded to the nearest 250 IU to account for available rFVIIIFc 




minutes. This regimen was simulated for four weeks to ensure steady state was reached, and the 
fourth Thursday dose or fifth Monday dose was used for analysis. Finally, the LLOQ for the 
simulations was defined as 1 IU dL-1 as this is the most common LLOQ in practice [229].      
Next, adolescent (12-year-olds) and pediatric (2-year-olds) populations were generated. 
Body weight distributions for each age were based on the empirical distributions found in the 
NHANES database [215], and PK parameters were simulated using the estimates from the 
Nestorov model. A description of the model derivation data and the populations simulated in this 
study can be found in Table 17. In the younger populations, where it was common for the 
Thursday or Monday predose to be below the limit of quantification (BLQ), an alternative dosing 
schedule was used, consisting of three weeks of Monday-Thursday dosing followed by doses on 
Monday and Wednesday in the fourth week, with the Wednesday dose being used for analysis; in 
this scenario, the predose sample is now 48 hours after the previous dose rather than 72 






Table 17. Demographic data of rFVIIIFc studies used for development of Nesterov model and of 
simulated populations.  
 
Study Populations Simulated Populations 
Phase 1/2a 
[106] 























25  12 2 
Doses (IU kg-1) 25 and 65 
25, 30, 35, 






13–16  5–8  6 
Sampling 
Duration (h) 
168–240   96–120  96 
Phase 1/2a study data presented as mean (range). Phase 3 study data presented as median 
(range). Simulated population data presented as median (range).  
Age was not explicitly simulated as it is not a covariate in the model.  
 
Design of limited sampling strategies 
We began with a rich sampling scheme that included a predose measurement (-0.5 h) and 
samples at 1, 24, 48, 72, and 96 hours post-infusion. Limited sampling schedules were created by 
systematically excluding sample points from this rich sampling scheme. Overall, twenty-one 
sampling schemes were created. Each scheme had between 1 and 5 samples. The details of the 
sampling schemes are described in Table 18. 
In addition to the timing of post-infusion samples, we also investigated the importance of 
handling a predose measurement appropriately. We compared two methods of predose handling: 
in Method A, no knowledge of prior doses was used for the estimation; in Method B, information 
about the date and dose of the previous infusion was incorporated. Additionally, we looked at the 
timing of this predose sample relative to the prior dose. For example, if the patient is on a 




sampled at 96 hours after the last dose while a PK study performed on Thursday will have a 
predose sampled at 72 hours after the last dose. For the two younger patient groups, the 
Wednesday PK study described above was also simulated.  With all combinations of predose 
handling and study day, a total of 126 sampling strategies were explored. Bayesian estimation 
was performed in NONMEM to obtain individual PK estimates from each sampling strategy, for 






Table 18. Details and nomenclature of tested limited sampling strategies. All doses were 50 IU 
kg-1 (rounded to the nearest 250 IU vial) unless otherwise indicated 
Timing of Samplesa 
(h) 
Handling of Predoseb 
Predose Method A Predose Method B 













-0.5, 1, 24, 48, 72, 96 AT1  AW1 BT1  BW1 
-0.5, 1, 24, 48, 72 AT2 AM2 AW2 BT2 BM2 BW2 
-0.5, 1, 24, 48, 96 AT3  AW3 BT3  BW3 
-0.5, 1, 24, 72, 96 AT4 AW4 BT4 BW4 
-0.5, 1, 48, 72, 96 AT5 AW5 BT5 BW5 
-0.5, 1, 72, 96 AT6 AW6 BT6 BW6 
-0.5, 1, 48, 96 AT7 AW7 BT7 BW7 
-0.5, 1, 24, 96 AT8 AW8 BT8 BW8 
-0.5, 1, 48, 72 AT9 AM9 AW9 BT9 BM9 BW9 
-0.5, 1, 24, 72 AT10 AM10 AW10 BT10 BM10 BW10 
-0.5, 1, 24, 48 AT11 AM11 AW11 BT11 BM11 BW11 
-0.5, 1, 24 AT12 AM12 AW12 BT12 BM12 BW12 
-0.5, 1, 48 AT13 AM13 AW13 BT13 BM13 BW13 
-0.5, 1, 72 AT14 AM14 AW14 BT14 BM14 BW14 
-0.5, 1, 96 AT15  AW15 BT15  BW15 
-0.5, 1 AT16 AM16 AW16 BT16 BM16 BW16 
1, 24 AT17 AM17 AW17 BT17 BM17 BW17 
1, 48 AT18 AM18 AW18 BT18 BM18 BW18 
1, 72 AT19 AM19 AW19 BT19 BM19 BW19 
1, 96 AT20  AW20 BT20  BW20 
1 AT21 AM21 AW21 BT21 BM21 BW21 
a -0.5 h indicates a predose sample. b ’Handling of Predose’ refers to whether information about 
the previous dose was incorporated into the estimation. c ‘Study Day’ refers to the day the dose is 
given for the PK study; the length of time since the last dose is indicated in parentheses. d The 
reference sampling scheme for the AM and BM series does not contain the 96 h sample, since 
the next  dose would be given at 72 h post-infusion in this scenario. Consequently, LSSs with the 






Evaluation of limited sampling strategies 
Each of the limited sampling strategies was evaluated by assessing the error and absolute 
error (AE) of the estimated PK parameters (clearance, central volume, half-life) and predicted 
activity at 72 and 96 hours post-infusion (C72 and C96 – troughs corresponding to a Monday-





𝐴𝑏𝑠𝑜𝑙𝑢𝑡𝑒 𝐸𝑟𝑟𝑜𝑟𝑖 = |𝐸𝑟𝑟𝑜𝑟𝑖| 
 
where 𝜑𝑖,𝑓𝑢𝑙𝑙 and 𝜑𝑖,𝐿𝑆𝑆 represent the estimates of PK parameter 𝜑 estimated by the rich and 
limited sampling strategies, respectively, for individual 𝑖. 
 
Trough levels at 72 and 96 hours guide clinical decision-making and drive dose 
adjustments, so accurate prediction of FVIII activity at these times is critical. In this study, we 
aimed to keep FVIII activity above 1 IU dL-1 at all times. If the predicted troughs (i.e. C72 and 
C96) were both above this value, the regimen was deemed appropriate; otherwise, the regimen 
required a dose adjustment. If the regimen decision was inconsistent between an LSS and the 
rich sampling strategy (i.e. if a trough predicted by an LSS was greater than 1 IU dL-1 but less 
than 1 IU dL-1 for the rich sampling strategy - or vice versa), it would result in an inappropriate 
dosing adjustment. This inappropriate dosing adjustment rate (IDAR72, IDAR96) was also used to 







A complete listing of the AE on half-life and trough levels, as well as the IDARs, for all 
sampling strategies in all populations can be found in Supplementary Table S7, Table S8,  
Table S9 and Table S10. A summary of the simulated PK outcomes for each age group 
(including a comparison to previously reported values for half-life) is given in Table 19. 
 
Table 19. Pharmacokinetic outcomes for simulated populations from the rich sampling design. 
Results are presented as mean (standard deviation). Age is presented as median (range), except in 
the adult case where the median for the PK subgroup was unknown. Simulated values of PK 
parameters are presented as mean (SD); reported values of half-life are presented as mean (95% 
CI). 
 
Adults Adolescents Children 
Simulated Reported  Simulated Reported Simulated Reported 
Age 20 (12–65)  12 8.0 (6 – 11) 2 4.0 (1 – 5) 
PK Outcome 

















 C96 (IU dL-1) 3.2 (3.0) 1.4 (1.4) 0.3 (0.1) 
TAT1% (h) 125.4 (33.3) 97.1 (27.8) 48.6 (14.2) 
 
Adult Population 
A summary of the results for the 2- and 3-sample schemes is shown in Table 20. If we 
first consider the AT series of sampling designs (i.e. those using Method A for predose handling, 
with the study taking place on Thursday), most strategies – including several 2-sample designs – 
perform well, with mean AE below 7% and 17% for PK parameters and trough levels, 
respectively (Figure 22). The IDARs were generally low (<8%) for most sampling schemes. Of 
particular note, designs AT9 (Pre-1-48-72h) and AT14 (Pre-1-72h) were the best 4- and 3-




and performed the best of the 2-sample designs, emphasizing the importance of the 72-hour 
sample in this population. Additionally, central volume was well-estimated (mean AE <5%) for 
all designs as all sampling strategies included a peak level; future references to PK parameters 
refer to half-life and clearance only. 
 The exceptions to this largely good performance are designs AT16 (predose and peak) 
and AT21 (peak only). These designs performed equally poorly, with mean [95th percentile] AE 
greater than 20% [52%] on PK parameters and greater than 75% [290%] on trough levels. The 
IDAR, while still low at 72 hours, increased to more than 20% at 96 hours. Furthermore, all 
cases of inappropriate dose adjustment overpredicted the trough level, resulting in a failure to 
increase dose and time spent below 1 IU dL-1. Strategies where the latest sample was taken at 24 
hours post-infusion (AT12 and AT17) also performed poorer than most (mean AE ≈10% for PK 
parameters, ≈25% for trough levels; IDAR96 = 8%). Finally, strategies AT15 (Pre-1-96 h) and 
AT20 (1-96 h) performed well for PK parameter estimation but had slightly elevated IDAR96 





Table 20. Comparison of predose methods A and B for 2- and 3-sample designs following 
Thursday sampling in adults. Absolute errors are presented as mean [95th percentile]. 
Method A PK Parameters Trough Levels IDAR 
Design Half-Life Clearance 
Central 
Volume 
C72 C96 72 h 96 h 
AT6 1.3 [3.7] 3.6 [9.4] 3.2 [7.9] 5.3 [15.3] 5.2 [14.9] 0.9% 0.9% 
AT7 2.2 [6.0] 3.3 [8.6] 2.7 [6.4] 6.2 [17.2] 7.1 [18.1] 0.2% 2.9% 
AT8 3.1 [9.0] 3.7 [10.2] 1.3 [3.2] 8.8 [25.9] 10.0 [28.1] 0.5% 3.4% 
AT9 2.7 [7.3] 3.0 [8.0] 2.9 [7.1] 6.2 [15.1] 7.6 [19.3] 0.0% 1.0% 
AT10 3.5 [9.5] 3.4 [9.2] 1.6 [4.2] 8.4 [20.8] 10.1 [24.9] 0.6% 1.6% 
AT11 5.8 [15.0] 4.4 [13.0] 2.1 [5.2] 12.6 [30.5] 15.8 [38.6] 0.1% 2.9% 
AT12 10.9 [26.8] 10.9 [31.5] 2.3 [5.7] 26.3 [64.2] 32.0 [77.3] 0.7% 6.6% 
AT13 6.1 [15.8] 6.1 [17.1] 3.0 [7.3] 14.2 [35.0] 17.3 [42.2] 0.2% 4.1% 
AT14 3.7 [10.3] 4.9 [13.1] 3.2 [8.0] 9.8 [24.1] 11.2 [28.2] 0.8% 1.6% 
AT15 3.8 [11.4] 5.6 [15.7] 3.3 [8.2] 12.8 [38.4] 13.1 [40.5] 1.5% 4.4% 
AT16 21.1 [52.6] 23.3 [60.7] 3.4 [8.8] 73.9 [279.6] 88.3 [339.2] 1.5% 13.1% 
AT17 10.7 [25.8] 9.9 [22.9] 4.7 [12.2] 26.2 [66.7] 32.6 [85.9] 0.5% 6.5% 
AT18 6.2 [15.8] 6.8 [16.6] 4.7 [12.0] 14.0 [35.3] 17.3 [43.5] 0.2% 4.0% 
AT19 4.4 [11.9] 6.6 [16.2] 4.7 [11.7] 9.9 [24.1] 11.3 [27.6] 0.8% 1.7% 
AT20 4.3 [11.4] 7.0 [17.1] 4.6 [11.3] 13.0 [38.3] 13.1 [40.6] 1.5% 4.4% 
 
Method B PK Parameters Trough Levels IDAR 
Design Half-Life Clearance 
Central 
Volume 
C72 C96 72 h 96 h 
BT6 0.9 [2.4] 2.9 [6.8] 3.0 [7.0] 3.8 [10.2] 3.6 [10.0] 0.7% 0.8% 
BT7 1.5 [3.9] 2.4 [6.0] 2.6 [6.4] 4.3 [10.8] 4.8 [11.8] 0.2% 1.5% 
BT8 1.9 [5.0] 2.3 [5.8] 1.1 [2.7] 5.5 [15.2] 6.2 [16.4] 0.2% 1.5% 
BT9 2.0 [5.3] 2.2 [5.5] 2.9 [7.1] 4.4 [10.2] 5.4 [13.1] 0.2% 0.6% 
BT10 2.4 [6.3] 2.1 [5.2] 1.6 [4.3] 5.8 [14.3] 7.0 [16.9] 0.6% 1.4% 
BT11 3.2 [8.6] 1.8 [5.0] 1.9 [5.2] 7.1 [18.0] 8.9 [23.5] 0.1% 2.3% 
BT12 4.2 [10.7] 3.4 [8.6] 2.0 [5.2] 10.1 [25.4] 12.2 [30.2] 0.3% 2.9% 
BT13 3.3 [8.8] 3.0 [7.7] 3.0 [7.3] 7.7 [19.3] 9.4 [23.5] 0.2% 2.5% 
BT14 2.5 [6.6] 3.3 [7.9]  3.1 [7.7] 6.6 [15.9] 7.5 [18.4] 0.7% 1.2% 
BT15 2.0 [5.7] 3.6 [8.7] 3.0 [7.2] 6.7 [19.1] 7.0 [19.2] 0.8% 2.6% 
BT16 4.4 [11.8] 4.8 [12.2] 3.1 [7.8] 11.6 [29.5] 13.4 [33.4] 0.9% 3.7% 
BT17 10.1 [23.9] 9.2 [25.6] 2.8 [6.7] 25.3 [60.7] 30.4 [72.2] 0.8% 6.3% 
BT18 6.0 [15.0] 5.7 [15.9] 3.1 [7.6] 14.5 [36.1] 17.4 [42.7] 0.1% 4.1% 
BT19 3.8 [10.1] 4.8 [13.1] 3.1 [8.0] 10.4 [26.8] 11.8 [29.3] 0.9% 2.2% 
BT20 4.1 [12.1] 5.7 [16.4] 3.1 [7.9] 13.8 [40.9] 14.4 [41.9] 1.6^ 4.5% 
 
 Results were fairly similar using both methods of predose handling for most designs 
(Table 20), except for the case of the predose-peak sampling strategy (AT16 vs. BT16). Briefly, 
mean AE on half-life and clearance decreases from greater than 20% to below 5%, mean [95th 
percentile] AEs on trough levels decrease from over 75% [≈300%] to less than 13% [≈30%]. 




difference was less dramatic, strategies using Method B and lacking a 48- or 72-hour sample (i.e. 
BT8, BT12, and BT15) also had lower mean AE than their respective AT counterparts.    
 Due to the higher percentage of patients with BLQ factor levels at 96 hours compared to 
72 hours (21.2% vs. 2.6%; 𝑝 < 0.0001), we hypothesized that the sampling day would be 
influential when Method B was used to handle predose. For most sampling schemes, the AEs on 
PK parameters and troughs were quite similar for both sampling days.  However, major 
differences in these outcomes were observed for two designs: BM15 (predose, 1 h, 96 h) and 
BM16 (predose, 1 h); in these cases, errors were considerably higher when sampling on Monday 
as compared to Thursday (Figure 24). Furthermore, there were five designs that resulted in at 
least one IDAR that was significantly higher when sampling was done following a Monday dose 
rather than a Thursday dose: BM6 (IDAR72 1.6% vs. 0.5%, 𝑝 = 0.016), BM11 (IDAR96 3.1% vs. 
1.7%, 𝑝 = 0.041), BM14 (IDAR72 1.6% vs. 0.6%, 𝑝 = 0.032), BM15 (IDAR72 2.8% vs. 1.1%, 𝑝 = 








Figure 22. Boxplot of relative error on half-life estimates from limited sampling strategies using 
(top) Method A and (bottom) Method B for predose handling in a simulated adult population. 





Pediatric and Adolescent Populations 
 Next, we explored whether different LSSs are required when dealing with a younger 
population. When comparing the AT-series designs for the 2-year-old group, a number of 
designs still perform quite well; AT10 (Pre-1-24-72), AT12 (Pre-1-24), and AT17 (1-24) were 
the best 4-, 3- and 2- sample designs, with mean AEs below 10% on all PK parameters and 
troughs, and IDARs below 3%. In fact, IDAR96 is below 1% for all designs in this series ( 
Table S9). However, this is due to the fact that most simulated 2-year-olds reach a factor activity 
level of 1 IU dL-1 well before 96 hours (mean ± SD time to 1 IU dL-1: 49 ± 14 h) while around 
80% of adults are still above this threshold at 96 hours (mean ± SD time to 1 IU dL-1: 125 ± 33 
h). Designs without a sample at 24 or 48 hours (i.e. AT6, AT14–AT16, and AT19–AT21) result 
in estimates with considerably higher mean [95th percentile] AEs for both PK parameters (≈15% 
[>38%]) and 72-hour trough level (≈25% [>65%]).    
 The incorporation of predose data did not result in the same degree of improvement in the 
pediatric population as in the adults. Means and 95th percentiles of AE were improved for the 
same sampling designs (i.e. BT8, BT12, BT15, and BT16), but with less dramatic results (Figure 
23). Taking the BT16-series designs as an example, mean AE was reduced from 21% to 4% for 
half-life and from 87% to 13% for C96 in adults when prior dose knowledge was included; the 
same change in simulated 2-year-olds reduced half-life mean AE from 17% to 14% and C96 
mean AE from 42% to 30%. We attributed this reduced impact to the higher proportion of BLQs 








Figure 23. Effect of predose handling on estimates of PK parameters and IDAR for adults, 








Due to an even higher proportion of BLQs than expected, additional simulations were 
performed for the pediatric population – one using a higher dose (80 IU kg-1, as recommended in 
product guidelines) with the same sampling strategies, and another using the 50 IU kg-1 dose but 
collecting a predose sample that is 48 hours after the last dose rather than 72 or 96 hours 
(equivalent to performing the study on Wednesday for a Monday-Thursday regimen). Increasing 
the dose to 80 IU kg-1 did not result in any reduction in error on PK estimates, likely because this 
dose adjustment did not significantly reduce the proportion of patients who were BLQ at 72 
(83.8%) or 96 (97.5%) hours. However, taking the predose sample at 48 hours (when less than 
half the population is BLQ) improved the error on half-life estimate considerably (Figure 23, 
Figure 24). For the predose-peak sampling strategy, mean [95th percentile] AE on half-life 
decreases from 14% [38%] when sampled after the Thursday dose to 7% [20%] when sampled 
after the Wednesday dose. Estimates of trough levels are similarly improved at both 72 hours 
(12% [29%] vs. 29% [70%]) and 96 hours (5% [18%] vs. 14% [51%]). However, the IDARs 
obtained from Wednesday sampling are slightly higher than those from Thursday sampling 
(IDAR72: 3.3% vs. 2.4%, 𝑝 = 0.23; IDAR96: 1.1% vs. 0.3%, 𝑝 = 0.032). 
 Since there were striking differences between the adult and pediatric populations, we 
decided to investigate an intermediate population of adolescents.  Similar to the adults, most 
sampling designs in the AT series estimate the PK parameters and troughs well (mean AE <10% 
for PK parameters and <15% for trough levels, Table S8), with strategies containing a 48- or 72-
hour sample (e.g. AT13 and AT14 for the 3-sample case) outperforming those relying on a 24- or 
96-hour sample (e.g. AT12 and AT15). As with both the adult and 2-year-old populations, AT16 
and AT21 showed much worse performance than other strategies, with mean AE ≈20% on half-




counterparts, the IDAR at both 72 and 96 hours was much higher for the adolescent group 
(16.1% and 34.5%, respectively) than for adults (1.5% and 13.1%; Figure 2, Figure 3). This can 
be attributed to the fact that the mean time to 1 IU dL-1 for the simulated 12-year-olds was 102 h 









Figure 24. Influence of study day on PK parameters and IDAR for different simulated age 
groups. Predose is handled using Method B. 
126 
 
 When predose was handled using Method B, the adolescent group was similar to the 
adults and saw dramatic improvement in error on PK parameters and in IDAR (Figure 23). 
Compared to the 2-year-old group, the proportion of adolescent patients who are BLQ at 72 
hours is fairly low (≈15%). Consequently, performing the study on Wednesday or Thursday 
generally produces similar results (Figure 3). However, the IDAR72 was significantly reduced 
when the PK study was performed on Wednesday for the eight sampling designs that include a 
predose sample but not a 48-hour point (i.e. BW4, BW6, BW8, BW10, BW12, BW14, BW15 





The results of this study suggest that the pharmacokinetics of rFVIIIFc can be accurately 
estimated from as few as two samples using Bayesian forecasting.  Of the strategies containing 
two post-infusion samples, those with a sample at 48 or 72 hours perform better than those with 
24- or 96-hour samples in adult and adolescent populations. For these populations, a 24-hour 
point does not provide enough information about the late stages of the profile, resulting in greater 
error on clearance and slightly higher (albeit still quite low) IDARs. Conversely, choosing a 
point that is very late in the profile (i.e. 96 hours) increases the likelihood that the sample will be 
BLQ; while this has less impact on the estimation of clearance, it results in increased IDARs. 
However, the best strategies for young children were those containing the 24-hour sample as 
patients of this age reach FVIII levels that are BLQ much earlier. 
 We also sought to determine whether samples from a single clinic visit (i.e. 16-series 




PK of rFVIIIFc, as this sampling strategy is not only more convenient for patients, but also 
reduces clinic resources compared to sampling at multiple visits over several days. The results of 
this sampling strategy are highly variable, and depend on two factors: (i) how the predose sample 
is handled, and (ii) the day in the regimen on which the PK study takes place. If the time and 
dose of the previous infusion are not taken into account (Method A), errors on half-life, 
clearance, and trough levels are high, as is the risk of overpredicting the 96-hour trough level and 
thereby failing to adjust the regimen. However, if prior dose information is available (Method 
B), errors on these parameters are greatly reduced and troughs are more accurately predicted, 
resulting in fewer instances of inappropriate dose adjustment. Handling predose in this way 
allows for the assessment of PK on two infusions per patient; when the time and amount of the 
previous dose are provided, the predose level serves as a trough for the prior dose, giving an 
additional late observation to assist with estimation. The benefit of handling predose in this 
manner was observed for all three of the investigated ages. Conversely, the ideal sampling day is 
more a function of half-life and thus depends on age, as children are known to have shorter 
rFVIIIFc half-lives than adults [230]. Since BLQ predose samples are less informative and all 
ages have a significant proportion of BLQs at 96 hours, performing the PK study around the 
Monday dose of a Monday-Thursday regimen is not ideal; it results in greater errors on all 
outcomes of interest and higher IDARs in almost all cases. Thursday sampling produces 
favourable results in the adult population, while Wednesday sampling is required to reduce the 
risk of a BLQ predose sample in the 2-year-old group. The results for the adolescent population 
are similar for both Wednesday and Thursday sampling, so it is likely not worth disrupting the 




 A major limitation of this exercise is the lack of a rFVIIIFc model that is validated for 
pediatric populations. As seen in Table 17, the youngest patients in the derivation dataset are 12 
years old and models of this type are not usually suitable for extrapolation. However, half-life 
estimates obtained from the Nestorov model for the pediatric population (mean [95% CI] 10.0 
[6.6 – 15.5] hours) are reasonable when compared with observed values for similarly aged 






In summary, we performed a limited sampling analysis using a published model for 
rFVIIIFc and found that PK parameters and key trough levels could be accurately predicted from 
as few as two sample points. For accurate estimation of all relevant PK parameters and trough 
levels, inclusion of a 72-hour, 48-hour, or 24-hour point is recommended for adult, adolescent, 
and pediatric patients, respectively. When trying to make the most of samples collected from a 
single clinic visit (i.e. predose and peak measurements), treatment providers should be conscious 
of the benefit of including knowledge of the timing and amount of the patient’s previous dose, 







Chapter 7: Clinical application of Web Accessible Population 
Pharmacokinetic Service – Hemophilia (WAPPS-Hemo): Patterns of blood 
sampling and patient characteristics among clinician users 
 
This chapter is reflective of an original manuscript published by the Ph.D. candidate (Alanna 
McEneny-King) in Haemophilia. All pertinent dialogue in this chapter was written by the Ph.D. 
candidate. 
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While the success of prophylactic factor replacement for hemophilia A and B has been 
well established [9,166,231], the nuances of ‘optimal’ prophylaxis taking into account a patient’s 
historical bleeding phenotype, target joints, type and intensity of physical activity, venous access, 
and the availability of factor concentrate are less well-defined. The significant annual cost of 
hemophilia therapy coupled with the expanding availability of newly designed factor 
concentrates [232] has created an opportunity for pharmacokinetic (PK) data to contribute to 
prophylaxis regimen decision-making. The addition of PK-tailored dosing may facilitate a 
provider’s ability to individualize hemophilia prophylaxis [233–237], maximizing the 
musculoskeletal health of patients by increasing trough levels while minimizing factor 




the PK of both factor VIII (FVIII) and factor IX (FIX) clotting factor concentrates (CFCs) 
[167,168], suggests that empiric dosing regimens based on adult mean half-life and adjusted 
based on bleeding pattern or measured trough levels may be improved upon [181,240,241]. 
Within the hemophilia A population, an association has been demonstrated between an increased 
risk of musculoskeletal bleed events and duration of time (hours per week) an individual spends 
with FVIII activity levels below 1 IU/dL [10]. 
Implementation of population pharmacokinetics (PopPK) for hemophilia A and B has 
facilitated a practical approach to individualizing prophylactic factor replacement regimens 
informed by a patient’s PK profile. Use of PopPK eliminates the need for a washout period and 
dense blood sampling following CFC infusion when performing PK analysis [181,242,243]. 
Historically, incorporation of PK into routine clinical practice has been impeded by the rigorous 
sampling required for classical PK methodology [244,245], limited access to provider-friendly 
tools for PK analysis, and provider and patient uncertainty about the magnitude of improvement 
to be gained by adding PK information to decision-making. Increasingly, PopPK models and 
interfaces have become available to clinicians. The required timing for blood samples, CFC-
specific modelling, and regional availability of resources have impacted specific tool utilization 
by providers [170,234]. The Web Accessible Population Pharmacokinetic Service – Hemophilia 
(WAPPS-Hemo) is a globally available service with specific models for most commercially 
available FVIII and FIX CFCs. The WAPPS-Hemo network currently consists of over 400 
centres, and the service has received over 1,200 infusions in the first half of 2019. Clinicians are 
able to submit de-identified patient covariates, factor infusion details, and post-infusion factor 
activity levels, and then receive a validated, individual PK profile report for their patient. The 




(ISTH) recently published guidance on the use of PopPK in hemophilia management, suggesting 
post-infusion blood sampling windows for both standard half-life (SHL) and extended half-life 
(EHL) FVIII and FIX CFCs [169,181,246].  
Success of PK-guided prophylaxis with respect to the potential for increased trough 
factor levels and reduction in factor concentrate utilization has been modeled and also 
demonstrated in small cohorts of primarily hemophilia A patients [234,237–239]. While the 
implementation of PK-tailored prophylaxis is increasingly featured at national and international 
congresses in both educational sessions and the scientific programs, utilization of PopPK profiles 
in clinical practice remains vague [245]. This retrospective study investigated the evolution of 
clinician use of WAPPS-Hemo for individual PK profile estimation by specifically examining 
the changes in laboratory data and patient characteristics submitted by all providers within the 
global WAPPS-Hemo Network. Secondarily, we assessed whether there was a difference in 
sampling strategies and patient characteristics for requested PK profiles between high-use 




Infusion data for pediatric and adult patients with hemophilia A or B, of all severities, 
submitted to WAPPS-Hemo from participating sites were extracted during two time periods: 
October 1, 2015 through September 30, 2016 (Period 1, early availability) and October 1, 2017 
through September 30, 2018 (Period 2, recent use). Infusions were excluded if they were 
identified to be duplicates (based on timestamps) or were for a patient marked as positive for 




infusion blood sampling. Furthermore, we excluded infusions that appeared to contain a single 
confirmatory point, as these samples were collected with the intention of confirming a current 
prophylaxis regimen rather than for PK parameter estimation. Confirmatory points were defined 
as infusions that contained only one sampling point and had a more detailed PK profile for the 
same product within six months prior. The final dataset included de-identified patient 
characteristics (age, weight) as well as infusion details (factor product, assay method, infusion 
time, and FVIII or FIX activity levels with post-infusion timestamp). Details of whether data 
submitted was at steady state or following a single dose were not collected in WAPPS-Hemo 
during the timeframes investigated. CFCs were dichotomized into SHL or EHL product groups 
for both FVIII and FIX CFCs. EHL CFCs were defined as those with a moiety added (Fc-fusion, 
pegylation, or albumin) with the intention of reducing exogenous factor clearance.  
Statistical analysis for continuous variables was performed using a T-test to describe 
differences between Period 1 and Period 2. Pearson’s chi-square tests were employed for 
analysis of categorical covariates. Graphical representations of covariate distributions and plots 
of sampling times were created in MatLab (R2017b). Timing of blood samples was evaluated 
using the windows suggested in the ISTH PopPK guidance [169]. 
We analyzed the association between centre submission volume for PopPK analysis and 
the characteristics of patients and the number and timing of post-infusion blood samples. A de-
identified list of centres participating in the WAPPS-Hemo Network and the cumulative number 
of infusions submitted since their initial participation were used to categorize centres according 
to the number of PK profiles requested. Only centres who had submitted at least one infusion 




submitted at the time of analysis. T-tests compared HUCs versus non-HUCs with respect to 




Of the 1,931 eligible infusions entered into WAPPS-Hemo during the timeframes 
investigated, 468 were entered during Period 1 and 1,463 were entered during Period 2 (Table 
21). There was a greater than 3-fold increase in the number of infusions entered during Period 2, 
driven by FVIII CFCs, particularly EHL FVIII. One-stage clotting assays for quantification of 
factor activity levels dominated during both periods. Infused doses (IU/kg) increased between 
Periods 1 and 2 (Figure 25) for both SHL FVIII (𝑝 = 0.0074) and EHL FIX CFC (𝑝 = 0.021). 
While PopPK was predominantly used in the adult population, patients entered were overall 





Table 21. Categorical covariate summary for final WAPPS-Hemo dataset for Period 1 and 2 
COVARIATE PERIOD 1 PERIOD 2 𝒑-VALUE 
Number of infusions 468 1,463  
Number of patients 413 1,286  
Number of centres 65 158  
Age (years), Mean (SD) 
     Median [Range] 
28.1 (17.8) 
26 [0.5 – 77] 
23.7 (17.0) 
18 [0.5 – 81] 
𝑝 < 0.001 
Body weight (kg), Mean (SD) 
     Median [Range] 
64.6 (26.0) 
68.3 [8.8 – 204] 
61.8 (28.2) 
65 [6.9 – 179] 
𝑝 = 0.042 
Hemophilia Type    
      Hemophilia A 405 (86.5%) 1,248 (85.3%) 
𝑝 = 0.508 




      SHL FVIII 336 (71.8%) 826 (56.5%) 𝑝 < 0.001 
      EHL FVIII 69 (14.7%) 422 (28.8%) 𝑝 < 0.001 
      SHL FIX 16 (3.4%) 79 (5.4%) 𝑝 = 0.085 




      One-Stage 406 (86.8%) 1,326 (90.6%)  
      Chromogenic 57 (12.2%) 82 (5.6%)  
      Two-Stage 5 (1.1%) 11 (0.8%)  







Figure 25. Dosages (IU/kg) of FVIII (A: Period 1; B: Period 2) and FIX (C: Period 1; D: Period 
2) administered for infusions submitted for PK analysis  
 
Figure 26. Age (A: Period 1; B: Period 2) and body weight (C: Period 1; D: Period 2) 




The post-infusion blood sampling strategy used by providers for PopPK estimation varied 
considerably. The median number of factor activity samples obtained per infusion decreased in 
Period 2 for FIX products (though not significantly), and did not change for FVIII products 
(Table 22, Figure 27).  
 
Figure 27. Number of samples collected per infusion for each of the product types (A. SHL 





Table 22. Mean and median number of blood samples per patient per infusion for each group of 
factor products during Period 1 and 2 
 
Examination of the timing of blood samples for PK analysis demonstrated that peak 
levels continued to be frequently collected, despite ISTH recommendations; however, the timing 
of subsequent blood samples were consistent with suggested sampling windows based on CFC 
group (Figure 28). Of the non-peak samples submitted (𝑛 = 4,557), 71% were within 
recommended sampling windows for their respective product group. Among all of the 6,734 
factor activity levels submitted during the study periods, the proportion of post-infusion levels 
within the ISTH recommended sampling windows were greater for FVIII CFCs (49% for SHL 
and 54% for EHL) compared to those for FIX CFCs (31% for SHL and 34% for EHL). 
Additionally, 83% of samples (5,592/6,734) were considered ‘useful’ in PopPK analysis (i.e. 
non-peak and not below level of quantification). 
Factor Product Group Period 1 Period 2 𝒑-value 
SHL FVIII  
     Mean (SD)      
     Median [Range] 
 
3.5 (1.9) 
3 [1 – 12] 
 
3.3 (1.5) 
3 [1 – 10] 
𝑝 = 0.047 
EHL FVIII  
     Mean (SD)      
     Median [Range] 
 
3.7 (1.6) 
4 [1 – 8] 
 
3.6 (1.7) 
4 [1 – 10] 
𝑝 = 0.917 
SHL FIX  
     Mean (SD)      
     Median [Range] 
 
3.9 (2.0) 
5 [1 – 7] 
 
3.4 (1.7) 
3 [1 – 9] 
𝑝 = 0.336 
EHL FIX  
     Mean (SD)      
     Median [Range] 
 
3.8 (1.5) 
4 [1 – 8] 
 
3.9 (2.0) 
4 [1 – 11] 





Figure 28. Post-infusion timing of factor activity levels for each of the product types (A. SHL 
FVIII, B. EHL FVIII, C. SHL FIX, and D. EHL FIX) collected during Period 1 (left) and Period 
2 (right). Shaded regions represent sampling windows recommended by ISTH subcommittee for 
the specific product type: SHL FVIII: 4 – 8 h, 16 – 28 h, and 40 – 60 h, EHL FVIII add 60 – 84 





Approximately 10% of infusions during the periods studied had only a single factor 
activity measurement submitted for PopPK analysis. The vast majority of these single factor 
level infusions were submitted in isolation, without evidence of another infusion with the same 
product and dosage within six months. The timing of the single post-infusion factor level varied 
by product group (Figure 29). The majority (70%) were obtained at least 24 hours post-infusion. 
The majority of single samples for SHL FVIII were obtained around 24 hours post-infusion, 
consistent with ISTH guidance, while single samples for EHL products tended to be taken at 
later timepoints. A minority of single samples (7.6%) were obtained less than 4 hours post-
infusion and were not adequate for reliable PopPK analysis.  
 
Figure 29. Factor activity levels for infusions containing a single sample, excluding 
confirmatory samples. SHL FVIII – blue circles, SHL FIX – red squares, EHL FVIII – green 




Across all WAPPS-Hemo sites (𝑛 = 204 at time of data extraction), the median number 
of individual patients with at least one infusion submitted was 8 [IQR 3–21]. The top 25th 
percentile was represented by 51 HUCs who submitted infusions for 22 patients or more. Of 
these 51 HUCs, 50 centres submitted infusions during at least one of the time periods studied and 
were included in the analysis. Of the 165 total centres who submitted infusion data during the 
time intervals studied, the median number of infusions entered per centre was 6 [IQR 3–13]. 
Across Period 1 and Period 2, the 50 HUCs contributed a total of 1,385 infusions (mean: 
27 infusions per centre) compared to the 567 infusions submitted by the remaining 115 non-
HUCs. Nearly 75% of the infusions submitted by HUCs during Period 1 were for SHL FVIII 
products, compared to about 60% of the submissions from non-HUCs during the same timeframe 
(𝑝 = 0.105). A full comparison of patient characteristics between HUCs and non-HUCs across 
both time periods can be found in Table S1.  
During Period 1, infusions submitted by non-HUCs typically included more samples than 
those from HUCs (mean 4.3 for non-HUCs and 3.5 for HUCs, 𝑝 = 0.009). Although this 
difference narrowed during Period 2, it continued to be statistically significant. Despite an 
overall trend toward fewer samples collected at HUCs, this was not consistently observed for 
different product types (Table S2). Although HUCs submitted fewer blood samples compared to 
non-HUCs for SHL products, the opposite trend was initially observed for EHL FVIII products. 
No differences were observed across time period or centre type for EHL FIX. Timing of post-
infusion blood samples from both groups aligned well with the ISTH recommended sampling 
windows; however, direct comparison of timing of samples between HUCs and non-HUCs was 






A wide range of sampling strategies was employed across providers for PK curve 
estimation, in terms of both number and timing of samples. It is reassuring to see a gradual 
decline in the average number of blood samples obtained. This may reflect increasing provider 
confidence with the reliability of fewer, well-timed samples for a PK estimation and also 
application of the international guidance supported by the ISTH subcommittee. The benefits of 
fewer sampling points for the patients are fewer venipunctures or accessing of a central line, and 
reduced time away from school or work for phlebotomy. Although the number of samples 
collected is decreasing, providers still tended obtain more than the minimum required sampling 
points and, in particular, continue to obtain peak levels. This may be due to interest in in vivo 
recovery or convenience if infusion occurred on site; however, this level is not included in the 
ISTH guidance for use of PopPK. It is important to note that all additional blood samples beyond 
the minimal proposed further improve accuracy of PK profile estimates for an individual patient 
but from a resource utilization perspective may not be necessary. Across both time periods, the 
timing of post-infusion factor activity measurements by clinicians was generally consistent with 
the timeframes recommended by the ISTH subcommittee. While the majority of post-infusion 
data points, excluding the peak values, fell into the windows first suggested by Björkman and 
others [57,178,243] and refined for EHL concentrates by the ISTH guidelines [169], it is 
important to note that blood samples were taken throughout those windows. This reinforces the 
value of flexibility in sampling timepoints in successful execution of PopPK in routine clinical 
practice.  
PopPK was applied across the full age spectrum of hemophilia patients, ranging from 




validated across the age and weight range of the patient population. There is a trend toward 
application of PK profiles in younger patients; the median age and proportion of patients greater 
than 18-years-old decreased over time. This may represent increased interest in understanding 
the potential impact of PK for prophylaxis regimen tailoring among pediatric (27% of Period 2 
infusions) and young adult (22% of Period 2 infusions) patients, or increased switching between 
SHL and EHL informed by PK occurring in younger age cohorts.  
Given the higher prevalence of hemophilia A, it is not surprising that the majority of 
infusions were submitted for FVIII CFCs; however, compared to the anticipated ratio of 
hemophilia A to B patients, PopPK may be underutilized for those using FIX CFCs. This 
discrepancy may be due to the longer half-life of FIX CFCs, as well as the reduced bleed 
frequency in patients with severe hemophilia B compared to severe hemophilia A [199]. These 
factors may prompt providers to continue to rely predominantly on measured troughs and clinical 
phenotype to tailor FIX prophylactic dosing rather than use of PopPK. Another possible 
explanation for slower uptake of PopPK in hemophilia B may be that evidence supporting a 
particular therapeutic target is less established as compared to hemophilia A. 
There are several limitations of our current study. Insight into a clinician’s motivation or 
rationale for the submitted samples was not available. There may be many reasons for submitting 
a single sample, including lack of PopPK knowledge, self-editing (e.g. not including trough 
levels that are below limit of quantification), or patient refusal to return for more than one blood 
draw. We analyzed two timeframes to assess changes in use of PopPK, but this field and clinical 
practice continue to evolve; perhaps brand-specific analysis may be of interest in the future as 
the newer EHL CFCs achieve more widespread use globally. Despite emergence of non-factor 




globally as FVIII CFCs predominate for prophylaxis. Other PopPK tools are available from both 
manufacturer and academic groups, developed with different model assumptions and different 
requirements for post-infusion sampling. The patterns of use observed with WAPPS-Hemo 




 The use of PopPK in hemophilia treatment continues to expand with a greater than 
threefold increase in the number of infusions, patients and centres in the WAPPS-Hemo network 
between the timeframes queried. Infusions submitted during the recent use period contained 
fewer blood samples and younger patients than those from the early adoption phase. During both 
time periods, peak samples were frequently obtained but the remaining blood sample timepoints 





Chapter 8: The effect of unmeasurable endogenous plasma factor activity 
levels on factor VIII dosing in patients with severe hemophilia A 
 
This chapter is reflective of an original manuscript published by the Ph.D. candidate (Alanna 
McEneny-King) in Thrombosis Research. All pertinent dialogue in this chapter was written by 
the Ph.D. candidate. 
 
McEneny-King A, Chelle P, Iorio A, Edginton AN. The effect of unmeasurable endogenous 
plasma factor activity levels on factor VIII dosing in patients with severe hemophilia A. Thromb 
Res. 2018; 170(2018):53-59. DOI: 10.1016/j.thromres.2018.08.004 
 
Introduction 
Hemophilia A is an X-linked bleeding disorder affecting 1 in 6,500 newborn males 
worldwide [62]. Genetic mutations responsible for hemophilia A number in the hundreds 
[247,248] but are all localized to the factor VIII (FVIII) gene (F8) and translate into lower than 
normal FVIII clotting activity. Manifestations of this lowered clotting ability include internal 
bleeding, particularly in joints, which, in more severe hemophilia A cases, is spontaneous (i.e. 
not caused by external trauma or injury). The severe hemophilia A phenotype is clinically 
assessed as <0.01 IU mL-1 FVIII activity level (<1% of normal) [69] and the prevalence of such 
severe cases in Canada is reported to be 31% of all hemophilia patients [62]. Treatment options 
include replacement of FVIII through intravenous injection, either on-demand or 
prophylactically on a regular schedule. Indeed, prophylactic treatment has been demonstrated to 
reduce the incidence of arthropathy in severe hemophilia A patients, a common and debilitating 




The aim of the classical prophylactic treatment scheme is to maintain FVIII activity 
above 0.01 IU mL-1 through regular administration of FVIII. The choice of this pharmacokinetic 
biomarker is based on a 1965 study where the rate of increase in joint score (a positive measure 
of progressive arthropathy) was halved in patients with a baseline FVIII activity between 0.01 
and 0.03 IU mL-1 as compared to patients with endogenous activity below 0.01 IU mL-1 [7]. 
Building on the results of this study, Nilsson et al [8] observed that the longer patients remained 
over the 0.01 IU mL-1 threshold, the lower their joint score (indicating improved joint function). 
Accordingly, FVIII concentrates are still labelled to be dosed between 15-50 IU kg-1 of total 
body weight, to be administered at a frequency of 2-4 times per week. The goal of this 
population-based dosing method is to maintain most patients above the 0.01 IU mL-1 threshold. 
The need for such a wide range of doses has been traditionally attributed to high variability of 
the FVIII PK in the population, and has driven the quest for individualized dose titration 
[167,234,250]. 
Historically, PK-based individualization of treatment has been hampered by the 
impracticality of drawing 10 or more blood samples as recommended by the International 
Society of Thrombosis and Haemostasis (ISTH) Scientific and Standardization Committee 
[250,251], and little effort was devoted to systematically using individual PK information to 
generate individual dosing regimens. With the advent and diffusion of the population 
pharmacokinetic (PopPK) approach, including Bayesian post hoc estimation to obtain individual 
profiles as recently recommended by the ISTH [169], far fewer blood samples are required and 
many more empirical sets of post-infusion samples have been collected through web-based PK 
software like the Web-Accessible Population Pharmacokinetics Service – Hemophilia (WAPPS-




individualized estimation technique from a PopPK model is presented in Bjorkman and Collins 
[243]. 
A system like WAPPS-Hemo offers a unique opportunity to explore the sources of 
variability of factor VIII (and IX) PK in the population. For example, analyzing the data 
collected via WAPPS-Hemo has prompted challenging the body weight metric currently used for 
dosing [253]. WAPPS-Hemo has an integrated clinical simulator module, which allows the 
clinician to predict the individual profile after any given combination of dose and infusion 
frequency, or to calculate the dose required to obtain a specific threshold after a given time. 
Implementing the algorithm used in the simulator has prompted the hypothesis that the amount 
of FVIII produced by individual patients in the range of 0 to 0.01 IU mL-1 is another determinant 
of the inter-individual PK variability.  
Indeed, for many patients, the baseline value is reported as <0.01 IU mL-1, either because 
the assay used to detect FVIII activity has a lower limit of quantification (LLOQ) of 0.01 IU mL-
1, or because the patient is phenotypically a severe hemophilia A patient (therefore defined as 
<0.01 IU mL-1 baseline), and the true baseline has not been measured or recorded. As a matter of 
fact, both the chromogenic and the one-stage clotting assays used to quantify FVIII activity 
typically had in the past a LLOQ of 0.01 IU mL-1, which is why this value was selected as the 
cut-off for severity. Modern assays can measure FVIII activity as low as 0.004 IU mL-1, which 
allows baseline values to be measured to lower values or defined as less than the LLOQ, for 
example <0.004 IU mL-1. 
The objective of the presented work was to assess the implications of imprecise 




published PopPK model that describes FVIII PK to generate estimates of PK parameters (e.g. 
clearance, volume of distribution) for virtual patients. We then used these virtual patients to 
assess how different assumptions of their baseline value affect optimal dosing regimen design, 
both on a population level as well as during therapeutic drug monitoring and individual dose 
adjustment. We also used real patient data collected through the WAPPS-Hemo project to 
explore the sensitivity of PK outcomes (e.g. half-life, time to a specific FVIII level) to changes in 
the baseline assumption. 
 
Methods 
Matlab (R2017b) was used for re-creation of the PopPK model, population generation, 
simulations and graphical outputs. 
 
Population pharmacokinetic modeling 
The PopPK model used to generate individual estimates of PK parameters is a 2-
compartment structure as described by Garmann et al [185] for a conventional recombinant 
FVIII. This model was built on a total of 183 subjects with body mass index (BMI) ranging from 





Table 23. Details of the model developed by Garmann et al [185] 
Parameter  Estimate Covariate Effectsc BSVd (%CV) 







clearance (Q, dL h-1) 
 1.90   






Peripheral volume (V2, dL)  6.37   
Proportional RUVa (%CVb)  26.7   
Additive RUV (IU dL-1)  1.10   
aResidual unexplained variability; bCoefficient of variation; c 𝜃𝑃represents the population mean 
for parameter 𝑃; dBetween subject variability 
 
Development of simulated populations 
Generated populations of 500 virtual individuals consisted of males with a uniform 
distribution of BMI in the range of 18-30 kg m-2. Heights were derived from the distribution 
provided by the NHANES database [215]. The distribution of BMI’s was simulated and the total 
body weights were calculated as the product of BMI and the square of height. Using these 
covariates, the PK parameters for each individual, as stated in Table 1, were generated from the 
model. 
Simulations 
The effect of the baseline assumption on optimal dose or frequency was assessed for 500 
populations each containing 500 individuals. For each individual, the PK parameters were 
generated and individual FVIII activity levels were simulated following various administrations 









where 𝐷𝑖 is the dose administered, 𝐴, 𝐵, 𝛼 and 𝛽 are the macro-constants calculated from the 
parameters listed in Table 1, and 𝑡𝐷𝑖 is the time at which dose 𝐷𝑖  was given. The infusion time 
was assumed negligible (usually less than 5 minutes) and not included.  Four weeks of 
prophylactic treatment were simulated in order to reach steady state, and the fifth week was used 
for analysis. 
First, the doses required to maintain 95% of patients above troughs of 0.01 IU mL-1, 0.03 
IU mL-1 and 0.05 IU mL-1 at 48 hours post-administration (Q48h) were calculated. To do so, the 
dose was increased by increments of 1 IU kg-1 (to a maximum dose of 300 IU kg-1) until 95% of 
each population maintained FVIII activity above the desired trough at steady state. Frequency 
was determined in a similar manner where, starting with a 40 IU kg-1 dose administered weekly, 
the dosing interval was decreased by 1 hour (down to a minimum of 12 hours or twice daily 
dosing) until 95% of each population maintained the desired trough activity of 0.01 IU mL-1, 
0.03 IU mL-1 and 0.05 IU mL-1. To explore how the assumption of baseline affects both optimal 
dose and frequency, baseline was increased from 0 IU mL-1 to 0.01 IU mL-1 in steps of 0.001 IU 
mL-1.  
The effect of the baseline assumption on individual dose adjustments using trough levels 
was also performed. This scenario is akin to the common clinical situation of adjusting a 
therapeutic regimen, with a patient having a trough level taken after a given dose and the 




scenario, a dose of 2000 IU generated a trough of 0.01 or 0.02 IU mL-1 at a given time. The 
implication of the true baseline (and corresponding assumptions when the true baseline is 
unknown or unmeasurable) was assessed by scaling the exogenous trough level to achieve either 
double or half the observed trough (0.02 or 0.01 IU mL-1, respectively). The exogenous (i.e. 
scalable) trough is the observed trough for a given dose (DoseObserved) minus the baseline level. 
Three different baseline activities were explored for each scenario: 0, 0.005, 0.008 IU mL-1. A 
new dose (DoseNew) was then calculated as:  
𝐷𝑜𝑠𝑒𝑁𝑒𝑤 =
𝐷𝑒𝑠𝑖𝑟𝑒𝑑 𝑇𝑟𝑜𝑢𝑔ℎ − 𝐵𝑎𝑠𝑒𝑙𝑖𝑛𝑒
𝑂𝑏𝑠𝑒𝑟𝑣𝑒𝑑 𝑇𝑟𝑜𝑢𝑔ℎ − 𝐵𝑎𝑠𝑒𝑙𝑖𝑛𝑒
∙ 𝐷𝑜𝑠𝑒𝑂𝑏𝑠𝑒𝑟𝑣𝑒𝑑 
This exercise was also conducted using higher observed and desired troughs to demonstrate the 
reduced impact of baseline assumptions at higher FVIII levels. 
 
Real patient data  
Using the WAPPS-Hemo platform, we used a Bayesian approach to estimate individual 
PK parameters for three real patients collected in the database, varying each patient’s baseline 
between 0 and 0.01 IU mL-1 by steps of 0.001 IU mL-1. The estimates of terminal half-life and 
times to specific trough levels were compared for the different baseline values to assess the 
sensitivity of these outcomes to the baseline assumption.  
 
Results 
Regardless of the targeted trough level, there is a 40 IU kg-1 dose requirement drop from 




mL-1, the baseline assumption between 0 and 0.01 IU mL-1 means the difference between dosing 
at 40 IU kg-1 and 0 IU kg-1, respectively. On a relative-to-dose basis, the importance of the 
baseline assumption is greatly reduced as the targeted trough increases. For example, when 
targeting 0.01 IU mL-1 and assuming a baseline of 0.005 IU mL-1 rather than 0 IU mL-1, the 
calculated dose required drops by 50%, from 40 to 20 IU kg-1. When targeting a 0.05 IU mL-1 
trough, the same change in the assumption about baseline leads to only a 10% decline in the 
required dose.   
 
Figure 30. The Q48h dose required to keep 95% of individuals above the trough as a function of 
baseline value. The shaded region is the 95% confidence interval of the mean of 500 populations 




Baseline also greatly affects the optimal frequency of dosing. If targeting 0.01 IU mL-1, 
frequency is asymptotic as it approaches an assumed baseline of 0.01 IU mL-1; this is expected 
since no drug needs to be given if the target is the same as the baseline (Figure 2). As baseline 
decreases, dosing interval decreases, and the drug needs to be administered more often. On the 
contrary, baseline assumptions between 0.007 and <0.01 IU mL-1 would result in a longer 
interval between infusions.  Similar to dose, as the targeted trough increases, the baseline 
assumption has less and less influence on the frequency outcome. For dose optimization 
purposes on a population level, assuming a baseline of 0 IU mL-1 is the most conservative means 
for assessing optimal dose and/or frequency as it will always lead to the highest dose and the 
lowest frequency (Figure 30, Figure 31).  
 
Figure 31. Effect of baseline assumption on the infusion frequency needed to keep 95% of 
individuals above a desired trough with a dose of 40 IU kg-1 when frequency is considered as a 
continuous variable. The shaded region is the 95% confidence interval of the mean of 500 




For dose adjustment using an observed individual level, the importance of baseline is also 
evident. When a patient’s baseline is known, any measurement can be partitioned into residual 
FVIII for prior doses and endogenous production; this step is critical for accurate dose 
adjustment since only the residual exogenous component is proportional to dose. The 
consequences of being unable to partition a FVIII measurement in this way are highlighted in 
Table 24. In this example, we suppose a trough of 0.01 IU mL-1 is observed following a 2000 IU 
dose, and a trough of 0.02 IU mL-1 is desired. If true baseline is 0 IU mL-1, then the entirety of 
the observed trough is due to exogenous FVIII and dosing is linear; to double the trough, double 
the dose. However, if true baseline is 0.005 IU mL-1, only 0.005 IU mL-1 of the observed trough 
can be attributed to the exogenous factor concentrate and, in order to achieve a trough of 0.02 IU 












Trough (IU mL-1) 
Exogenous Portion 
of Trough (IU mL-1) 
Dose Required to Achieve a 
0.02 IU mL-1 Trough (IU) 
A 
0 2000 0.01 0.01 
0.02 − 0
0.01
∙ 2000 = 4000 
0.005 2000 0.01 0.005 
0.02 − 0.005
0.005
∙ 2000 = 6000 
0.008 2000 0.01 0.002 
0.02 − 0.008
0.002
∙ 2000 = 12000 
 
Dose Required to Achieve a 
0.01 IU mL-1 Trough (IU) 
B 
0 2000 0.02 0.02 
0.01 − 0
0.02
∙ 2000 = 1000 
0.005 2000 0.02 0.015 
0.01 − 0.005
0.015
∙ 2000 = 667 
0.008 2000 0.02 0.012 
0.01 − 0.008
0.012
∙ 2000 = 333 
   
Dose Required to Achieve a 
0.03 IU mL-1 Trough (IU) 
C 
0 2000 0.05 0.05 
0.03 − 0
0.05
∙ 2000 = 1200 
0.005 2000 0.05 0.045 
0.03 − 0.005
0.045
∙ 2000 = 1111 
0.008 2000 0.05 0.042 
0.03 − 0.008
0.042
∙ 2000 = 1048 
 
The counterintuitive result that the patient with higher baseline activity requires a higher 
dose arises from having observed the same trough for both patients after giving the same dose; 
this observation means that the patient with no endogenous FVIII has a higher amount of 
exogenous FVIII at that time due to a better PK response. If the patient has a higher true 
baseline, the contribution of the administered dose to the measured trough is reduced, which 
results in a more extreme scaling factor (Table 24). Furthermore, if we perform this exercise 
using slightly higher troughs (as in Scenario C of Table 24), the impact of the baseline 





When estimating PK parameters using a Bayesian approach, not all parameters are 
sensitive to baseline FVIII activity. For example, half-life is relatively unchanged across baseline 
values between 0 and 0.01 IU mL-1 (Table 3). Conversely, the time at which a patient will reach 
a trough of 0.01 IU mL-1 is extremely sensitive to baseline. In all three patients, this time varied 
by over 20 hours as baseline increased from 0 to 0.009 IU mL-1 – an important observation given 
the demonstrated correlation between time below 0.01 IU mL-1 and occurrence of bleeds [10]. 
However, the times to reach slightly higher troughs (i.e. ≥0.02 IU mL-1) are much less affected 
(in most cases, varying by less than 3 hours).  





Dose            
(IU kg-1) 
Baseline   
(IU mL-1) 
Half-life               
(h) 
ΔHalf-life       
(%) 
Estimated Time (h) to Specified Trough (IU mL-1) 
0.01 0.02 0.03 0.04 0.05 
0.01 58.42 
0.000 10.18 --- 57.49 47.31 41.36 37.13 33.86 
0.002 10.01 1.7% 59.71 48.00 41.62 37.21 33.84 
0.005 9.81 3.6% 65.05 49.50 42.27 37.51 33.95 
0.008 9.64 5.3% 76.59 51.66 43.23 38.02 34.24 
0.010 9.55 6.2% n/a 53.62 44.06 38.48 34.51 
Range 0.63 --- 28.29 6.31 2.70 1.35 0.68 
0.015 46.15 
0.000 9.42 --- 56.09 46.66 41.15 37.24 34.21 
0.002 9.27 1.6% 58.14 47.29 41.38 37.29 34.17 
0.005 9.08 3.6% 63.03 48.63 41.94 37.53 34.24 
0.008 8.93 5.2% 73.67 50.60 42.79 37.97 34.47 
0.010 8.84 6.1% n/a 52.39 43.55 38.38 34.71 
Range 0.58 --- 26.07 5.73 2.40 1.14 0.54 
0.02 57.97 
0.000 8.47 --- 56.46 47.99 43.04 39.53 36.80 
0.002 8.27 2.3% 57.85 48.17 42.90 39.26 36.47 
0.005 8.00 5.6% 61.38 48.70 42.80 38.92 36.02 
0.008 7.75 8.5% 69.75 49.72 42.94 38.75 35.71 
0.010 7.61 10.1% n/a 50.82 43.21 38.76 35.60 





These trends are also demonstrated in Figure 32, which shows the estimated FVIII 
activity profiles for one of the patients for each assumed baseline. The curve is almost identical 
for all baselines up until a level of approximately 0.02 IU mL-1 (Figure 32, left). The profiles 
begin to diverge at this point, with the truly zero baseline continuing in a linear fashion while the 
curves representing non-zero baselines begin to plateau (Figure 32, right).   
 
Figure 32. Estimated FVIII activity profiles following a dose of ~60 IU kg-1, assuming different 








The effect of imprecise knowledge about baseline on population level dose regimen 
design is increasingly pronounced as the target trough level approaches 0.01 IU mL-1. When a 
trough of 0.01 IU mL-1 is targeted, within the range of realistic baseline values for severe 
hemophilia patients (0 through <0.01 IU mL-1), the required dose changes from approximately 
40 IU kg-1 to a theoretically negligible dose (practically approaching 0 IU kg-1) Q48h  –  a drastic 
100% difference depending on the assumed baseline. If baseline could be measured accurately, it 
would provide the clinician with a better starting point within this range when designing a 
regimen; for a patient with a baseline of 0.006 IU mL-1, Figure 1 suggests a starting dose of 25 
IU kg-1 while a patient with a baseline of 0.002 IU mL-1 may require closer to 40 IU kg-1 to 
maintain a trough of 0.01 IU mL-1. When targeting a trough of 0.05 IU mL-1, the effect of the 
baseline assumption on dose or frequency determination is minimal (approximately 10%). When 
targeting a 0.15 IU mL-1 target trough [254], baseline is essentially irrelevant, although standard 
half-life FVIII usage would be exceptionally high. In clinical practice, a trough of 0.01 IU mL-1 
is often targeted using doses in the 15-40 IU kg-1 range and ignoring the true baseline value of 
the patient may well explain part of the variability in the dose response to FVIII and the need for 
such a wide range of doses. 
To reduce this variability, we might examine data from clinical studies to understand the 
association between the variation in dose requirements and the actual baseline values in 
individual patients. In a single-centre study where the individual PK of hemophilia A and B 
patients was simulated for each of six years based on their actual prophylactic treatment, both 
doses (11-67 IU kg-1) and trough levels were highly variable. With regards to troughs, the study 




(3 times a week); however, 38% of the troughs were lower than 0.01 IU mL-1, 27% of the 
troughs were between 0.01-0.03 IU mL-1, and 35% of the troughs were higher than 0.03 IU mL-1 
[255].  This variability is partially a function of the variation in baseline values of severe 
hemophilia patients. 
When treating individual patients, the assumption of baseline affects dose adjustment. 
Björkman and Collins [243], on behalf of the Scientific and Standardization Committee of the 
ISTH, proposed that only those activities above 0.03 IU mL-1 be used in individual 
pharmacokinetic assessment as all values below are potentially inaccurate due to assay 
limitations and baseline.  This was demonstrated here where the assumption of a 0 IU mL-1 
baseline allows for linear kinetics to be used such that a doubling of a trough is precipitated by a 
doubling of the dose. As true endogenous baseline increases from 0 to 0.01 IU mL-1, the 
assumption of linearity is no longer valid. However, when performing dose adjustments, the 
more conservative, and therefore safer, approach is to assume a 0 IU mL-1 baseline when 
decreasing trough, and a non-zero baseline of at least 0.005 IU mL-1 when increasing trough.  
Replacement of an endogenous molecule that is missing or has limited endogenous 
production is not unique to hemophilia. Type 1 diabetes (insulin), Parkinson’s disease 
(dopamine) and hormone replacement therapy for Addison's disease (e.g. hydrocortisone), 
menopause (estrogen) or stunted growth (human growth hormone) are all examples of 
replacement therapies. However, none suffer from an assay sensitivity that hinders assessment of 
a pharmacokinetic or pharmacodynamic target as in hemophilia. In diabetes, glucose level drives 
insulin dose and the assay sensitivity range for glucose (≈2-33 mM) covers the relevant glucose 
target levels (≈ 4-7 mM). For Addison’s disease, while serum cortisol levels below the limit of 




normal cortisol levels (55-690 nM depending on time of day), which are above the assay 
sensitivity limit [256]. The combination of a target trough that is the same or similar in value to 
the assay LLOQ makes dose individualization in hemophilia uniquely dependent on assay 
sensitivity. 
The effect of baseline is independent from the nature of the test one uses to measure 
plasma FVIII activity levels. Two clotting assays are primarily used to assess FVIII activity in 
plasma: the chromogenic assay and the one-stage assay. According to a report by Chandler et al, 
the intra-assay imprecision was similar for both methods (CV = 13%) while inter-assay 
imprecision was lower for the one-stage (17.5%) compared to the chromogenic (26.7%) at low 
FVIII levels [257]. In recent peer-reviewed literature, the LLOQ for the chromogenic assay was 
0.01 IU mL−1 (single-chain recombinant FVIII) [258], 0.01 IU mL−1 (B-domain deleted 
recombinant FVIII) [182], 0.015-0.03 IU mL−1 (full length recombinant FVIII) [185] and 0.004 
IU mL−1 (recombinant FVIII Fc fusion protein) [106]. For the one-stage assay, the LLOQ was 
0.005 IU mL−1 (recombinant FVIII Fc fusion protein) [106], 0.01 IU mL−1 (B-domain deleted 
recombinant FVIII) [182], 0.005 IU mL−1 (recombinant FVIII Fc fusion protein; lower limit of 
reportable range = 0.007 IU mL−1) [184] and 0.005 IU mL−1 (recombinant FVIII) [184]. While 
there are LLOQ values below 0.01 IU mL-1 in the above referenced studies, the majority of 
participating clinical sites in WAPPS-Hemo report baseline as <0.01 IU mL-1. This suggests that 
0.01 IU mL-1 is the most common LLOQ in practice.  
Shima et al [259,260] have been active in the area of FVIII activity assay sensitivity. 
Thirty-six hemophilia A patients defined as severe based on the above conventional assays 
(<0.01 IU mL−1) were re-assayed using a more sensitive technique called clot waveform analysis 




IU mL−1 and 13 (36%) had levels between 0.002 and 0.01 IU mL−1 [260]. Another random 
sample of severe hemophilia A patients produced 12 (67%) patients with an endogenous FVIII 
level of <0.002 IU mL−1 and 6 (33%) with levels between 0.002 and 0.01 IU mL−1 [261]. 
Matsumoto went on to distinguish between those with a very low FVIII level (HA, <0.0025 
IU mL−1) and those patients with inhibitors (HA-ihb), who presumably have no FVIII activity. 
While there was some overlap between the maximum (HA-ihb) and minimum (HA) values of the 
two groups, for the most part, those patients with a <0.0025 IU mL−1 level had at least some 
FVIII activity, although it could not be directly quantified [262]. While different mutations have 
been correlated with the presence or absence of cross-reactive material (CRM) and thus 
immunologically measured amounts of FVIII with associated differential risk of inhibitor 
development [263], little is known about the clotting activity of those trace amounts. The 
potential for future studies correlating genotype with endogenous, not measurable, FVIII activity 
to translate clinical impact on dosing remains unknown. Furthermore, while F8 gene mutation is 
the largest determinant of baseline FVIII activity, other factors may contribute to baseline 
activity. In a study of mild/moderate hemophilia A patients, Loomans et al [264] found that 
patients with the same mutation had significantly different baseline activities (inter-individual 
variability = 45%). As a result, further development and implementation of assays that allow for 
detection at very low FVIII levels will be important to ensure both genotype/phenotype 
concordance for clinical purposes [259] as well as appropriate FVIII dosing.  
Researchers have attempted baseline estimation using a PopPK modeling approach. 
Brekkan et al [178] (plasma-derived FIX) estimated baseline with a typical value of 0.016 IU 
mL-1 in a cohort of severe and moderate patients. Abrantes et al [182] (B-domain deleted 




the severe and moderate cohort, respectively. In Stass [228], recombinant FVIII baseline for each 
individual was estimated to be less than 0.01 IU mL-1 and in-line with their severe status. While 
this may provide for a population level data description of baseline, baseline level is not 
estimated in the Bayesian post hoc estimation step with sparse data and thus this population 
estimation is irrelevant when it comes to individualized dosing.  
From a mathematical standpoint, it is interesting to contemplate an analytical solution to 
the quantification of an individual’s baseline that is below the LLOQ.  For this, one would 
require at least two FVIII levels at the same time point following different doses. With these two 
dose-level pairs, an analytical solution to baseline can be found by rearranging the equation used 







𝐷𝑜𝑠𝑒1 ∙ 𝐿𝑒𝑣𝑒𝑙2 − 𝐷𝑜𝑠𝑒2 ∙ 𝐿𝑒𝑣𝑒𝑙1
𝐷𝑜𝑠𝑒1 − 𝐷𝑜𝑠𝑒2
 
Equivalently, one could plot these dose-level pairs and determine the intercept of the line drawn 
through them. For example, suppose a patient was given a dose of 1000 IU and a subsequent 
dose of 3000 IU. By comparing the 24-hour level following each dose, one could determine 
baseline. While this calculation appears simple, its application can be challenging as the slightest 
deviation from the expected activity level can have dramatic consequences for the baseline 
calculation. For example, inaccurate activities (even within 10% of the true value) can result in a 




real patients from the WAPPS-Hemo repository resulted in either negative values or impossibly 
high baseline activity (i.e. >20%) for severe hemophilia patients, suggesting that the imprecision 
of real data will not allow for an analytical solution to determining baseline. Based on available 
information, whether it be estimation of baseline from a PopPK modeling approach or a more 
direct assay approach, baseline in severe hemophilia patients is expected to be greater than zero. 
Assuming no endogenous production will therefore always overestimate dosing requirements on 
a population basis. 
There are some limitations to our study approach. The PopPK model that was used to 
create the populations assumed a baseline of 0 for all patients and was partially based on FVIII 
activities below the limit of quantification (BLQ). In fact, the manuscript describing the model 
explicitly assessed PK estimation in the presence and absence of the BLQ data [185]. While the 
assumption of baseline FVIII activity during PopPK assessment in severe hemophilia is unlikely 
to greatly alter model parameters, simulation from the model to determine generic population 
doses is dependent on the baseline assumption. We have conducted this study using a single 
FVIII model, although there is no reason to imagine that similar results couldn’t be replicated by 
using any other brand or model. Similarly, we anticipate that the uncertainty about the true 
baseline level of clotting factor will have the same consequences for factor IX, where the 
imprecision could be even larger, as the CRM positive cases are proportionally more. 
As to clinical implications, all the above considerations about baseline do not diminish 
the importance of PopPK modeling and Bayesian estimation in deriving individual regimens, but 
emphasizes that the method is not helpful for deriving individual baselines. For all patients with 






The dosing of factor concentrates in severe hemophilia is affected by the true 
unmeasurable level of endogenous FVIII activity. The sensitivities of FVIII activity assays are 
close to the commonly targeted trough level – a situation that is unique to hemophilia. On a 
population level, variation in baseline FVIII levels is a contributing factor to the overall 
variability in PK response to FVIII. On an individual basis, assumptions of baseline activity 
greatly impact the estimation of time to 0.01 IU mL-1 and the tailoring of a dosing regimen based 
on observed levels. Further reducing assay sensitivity below 0.005 IU mL-1 will decrease the 
proportion of patients for whom there is uncertainty with respect to baseline FVIII activity. 
Alternatively, clinicians may choose to target slightly higher troughs (0.02 IU mL-1 and above), 






Chapter 9: Modeling of body weight metrics for effective and cost-efficient 
conventional factor VIII dosing in hemophilia A prophylaxis 
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Introduction 
Hemophilia A is an inherited bleeding disorder resulting from a deficiency in clotting factor 
VIII (FVIII), causing spontaneous and recurring joint bleeds, eventually leading to arthropathy 
and premature death if left untreated. The mainstay of severe hemophilia treatment is 
prophylactic replacement of the missing factor. The typical aim of prophylaxis is to maintain a 
clotting factor level of at least 1 IU dL−1, based on the observation that patients with moderate 
hemophilia (i.e., those with baseline factor levels >1 IU dL−1) are less prone to the spontaneous 
bleeds and subsequent arthropathy seen in more severe cases [69]. In a study of 65 boys with 
severe hemophilia A, only regular prophylactic infusions were shown to prevent joint damage as 
compared to on-demand treatment [9]. While there is global unanimity that prophylaxis should 
be initiated before joint disease is sustained [12,13], the implementation of this approach is quite 
variable [14]. No optimal dosing regimen has been identified; instead, an individualized 
approach that accounts for the patient’s physical activity, current (and accepted future) 




the patient’s pharmacokinetic (PK) profile is taken into account to define a truly individualized 
regimen that optimizes both safety and resource utilization [238]. To facilitate the adoption of 
PK-based dosing regimens, tools such as the Web Accessible Population Pharmacokinetics 
Service—Hemophilia (WAPPS-Hemo [170,252]) provide estimates of individual PK parameters 
from a minimal number of samples by leveraging population PK data. Despite the development 
of these platforms, the majority of hemophilia patients are still dosed according to total body 
weight, as initially proposed by Ingram in 1981 [266]. For instance, hemophilic children in 
Canada are started on a once-weekly regimen (50 IU kg−1), then step up to either twice weekly 
(30 IU kg−1) or every 48 h (25 IU kg−1) as required; prophylaxis regimens in the Netherlands 
(Utrecht protocol: 15–30 IU kg−1 three times per week) and Sweden (Malmö protocol: 25–40 IU 
kg−1 three times per week), though proposing different intensities and targeting different levels, 
are based on the same principle [267].  
The normalization of life expectancy of individuals with hemophilia brings new challenges 
to hemophilia care. Overweight and obesity rates amongst hemophiliacs now match the epidemic 
proportions that are seen in the general population [268]. A 2011 study conducted in Ontario 
found 28.8% of enrolled hemophiliacs were overweight or obese, compared to 26% of healthy 
controls [269]. Obesity also comes with a higher risk for hemophilic arthropathy; joint range of 
motion has been shown to negatively correlate with body mass index (BMI) [270]. Furthermore, 
the total body weight-based dosing regimen currently used in hemophilia treatment may not be 
appropriate for overweight and obese populations. Calculations for weight-adjusted dosing are 
based on the following formula: 
Dose (IU) = 






In vivo recovery (IVR) is a parameter used to describe clotting factor pharmacokinetics, and 
reflects the rise in factor activity (in this case, FVIII) after a dose is administered. Although it has 
been suggested that an individual IVR value be determined for each patient [271], typically an 
IVR of 2 IU dL−1/IU kg−1 is assumed. For example, a desired increase to normal FVIII levels 
(100%) would lead to a 50 IU kg−1 dose being administered. However, the assumption that IVR 
equals 2 for all is not always valid. A study by Henrard et al. found that overweight patients 
(BMI > 29.6 kg·m−2) had a median IVR of 2.70, while underweight patients (BMI < 20.3 
kg·m−2) had a median IVR of 1.60 [121]. 
The emerging proportion of overweight and obesity in the general population has prompted 
research efforts aimed at identifying pharmacokinetic differences (and the corresponding dose 
adjustments) in this population. The relationship between body size and clearance is well 
established; a 2012 systematic review of this topic found that more than half of all identified 
models for clearance included a covariate for body size, most commonly as a power function 
[272]. Obesity specifically influences several factors affecting drug disposition, including body 
composition, metabolism by CYP450 enzymes, and plasma protein levels [273]. The most 
striking differences are observed for highly lipophilic drugs, where volume of distribution 
changes dramatically in the obese population [274]. However, this is not the case for clotting 
factor concentrates. FVIII concentrates are typically confined to the vascular space, with 
volumes of distribution approximating plasma volume (48 mL·kg−1) [71]. Since vasculature 
represents a very small fraction (0.005–0.010) of adipose tissue volume [122], an excess (or 
scarcity) of fat does not significantly alter the volume of distribution of FVIII. As a result, 
overweight and obese patients are likely overdosed when dose is calculated using total body 




compound whose volume of distribution is approximately equal to the plasma volume; obese 
children achieved comparable anticoagulation at a lower weight-based dose [276]. Hemophilia 
treatment is expensive, with annual costs in the hundreds of thousands for those on prophylaxis 
[9], and while prophylaxis does achieve better health outcomes, these come at a significant cost 
that is not automatically offset by prevention of other expenses [277]. As the clotting factor itself 
represents the majority of the cost of prophylaxis [141], overdosing can introduce a significant 
waste of resources [278]. This study will explore alternative dosing regimens that optimize both 
safety and resource utilization in overweight and obese hemophiliacs. 
 
Methods 
Population generation, simulation, and data analysis were all conducted in MatLab R2009. 
Population Generation 
The generated population of virtual individuals consists of two equal sized bins classified by 
BMI using the cut-offs defined by Henrard et al. [121] The first group consists of average weight 
subjects (BMI between 20.3 and 29.6 kg·m−2); the second group represents an overweight and 
obese population with BMI between 29.6 kg·m−2 and 40.0 kg·m−2. These cut-off values for BMI 
were found to be the strongest predictors of FVIII IVR. Each group contains 1000 simulated 
subjects with a uniform BMI distribution. Heights were derived from the distribution provided 
by the NHANES database [215]. A uniform distribution of BMI’s was simulated and the total 





Definitions of Weight Metrics 
The following weight metrics were defined for each virtual patient from their simulated total 
body weight (TBW, kg), height (HT, cm) and BMI (kg·m−2): 
1. Lean body weight (LBW)  
LBW = 
9270 ∙ TBW





2. Ideal body weight (IBW—Lorentz formula) 







3. Adjusted body weight (ABW) 
ABW25 = IBW + 0.25 ∙ (TBW − BW) 
 





We used the semi-mechanistic model for LBW developed by Janmahasatian et al. [279] as it has 
been found to better describe the full range of adult heights and weights [274]. IBW was 
calculated using Lorentz’s formula, which takes into account the patient’s height and sex but not 
total body weight. ABW was the first weight metric intended for use in pharmacokinetic studies; 
it involves adding a proportion of the excess weight above IBW [280]. This proportion is 
variable, ranging from 25%–50%, with 40% being used most commonly; in this study, we 




body size metrics are presented in Supplementary Figure S6 and Figure S7 for normal and 
overweight/obese individuals, respectively. 
Population Pharmacokinetic Model 
Simulations were performed using the 2-compartment structure described by Garmann et al. 
[185] for BAY 81-8973 (Kovaltry®), built on 183 subjects. Of the 109 patients above 18 years of 
age, the BMI range was 15.0–38.3 kg∙m-2. The details of the model structure are presented in 
Table 26. For each simulated individual, PK parameters were calculated. Each virtual individual 
was then dosed based on various weight metrics and their PK was simulated. 
 
Table 26. Details of the model developed by Garmann et al [185] 
Parameter Estimate Covariate Effectsc BSVd (%CV) 







clearance (Q, dL h-1) 
1.90   






Peripheral volume (V2, dL) 6.37   
Proportional RUVa (%CVb) 26.7   






Simulation and Assessment of Treatment Regimens 
For each virtual individual, FVIII levels and individual PK parameters were simulated 
assuming a baseline factor level of 0.5 IU dL-1. FVIII levels were simulated using time steps of 
0.2 h following dosing regimens for four weeks to ensure that steady state was reached, and 
results from the 5th week were used in subsequent analysis steps. In a first instance, we analyzed 
a typical dosing strategy (20 IU kg−1 TBW every 48 h) to evaluate its appropriateness.  
We then simulated various regimens wherein equal doses were given at regular intervals 
(i.e., 48 h). Each patient was dosed from 10 IU kg−1 for each weight metric (10 IU kg−1 of TBW, 
10 IU kg−1 of LBW, etc.) up to 210 IU kg−1. Initially, the dose step was 2 IU kg−1 for doses up to 
100 IU kg−1 and 10 IU kg−1 for doses between 100 and 210 IU kg−1. After reviewing the results, 
the dose step was reduced to 0.1 IU kg−1 between 20 and 30 IU kg−1, as this was the range of 
most interest. A regimen was considered to be safe for a BMI group if 95% of the simulated 
population within that group had factor levels above 1 IU dL−1 at all times (Cmin ≥ 1 IU dL
−1). 
The lowest dose per weight metric that met this safety criterion was identified and considered to 
be the optimal regimen for that particular metric and BMI group. A secondary measure of safety 
was the 95th quantile for time spent below 1 IU dL−1; in other words, the amount of time per 
week spent below trough for the 5% of the population not meeting the safety criteria. To evaluate 
economic differences between regimens, we calculated the mean weekly consumption on each 
optimal regimen to determine which dosing regimen met safety requirements while minimizing 
resource expenditure. This process was then repeated for a Monday-Wednesday-Friday (M-W-F) 
dosing schedule. For these simulations, the optimal dose for each metric (determined in the 
previous simulations) was administered on Monday and Wednesday, and the Friday dose was 




assumption of 0.5 IU dL−1 baseline, we repeated the above simulations assuming a baseline of 0 
IU dL−1 to observe if similar trends emerged.  
 
Results 
Simulations of the typical regimen of 20 IU kg−1 TBW every 48 h were completed and the 
results are summarized in Table 27. We then investigated the hypothesis that a TBW-based 
dosing regimen results in overdosing in overweight and obese patients by determining the TBW-
based dose required to meet the 1 IU dL−1 safety criterion in 95% of these patients. At a dose of 
20 IU kg−1 TBW, the median minimum concentration (Cmin) throughout the week for these 
patients was 5.4 IU dL−1; the average consumption associated with this dosing regimen was 7.25 
× 103 IU per person per week. However, this population requires only 14 IU kg−1 TBW to meet 
the 95% safety criterion, which corresponds to an average weekly consumption of 5.07 × 103 IU 
per person.  
 
Table 27. Comparison of the typical 20 IU kg−1 total body weight (TBW) dose and the lowest 
dose meeting the safety threshold (i.e., 14 IU kg−1 TBW) in overweight and obese patients. 
Results are presented as median (90% confidence interval). 
Criterion 
Regimen 
20 IU kg−1 TBW, Q48 h 14 IU kg−1 TBW, Q48 h 
Cmin (IU dL−1) 5.4 (1.2–17.3) 3.9 (1.0–12.3) 







Following this initial investigation, we explored dosing regimens using alternative weight 
metrics. The correlation between each weight metric and BMI is shown in Figure 33. We began 
by administering a dose of 10 IU kg−1 of each weight metric on a Q48 h dosing schedule. Once 
steady state was reached, the percentage of patients with Cmin ≥ 1.0 IU dL
−1 was calculated. If 
this percentage was below 95%, the dose was incrementally increased until this threshold was 
reached. We then calculated the mean weekly consumption associated with the minimum dose 
required to reach the safety criterion for each metric to assess cost-effectiveness. Since a 
Monday-Wednesday-Friday dosing schedule is commonly used in hemophilia A prophylaxis, we 
performed analogous simulations using this schedule instead of a regular 48 h interval. We used 
the optimal doses found in the previous study on Monday and Wednesday, and then increased 
the dose on Fridays to compensate for the longer interval until the safety criterion was met.  
 
Figure 33. Correlation of body weight metrics with body mass index (BMI) for each BMI 
subgroup (blue = normal weight, red = overweight and obese). TBW: total body weight; HT: 





Table 28 and Table 29 summarize the doses per kg of each weight metric required to 
reach the 95% safety criterion (when infused every 48 h or Monday-Wednesday-Friday, 
respectively) and the associated weekly consumption in each of the BMI categories and in the 
merged population, assuming a baseline factor level of 0.5 IU dL−1. The most appropriate 
regimen is the one that meets the safety requirements while consuming the least amount of factor 
concentrate. For patients within the normal BMI range, LBW produced the optimal regimen for 
both dosing schedules; for the overweight and obese cohort, an IBW-based dosing regimen was 
found to be most cost-effective. Furthermore, the range of mean weekly consumption across the 
various weight metrics was much tighter for the normal BMI subgroup (125 IU per person per 
week) as compared to the overweight/obese subgroup (483 IU per person per week). When the 
two subgroups were combined, ABW with a 25% correction factor proved to be ideal for the 
Q48 h regimen, with IBW a very close second with a difference of just 5 IU per person per week. 
Both ABW25 and IBW perform almost identically in terms of safety for both BMI subgroups for 
the Q48 h regimen (Figure 34). However, IBW performed better than all other weight metrics 
when a Monday-Wednesday-Friday schedule was adopted, with a difference in consumption of 
over 100 IU per person per week when compared to the next best metric (LBW). Nevertheless, 
the amount of time spent below 1 IU dL−1 is significantly greater when following a Monday-
Wednesday-Friday regimen as compared to the Q48 h dosing schedule (Figure 35b); 
additionally, an extremely high Friday dose (>125 IU kg−1 TBW) is required to meet the 95% 
safety requirement, whereas a dose of 18 IU kg−1 TBW is successful for the Q48 h regimen 




Table 28. Summary of safety and economic evaluations of different weight metrics used in a Q48 h regimen across BMI subgroups, 
assuming a baseline factor level of 0.5 IU dL−1. Dose is the dose required to have 95% of patients with a steady state Cmin over 1 IU 
dL−1. Optimal regimens for each subgroup and the overall population are bolded.  























TBW 20.0 5202 14.0 5074 18.0 5603 - 
LBW 25.6 5114 21.3 5028 23.8 5186 −417 
IBW 22.2 5222 20.7 4828 22.1 5176 −427 
ABW25 21.7 5239 20.0 5311 20.4 5171 −432 
ABW40 21.1 5173 18.0 5129 20.0 5301 −302 
 
 
Table 29. Summary of safety and economic evaluations of different weight metrics used in a Monday-Wednesday-Friday regimen 
across BMI subgroups, assuming a baseline factor level of 0.5 IU dL−1. Dose is the Friday dose required to have 90% of patients with 
a weekly Cmin ≥1 IU dL
−1. Optimal regimens for each subgroup and the overall population are bolded. 
 Normal Overweight and Obese All BMI Categories 
Metric Dose (IU kg−1) 
Mean 
Consumption 
(IU Per Person 
Per Week) 
Dose (IU kg−1) 
Mean 
Consumption 
(IU Per Person 
Per Week) 
Dose (IU kg−1) 
Mean 
Consumption 





TBW 74 8174 54 9320 62 8716 - 
LBW 94 8082 82 8740 88 8442 −274 
IBW 78 8213 84 8543 80 8312 −404 
ABW25 78 8195 72 8558 76 8459 −258 





Figure 34. Percentage of patients with Cmin ≥ 1 IU dL
−1 (safety) at increasing doses per kg of 
various weight metrics, stratified by BMI subgroup, administered at 48 h intervals. 
 
Figure 35. (a) Median and 90% confidence intervals for Cmin and (b) 95th quantile for time spent 
below 1 IU dL−1 (hours per week) for TBW-based dosing regimen administered at different 
intervals for the combined group (normal + overweight/obese) for both Q48 h (blue) and 
Monday-Wednesday-Friday (red) dosing schedules. For the Q48 h regimen, all doses are 
increasing along the X-axis; for the Monday-Wednesday-Friday schedule, only the Friday dose is 




Ideal body weight continued to perform well in simulations with an assumed baseline of 0 
IU dL−1. The safety ratio versus dose curves are once again nearly identical for both BMI 
subgroups (Figure 36), although consumption was approximately doubled as compared to the 
Q48 h regimen.  
 
Figure 36. Comparison of safety profiles for patients simulated with baseline (BL) 0.5 IU dL−1 
and 0 IU dL−1 for a Q48 h regimen. Safety (%) is the percentage of patients with Cmin ≥ 1 IU 
dL−1 at various doses per kg of IBW.  
 
Discussion 
We began by assessing the safety and cost-effectiveness of a typical 20 IU kg−1 TBW, Q48 h 
regimen in an overweight and obese patient population. For comparison, we determined the 
TBW-based dose required to meet the safety criterion. At a dose of 14 IU kg−1 TBW, 95% of 
patients had FVIII levels of at least 1 IU dL−1 at all times; the median Cmin was 3.9 IU dL
−1 and 
the mean consumption was just over 5000 IU per person per week. By contrast, the 20 IU kg−1 
TBW regimen produced a median Cmin of 5.4 IU dL
−1 with a mean consumption of 7250 IU per 




consumption than required in the overweight and obese population; assuming a cost of $1 US per 
unit of concentrate, this amounts to over $100,000 US in excess spending per person annually. 
From this evaluation, it is clear that TBW does not represent the optimal body weight metric to 
guide FVIII dosing.  
Simulations using dosing regimens based on alternative weight metrics (LBW, IBW, 
ABW25, and ABW40) were carried out using the two most common dosing schedules in 
hemophilia A prophylaxis: a regular 48 h regimen and a Monday-Wednesday-Friday regimen. 
Adapting a Monday-Wednesday-Friday timetable made it extremely difficult to meet the safety 
requirement, regardless of which weight metric was used to define the dose. While patients are 
often advised to increase their FVIII dose on Friday, a simple doubling of the dose is not 
sufficient. A potentially harmful Friday dose of 140 IU kg−1 TBW was required for 95% of 
patients to have a Cmin ≥1 IU dL
−1, compared to 18 IU kg−1 TBW to meet this safety minimum 
when infused every 48 h. Furthermore, the time spent below 1 IU dL−1 (and, consequently, the 
risk of bleeding events [10]) is significantly greater when following a Monday-Wednesday-
Friday regimen, even if the Friday dose is twice or three times greater than the Monday and 
Wednesday doses (Figure 3b). In fact, a 2010 study in which FVIII was administered three times 
per week found that over 80% of bleeds occurred 48–72 h post-infusion [281]. The Monday-
Wednesday-Friday treatment schedule, while more convenient, is no longer considered to be 
optimal therapy due to this increased vulnerability to bleeds during the weekend, with alternate 
day dosing representing the ideal regimen [205,233]. 
Due to analytical limitations, it can be difficult to obtain an exact measure of a patient’s 
baseline factor level. Many assays have a lower limit of quantification of 1 IU dL−1 [282,283], 




and resource utilization, we ran initial simulations with an assumed baseline of 0.5 IU dL−1. 
However, it is known that many severe hemophilia patients possess a genetic mutation such that 
no functional FVIII is produced endogenously. For this reason, the simulations were performed 
again using a baseline of 0 IU dL−1 to ensure similar trends were observed within this sub-
population. Notably, a 95% safe ratio can be achieved in a population with no endogenous FVIII 
production at a reasonable dose (34 IU kg−1 TBW) if administered every 48 h. However, it is not 
possible to meet that safety threshold in this population if a Monday-Wednesday-Friday dosing 
schedule is employed. If the safety criteria is lowered to 90%, it can be met, but only with 
extremely high Friday doses (between 130 and 180 IU kg−1 for the various weight metrics) and 
associated weekly consumption (>16,000 IU per person per week); a study by Collins et al. 
found similarly high doses (>100 IU kg−1 for patients with average half-lives, and up to 400 IU 
kg−1 in extreme cases) were required to maintain FVIII levels above 1 IU dL−1 throughout the 
week when following this dosing schedule [74]. These results suggest that a regular dosing 
interval of 48 h offers significant advantages over the weekly Monday-Wednesday-Friday 
schedule in terms of both safety and cost-effectiveness.  
After exploring all combinations of dosing schedule and baseline factor level, we 
determined that IBW-based dosing provides a safe and cost-effective regimen in the majority of 
scenarios, with ABW25 producing fairly similar results. Ideal body weight performed almost 
exactly the same in terms of safety between the normal and overweight groups across all of the 
doses and regardless of baseline, as evidenced by the closeness of the curves shown in Figures 2 
and 4. Further, IBW was the most cost-effective in three out of four simulations; in the fourth, it 
differed by only 5 IU per person per week from the optimal regimen (ABW25). If we compare the 




20 IU kg−1 TBW, this alterative regimen offers a savings of over 2000 IU per person per week 
(or nearly $110,000 US annually) for overweight and obese patients. Thus, IBW-based dosing 
offers a similar safety profile to the currently used TBW strategy while moderating the economic 
burden of clotting factor prophylaxis.  
This exercise was limited by the constraints of the data. The model used herein was built on 
PK data from a specific brand of FVIII concentrate, although brand has not generally been found 
to significantly influence PK. A second limitation to the applicability of this approach is that the 
source data is largely from older (10+ years of age) patients, and the opinions on use of 
prophylaxis in adults are varied [284–286]. Obesity rates are also increasing rapidly amongst 
pediatric patients and similar dosing adjustments are likely appropriate in this population, but 
cannot be confirmed in this study. Further study of pediatric populations (and validated pediatric 
population PK models) is required in order to determine a dosing regimen that applies not only to 
all BMI’s but also to all ages. 
As the prevalence of obesity has risen in the general population, a number of studies have 
been conducted to investigate the frequency of overweight and obesity among hemophilia 
patients, complications such as co-morbidities and decreased quality of life, and 
recommendations for management strategies. Many pharmacokinetic studies exploring the 
relationship between excess body weight and plasma volume (and, by extension, in vivo 
recovery) have postulated that dosing according to body weight results in overdosing and an 
ineffective use of resources, suggesting instead that dosing be guided by LBW or IBW 
[121,273,287,288]. This study compared several weight metrics and confirmed that an IBW-
based regimen is both safe and cost-effective across a range of BMI’s. Ideal body weight 




height; as shown in Figure 33, there is no correlation between IBW and BMI as observed with 
the other metrics investigated. 
Although we were able to identify a weight metric that is more suitable for a variable 
population, the high inter-individual variability in PK handling of factor concentrates precludes 
the definition of a single, “one dose fits all” strategy. In order to optimize prophylaxis, regimens 
should be tailored to the individual PK profile. This process has been facilitated by the 
development of the WAPPS-Hemo service (www.wapps-hemo.org), a Canadian-based user-
friendly and industry-independent platform that produces estimates of individual PK parameters 
through a Bayesian iterative approach. The WAPPS-Hemo service also includes a module for 
dosing regimen development, wherein clinicians can predict the effects of changing dose, 
frequency, or targeted trough for a specific patient before implementing these changes in 
practice. While PK-tailored dosing regimens may offer the best results, weight-based strategies 
are still the norm, but these can be optimized by adapting a different weight metric (i.e., IBW) to 
guide safe and cost-effective dosing at a population level.  
Conclusions 
In summary, we conducted simulations based on a previously published model of a 
conventional FVIII to explore the appropriateness of different weight metric-based dosing 
regimens for hemophilia A prophylaxis for overweight and obese patients. Regimens were 
required to produce a Cmin ≥1 IU dL
−1 in 95% of the population, and then the average 
consumption for each regimen was calculated to evaluate resource-effectiveness. From this 
study, we conclude that ideal body weight performs the best, maintaining safety while tempering 









 The overarching objective of this thesis is to develop PopPK models for clotting factor 
concentrates that enable dosing regimen individualization for hemophilia patients, and to 
understand the clinical factors that influence the performance of such models.  
 The opening chapter of the thesis consists of a comprehensive review of recent 
pharmacokinetic studies of FVIII concentrates, including plasma-derived and recombinant, 
standard and extended half-life products. This exercise had two primary objectives: (i) to 
summarize the variability observed in FVIII concentrate PK, thereby confirming the 
appropriateness of a PK-tailored dosing regimen in hemophilia, and; (ii) to identify covariates 
that have been found to influence FVIII PK. The often noted high inter-patient variability 
(particularly on clearance and, consequently, half-life) was extremely apparent; not only was 
there considerable discrepancy between studies (SHL FVIII half-life ranged from 9.4 to 17.4 h), 
but within-study variability was also high (>30%) in many cases.   
Age, weight, vWF level, and blood group were identified as important determinants of 
FVIII PK. However, the effects of age and blood group are related to vWF. Lalezari and 
colleagues found that vWF levels increase with age [120], hence the reduced FVIII clearance and 
longer half-lives observed in older hemophilia A patients. ABO blood group has also been 
shown to correlate with vWF level in several studies with a variety of patient populations 
[117,289–291], with blood group O individuals typically having approximately 25% lower 
plasma levels of vWF [292]. Furthermore, a 2018 study found an interaction between age and 




the non-O group than in those with O-type blood, leading to larger discrepancies later in life 
[117]. This proposed interconnectedness is reinforced by two studies that observed minimal 
blood group-related differences in vWF levels in children [117,293,294]. The details of the 
mechanism through which blood group and vWF levels are related remains unclear; one 
hypothesis proposes that O-type blood increases vWF susceptibility to cleavage by the protease 
ADAMTS13 [295], while another suggests that variations in antigen expression across blood 
groups mediates this effect [296].  
Chapter 2 outlines a data analysis protocol for model development and evaluation that 
began the process of standardizing the model-building procedure for the WAPPS-Hemo project, 
which is predicated on models that can reliably produce individual PK estimates from sparse 
samples. This section builds on a previously published data analysis protocol [170], drawing on 
the WAPPS-Hemo modelling team’s unique experience with PopPK models for Bayesian 
forecasting of clotting factor concentrate PK. The protocol was subsequently applied to build the 
generic SHL FVIII model (Chapter 4). This unique model is built specifically to meet the needs 
of the WAPPS-Hemo project; not only is the model fit for Bayesian forecasting, it is also able to 
predict the PK of SHL FVIII products outside of the modelling dataset. This second capability is 
of considerable importance, as a plethora of such products exist, but not all meet the data 
requirement for a brand-specific model. Since its implementation on the WAPPS-Hemo 
platform, the generic SHL FVIII model has been used to process over 2,000 PK requests in more 
than 1,240 patients; of particular note, 511 of these requests were for brands outside of the 
original modelling dataset.  
The data analysis protocol was once again put into practice in the development of the 




project, this model was used to answer a research question stemming from an ongoing clinical 
trial investigating the PK of the rFIX product IXINITY in children (NCT03855280). Several PK 
outcomes are to be estimated following a sampling schedule based on recommendations from the 
European Medicines Agency [297]. However, concerns arose that participating centres may be 
averse or unable to collect all five of the intended samples from young patients due to pediatric 
sample volume limitations. To determine how omission of a sampling point would impact PK 
parameter estimates, a limited sampling analysis was performed using the generic SHL rFIX 
model, which leveraged adult and pediatric PK data from other rFIX products and adult data 
from IXINITY to develop a PopPK model that is valid for all ages and all available brands of 
rFIX. The results of this analysis highlight the robustness of Bayesian forecasting in limited 
sampling conditions, especially compared to the traditionally used noncompartmental methods. 
Further, it confirmed the sensitivity of half-life estimation to sampling duration when using 
NCA. The original EMA-based sampling strategy produced biased estimates of half-life (mean 
error: –24%) as its latest sampling time was 48 h; the addition of a 72 or 96 h sample quickly 
remedied this problem, without significantly altering estimates of other outcomes of interest. 
In addition to developing original PopPK models using the WAPPS-Hemo database, 
previously published models were also employed to answer specific questions relevant to 
hemophilia treatment. First, the Nestorov model for Eloctate (rFVIIIFc) was used in Chapter 6 to 
determined limited sampling strategies for this relatively new EHL FVIII product. Sampling 
designs consisting of two to three timepoints were assessed not only on the accuracy of the PK 
parameter estimates, but also on whether the same clinical decisions regarding dose adjustment 
would be made compared to a rich sampling design. Distinct LSSs were determined for adult, 




strategies in children for other factor concentrate products, as current ISTH guidance provides 
one sampling strategy per product group, regardless of age [169].  
This study was undertaken while visiting St. Jude Children’s Research Hospital in 
Memphis, Tennessee. Since their hemophilia clinic runs on a weekly basis, the hematology team 
at St. Jude typically only obtains patient samples at predose and peak. For this reason, factors 
outside of sampling time were considered in order to optimize the results of this sampling 
strategy, such as predose handling and study day. Through this limited sampling analysis, it was 
determined that when prior dosing information is taken into account and the PK study is 
performed 48 hours after the last dose, reasonable estimates of troughs and PK parameters can be 
obtained (median AE <12%) and the rate of inappropriate dose adjustments is low (<4%) for 
pediatric patients. Clinicians at St. Jude identified that taking the typical 72-hour predose level 
often resulted in a BLQ sample, and altered their protocol to collect a 48-hour predose in its 
place; this simulation study provides justification for this modification and quantifies the 
improvement seen with this new strategy. In addition, the results of the investigation into predose 
handling have been incorporated into the WAPPS-Hemo platform, as a description of the 
patient’s regimen is now being collected.  
The Garmann model for Kovaltry, a full-length rFVIII product, was used to explore to 
consequence of unmeasurable endogenous FVIII activity. This project originated while 
designing the Clinical Calculator component of the WAPPS-Hemo service. In this module, 
clinicians enter two of the following parameters to calculate the third: dose, frequency, and target 
trough. This amounts to scaling the infusion that was submitted for PK estimation to the selected 
dosing scenario. However, only exogenous factor should be scaled, as the endogenous (or 




endogenous FVIII levels are often unmeasurable in severe hemophilia A patients and although 
the range of possible baseline values may be narrow, the consequences of mishandling this 
assumption can be quite significant. In Chapter 8, it is illustrated how baseline assumptions can 
contribute to the variation in dosing requirement to maintain the target trough of 1 IU/dL. When 
estimating individual PK outcomes, some parameters are more robust than others. For example, 
half-life differs minimally (<1 h difference) when the full range of undetectable baseline values 
is explored while the estimated time to reach 1 IU/dL varies by almost a full day. Although no 
way of calculating baseline was determined in this study, the potential error that can arise from 
disregarding the importance of baseline was quantified.   
The final example of repurposing an existing PopPK model is in Chapter 9, where the 
Garmann model was again used to determine a superior body weight metric for FVIII dosing for 
settings in which PK-tailored dosing is difficult to implement. The suspicion that total body 
weight may result in suboptimal dosing regimens for some patients is based on the high in vivo 
recovery observed for overweight and obese patients. This arises from the fact that FVIII stays 
primarily within the plasma space and plasma volume does not necessarily increase with total 
body weight, leading to the hypothesis that alternative weight metrics such as lean body weight, 
ideal body weight, or adjusted body weight may curtail overdosing in high BMI patients while 
maintaining safety. While overdosing of factor products does not generally result in toxicity due 
to their rapid clearance, overdosing is still of concern as clotting factor concentrates are an 
extremely expensive therapy. When considering variable endogenous FVIII production (0.5% 
baseline FVIII vs. true zero) and multiple dosing schedules (Q48h vs. Monday-Wednesday-
Friday), ideal body weight was found to produce the most cost-effective regimen that kept FVIII 




dose of 20 IU/kg of total body weight to 20 IU/kg of ideal body weight results in a 33% cost 
reduction, or over $125,000 saved per year.   
Finally, Chapter 7 chronicles the growth of the WAPPS-Hemo project in recent years, 
and demonstrates the clinical application of this particular tool for estimation of individual PK 
parameters to guide dosing decisions in hemophilia care. Although the potential benefits of 
individually tailored dosing regimens have been extolled since the early 1990s, uptake of PK-
tailored dosing has traditionally been hampered by rigorous sampling requirements, the need for 
a washout period, and limited availability of tools for PK analysis. By examining two distinct 
periods since WAPPS-Hemo was launched in 2015, trends regarding both patient characteristics 
and sampling patterns could be elucidated. The use of WAPPS-Hemo by hemophilia treatments 
providers increased by more than 3-fold between the two periods investigated. More than 1,900 
infusions were eligible for the analysis, with 85% corresponding to FVIII concentrates. 
Unsurprisingly, the usage of EHL FVIII products increased considerably during Period 2, nearly 
doubling from 15% to 29%. Patients also tended to be younger during the second timeframe, 
though still adult (median age 26 vs. 18). During both time periods, sampling times were well 
aligned with the windows recommended in recent ISTH guidance. However, providers continue 
to collect peak samples, despite no formal suggestion to do so. In terms of number of samples, 
there were minimal differences across the two time periods; while there was a trend towards 
fewer samples per infusion, a significant difference was only noted for SHL FVIII products. It 
was also hypothesized that increased familiarity with the PopPK approach might influence 
sampling strategy or patient selection. Lower use centres tended to submit infusions for younger 
patients, and sampled more heavily than high use centres; however, the differences between 




recent uptake of the WAPPS-Hemo platform for implementation of PK-tailored dosing regimens 
in hemophilia. For the WAPPS-Hemo network, this provides an understanding of how the 
service is being utilized in practice, identifies key populations for consideration during model 
development, and, in light of the LSA results of Chapters 5 and 6, indicates potential 
opportunities for user education. Furthermore, this chapter highlights the timeliness of the 
research contained in this thesis, as the hemophilia community has clearly embraced the PopPK 
approach in recent years.  
 
Conclusions 
Although several novel therapies from monoclonal antibodies to gene therapy are being 
explored and incorporated into hemophilia care, prophylactic use of clotting factor concentrates 
still dominates globally. The use of PopPK to individualize the doses of these products is 
relatively new to the hemophilia community, but has grown rapidly in recent years. The first 
formal guidance on the utilization of PopPK for dose individualization was published in 2017. 
The WAPPS-Hemo network has expanded enormously over the course of this project, from 
fewer than 25 centres in 2015 to over 400 centres at the time of this thesis, and individual PK 
estimates have been generated for over 6,000 patients from more than 40 countries.  
The collective aim of this work is to improve the safety and efficiency of hemophilia 
treatment through pharmacokinetic modelling. The dissertation presents two original PopPK 
models, one for SHL FVIII products and one for SHL rFIX concentrates. Both models have been 
incorporated into the WAPPS-Hemo platform, and have been used in the estimation of over 
2,100 individual PK profiles to date. A number of simulation studies were also performed to 




to identify not only the optimal timing of samples for Bayesian forecasting, but also to explore 
the influence of predose handling and the choice of PK study day on PK estimates, and to 
compare the performance of Bayesian methods against traditional noncompartmental methods in 
limited sampling conditions.  Simulation studies were performed to demonstrate how uncertainty 
around endogenous factor production affects PK parameter estimation, and to propose alternative 
weight-based dosing strategies when PK-based tailoring is infeasible.  
 
Future Directions 
The WAPPS-Hemo project continues to grow, and recent focus has shifted from model 
development to tackling research questions that emerge in routine hemophilia care. The PK data 
repository assembled since the program was launched uniquely positions the WAPPS-Hemo 
team to answer questions in the hemophilia space, ranging from the practice-based (e.g. what is 
the prevalence of off-label dosing in hemophilia?) to the physiological (e.g. can we predict a 
patient’s vWF level from other characteristics such as age and blood group?). The newly 
launched patient app (myWAPPS) may allow for the study of patient adherence and the benefits 
of increased patient awareness and involvement in their treatment. 
As mentioned, the uptake of the PopPK approach in routine hemophilia care is ongoing. 
An important task will be the continued advocacy for this approach, and education to ensure the 
best possible results are obtained. Results from a pilot trial using WAPPS-Hemo published in 
2019 reported a significant reduction in annual joint bleed rate and increased quality of life when 
patients were switched to PK-tailored prophylaxis [237]; further additions to the evidence base in 




Despite the recent progress of PopPK in this area, some patient populations remain 
underserved, particularly patients with inhibitors. The development of neutralizing antibodies 
against the exogenous clotting factor presents a significant challenge in hemophilia A, as roughly 
one third of severe patients will present with inhibitors at some point during treatment. Inhibitors 
are typically eradicated using immune tolerance induction (ITI, regular infusion of large doses of 
FVIII) though the specifics of this method (e.g. factor product, dosing, and use of immune 
modulators) remain undefined. Provided longitudinal data is available, a PopPK model built on 
patients with inhibitors could provide insight into the terminal phase of ITI, during which 
patients’ half-lives begin to normalize. The time required for this half-life normalization can vary 
significantly between patients; a PopPK model could identify covariates responsible for this 
variability. The final criterion for successful ITI is a half-life of at least 6 hours; a limited 
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Table S1. Categorical covariate summary among high-use centres (HUCs, top 25th percentile) 
and other centres (non-HUCs) for Period 1 and Period 2 
 PERIOD 1 PERIOD 2 
HUCs Non-HUCs HUCs Non-HUCs 
Number of infusions 405 63 961 502 
Number of patients 359 54 849 437 
Number of centres 37 28 48 110 
Age (years), Mean (SD) 
                Median [Range] 
28.5 (17.6) 
27 [0.5 – 77] 
26.0 (19.6) 
19 [0.5 – 68] 
24.6 (16.9) 
19 [0.5 – 79] 
22.0 (17.0) 
17 [0.5 – 81] 
Body weight (kg), Mean (SD) 
                Median [Range] 
65.9 (25.4) 
70 [11.5 – 204] 
56.1 (27.9) 
60 [8.8 – 114] 
62.9 (27.5) 
65 [10.63 – 176] 
59.6 (29.4) 
64 [6.9 – 179] 
Infusions by Hemophilia Type 
     Hemophilia A 87.8% 79.4% 84.5% 86.1% 
     Hemophilia B 12.2% 20.6% 15.5% 13.9% 
Infusions by Product Type 
      SHL FVIII 73.4% 63.5% 57.9% 53.4% 
      EHL FVIII 14.4% 15.9% 26.6% 32.7% 
      SHL FIX 2.7% 7.9% 5.3% 5.4% 







Table S2. Summary of number of samples per patient per infusion for each product type for 











SHL FVIII    
     Mean (SD) 3.4 (1.8) 3.3 (1.5) 𝑝 = 0.472 
     Median [Range] 3 [1–9] 3 [1–10]  
EHL FVIII      
     Mean (SD) 3.8 (1.6) 3.3 (1.6) 𝑝 = 0.050 
     Median [Range] 4 [1–8] 3 [1–7]  
SHL FIX    
     Mean (SD) 3.0 (1.7) 3.0 (1.4) 𝑝 = 0.972 
     Median [Range] 2 [1–5] 3 [1–7]  
EHL FIX      
     Mean (SD) 3.7 (1.6) 3.8 (2.1) 𝑝 = 0.724 
     Median [Range] 4 [1–8] 4 [1–8]  
Non-HUCs    
SHL FVIII    
     Mean (SD) 4.4 (2.6) 3.2 (1.6) 𝑝 = 0.007 
     Median [Range] 4.5 [1–12] 3 [1–10]  
EHL FVIII      
     Mean (SD) 3.0 (1.8) 4.1 (1.8) 𝑝 = 0.082 
     Median [Range] 2 [1–7] 4 [1–10]  
SHL FIX    
     Mean (SD) 5.8 (0.8) 4.0 (2.2) 𝑝 = 0.005 
     Median [Range] 5.5 [1–7] 4 [1–9]  
EHL FIX      
     Mean (SD) 4.3 (1.3) 4.1 (1.8) 𝑝 = 0.776 




Table S3. Model building log 
Structural Model 
Run Structure BSV Terms RUV Model OFV 
1 2-compartment None Additive 30015 
2 2-compartment None Proportional 35072 
3 2-compartment None Combined 32691 
4 2-compartment CL, V1, Q, V2 Additive 1E+07 
5 2-compartment CL, V1, Q, V2 Proportional 34480 
6 2-compartment CL, V1, Q, V2 Combined 27517 
7 2-compartment CL, V1 Additive 30015 
8 2-compartment CL, V1 Proportional 26044 
9 2-compartment CL, V1 Combined 26033 
Covariate Model 





Body weight  
































































18 Individual 25321 25369 24 
19 Based on Run 18 25325 25367 21 
20 Source  25417 25417 14 






Table S4. Results of 5-fold cross-validation of final SHL FVIII model 
Parameter Median Error 95th Percentile of Error 
Half-Life 0.42% 1.82% 
Time to 2% Activity 0.23% 1.19% 
CL 0.21% 0.96% 























Design 1 Pre-1-24 4.6% 17.6% 2.9% 11.7% 5.3% 15.9% 4.0% 15.5% 
Design 2 Pre-1-30 3.4% 13.9% 2.6% 9.0% 5.4% 16.0% 2.9% 11.9% 
Design 3 Pre-1-48 1.9% 8.1% 3.0% 9.7% 5.4% 16.0% 1.4% 6.0% 
Design 4 Pre-1-54 1.6% 7.2% 3.2% 10.5% 5.4% 16.0% 1.2% 5.2% 
Design 5 Pre-1-72 1.4% 16.8% 4.2% 18.0% 5.3% 15.7% 1.0% 18.7% 
Design 6 Pre-3-24 5.5% 19.6% 2.9% 11.3% 7.1% 20.5% 4.5% 16.8% 
Design 7 Pre-3-30 4.2% 15.5% 2.9% 9.6% 7.0% 20.1% 3.2% 13.0% 
Design 8 Pre-3-48 2.3% 9.0% 3.7% 10.9% 6.7% 19.4% 1.5% 6.5% 
Design 9 Pre-3-54 2.0% 7.8% 3.9% 11.7% 6.6% 19.2% 1.3% 5.5% 
Design 10 Pre-3-72 1.8% 16.7% 4.8% 17.4% 6.5% 18.9% 1.0% 17.7% 
Design 11 24-30-48 5.5% 16.3% 7.0% 19.7% 15.5% 40.2% 2.3% 10.0% 
Design 12 24-30-54 4.9% 14.0% 6.9% 19.2% 14.3% 37.9% 1.9% 7.9% 
Design 13 24-30-72 5.5% 13.9% 8.0% 20.3% 15.8% 36.2% 2.4% 7.0% 
Design 14 24-48-54 6.0% 17.5% 10.2% 24.4% 19.5% 42.3% 2.1% 10.1% 
Design 15 24-48-72 5.0% 12.9% 9.7% 23.5% 17.4% 38.1% 1.6% 5.9% 
Design 16 30-48-54 6.6% 18.7% 11.7% 27.3% 21.8% 45.9% 2.1% 10.6% 
Design 17 30-48-72 5.4% 14.0% 10.9% 26.2% 19.2% 41.4% 1.6% 6.2% 
Design 18 30-54-72 5.8% 15.7% 15.3% 35.4% 24.6% 52.3% 1.3% 6.8% 
Design 19 48-54-72 5.8% 15.5% 14.3% 33.2% 23.8% 49.7% 1.2% 6.7% 
Design 20 24-30 12.4% 31.4% 8.3% 21.9% 24.9% 49.3% 7.7% 24.0% 
Design 21 24-48 7.6% 21.0% 9.7% 23.8% 20.6% 43.7% 3.4% 13.8% 
Design 22 24-54 6.6% 18.4% 9.8% 23.8% 19.6% 42.1% 2.8% 11.2% 
Design 23 24-72 5.6% 14.9% 9.6% 23.6% 17.6% 39.7% 2.2% 7.5% 
Design 24 30-48 7.9% 21.8% 11.2% 27.1% 23.0% 47.5% 3.3% 14.1% 
Design 25 30-54 7.1% 19.4% 11.3% 27.0% 21.8% 45.6% 2.6% 11.5% 
Design 26 30-72 5.8% 15.0% 10.9% 26.5% 19.4% 42.6% 2.0% 6.8% 
Design 27 48-54 7.0% 19.8% 14.5% 33.6% 25.7% 53.1% 2.0% 10.7% 
Design 28 48-72 5.8% 15.5% 14.6% 33.6% 23.8% 50.2% 1.4% 6.6% 
Design 29 54-72 5.8% 15.7% 15.3% 35.4% 24.6% 52.35% 1.3% 6.8% 
Design 30 3-24 10.4% 28.7% 4.0% 15.2% 11.4% 27.3% 8.4% 25.6% 
Design 31 3-30 7.9% 23.8% 3.5% 11.5% 10.6% 26.5% 6.0% 20.1% 
Design 32 3-48 4.3% 13.9% 4.1% 11.6% 9.1% 24.0% 2.6% 10.5% 
Design 33 3-54 3.7% 12.2% 4.3% 12.4% 8.7% 23.3% 2.2% 9.1% 






Table S6. Median [95th percentile] absolute error on PK outcomes for limited sampling designs 
for the 2-year-old population. 
















































































































































































































































































































































































































































































































































Table S7. Absolute error (%, as median [95th percentile]) on half-life estimates, for all 
permutations of study day and predose handling for each age group. To assist with interpretation, 




TH M W 






2 Pre-1-24-48-72 2.7 [7.4] 2.0 [5.2] 2.8 [7.6] 1.8 [4.4] 
    
3 Pre-1-24-48-96 2.1 [5.3] 1.5 [3.6] 2.3 [5.7] 1.4 [3.7] 
    
4 Pre-1-24-72-96 1.2 [3.5] 0.8 [2.1] 1.1 [3.3] 0.7 [2.6] 
    
5 Pre-1-48-72-96 0.3 [1.0] 0.3 [1.1] 0.3 [1.0] 0.4 [1.1] 
    
6 Pre-1-72-96 1.3 [3.7] 0.9 [2.4] 1.3 [3.3] 0.9 [2.6] 
    
7 Pre-1-48-96 2.2 [6.0] 1.5 [3.9] 2.4 [5.9] 1.5 [3.9] 
    
8 Pre-1-24-96 3.1 [9.0] 1.9 [5.0] 3.3 [9.0] 2.1 [6.5] 
    
9 Pre-1-48-72 2.7 [7.3] 2.0 [5.3] 2.9 [7.6] 1.8 [4.5] 
    
10 Pre-1-24-72 3.5 [9.5] 2.4 [6.3] 3.8 [9.7] 2.3 [5.5] 
    
11 Pre-1-24-48 5.8 [15.0] 3.2 [8.6] 5.5 [14.9] 2.8 [6.7] 
    
12 Pre-1-24 10.9 [26.8] 4.2 [10.7] 10.1 [25.9] 3.9 [9.5] 
    
13 Pre-1-48 6.1 [15.8] 3.3 [8.8] 6.0 [15.5] 2.9 [6.7] 
    
14 Pre-1-72 3.7 [10.3] 2.5 [6.6] 4.0 [10.1] 2.4 [5.7] 
    
15 Pre-1-96 3.8 [11.4] 2.0 [5.7] 3.9 [10.9] 2.4 [7.2] 
    
16 Pre-1 21.1 [52.6] 4.4 [11.8] 21.4 [55.3] 4.5 [11.7] 
    
17 1-24 10.7 [25.8] 10.1 [23.9] 9.6 [23.9] 9.9 [25.9] 
    
18 1-48 6.2 [15.8] 6.0 [15.0] 5.9 [15.0] 6.4 [17.0] 
    
19 1-72 4.4 [11.9] 3.8 [10.1] 4.2 [10.6] 4.5 [11.4] 
    
20 1-96 4.3 [11.4] 4.1 [12.1] 4.1 [10.8] 4.8 [12.4] 
    
21 1 20.7 [52.3] 20.0 [52.1] 21.2 [54.8] 21.5 [55.8] 









2 Pre-1-24-48-72 1.6 [4.9] 1.2 [3.4] 1.6 [5.0] 1.2 [3.2] 1.8 [5.3] 1.4 [4.5] 
3 Pre-1-24-48-96 2.2 [5.4] 1.5 [3.7] 2.3 [5.8] 1.8 [4.6] 2.1 [5.9] 1.6 [4.3] 
4 Pre-1-24-72-96 2.1 [6.7] 1.5 [4.7] 2.2 [6.1] 1.8 [5.9] 2.0 [6.2] 1.3 [3.5] 
5 Pre-1-48-72-96 0.8 [3.2] 0.7 [2.5] 0.8 [2.9] 0.8 [2.9] 0.7 [3.2] 0.4 [1.8] 
6 Pre-1-72-96 3.3 [11.6] 2.3 [7.5] 3.4 [12.6] 3.0 [12.1] 3.2 [10.9] 1.6 [4.7] 
7 Pre-1-48-96 2.8 [7.3] 1.9 [4.8] 2.8 [7.0] 2.3 [6.3] 2.6 [6.8] 1.9 [4.6] 
8 Pre-1-24-96 4.4 [11.7] 2.6 [6.9] 4.5 [12.2] 3.4 [9.8] 4.1 [11.2] 2.6 [6.3] 
9 Pre-1-48-72 2.2 [5.9] 1.6 [4.4] 2.2 [5.8] 1.7 [4.2] 2.2 [6.2] 1.6 [4.8] 
10 Pre-1-24-72 3.4 [8.2] 2.3 [5.8] 3.3 [8.2] 2.6 [6.6] 3.4 [8.3] 2.3 [5.8] 
11 Pre-1-24-48 3.7 [10.6] 2.3 [5.8] 3.8 [10.8] 2.6 [6.8] 4.0 [11.3] 2.8 [7.9] 
12 Pre-1-24 7.9 [20.9] 3.6 [8.8] 7.9 [20.1] 4.6 [12.1] 8.7 [21.9] 4.2 [11.3] 
13 Pre-1-48 4.5 [12.1] 2.7 [7.0] 4.6 [12.4] 3.2 [8.0] 4.7 [12.7] 3.0 [8.5] 
14 Pre-1-72 4.8 [13.0] 3.1 [8.2] 4.7 [13.8] 3.8 [12.1] 4.6 [13.1] 2.6 [6.7] 
15 Pre-1-96 7.8 [26.2] 3.8 [11.5] 7.8 [25.3] 6.1 [21.7] 7.5 [25.7] 3.0 [7.6] 
16 Pre-1 19.4 [48.3] 5.1 [12.6] 19.1 [48.6] 8.2 [27.7] 20.8 [52.4] 4.9 [12.7] 
17 1-24 7.8 [20.5] 7.6 [20.0] 7.8 [19.7] 7.8 [19.6] 8.9 [23.8] 7.8 [19.8] 
18 1-48 4.6 [12.1] 4.6 [12.2] 4.6 [11.9] 4.7 [12.5] 5.2 [13.1] 4.5 [11.9] 
19 1-72 4.8 [12.6] 4.9 [12.8] 4.8 [13.8] 5.0 [13.8] 5.4 [13.5] 4.5 [13.1] 
20 1-96 8.0 [26.2] 7.9 [27.3] 7.8 [25.4] 8.0 [25.3] 8.4 [26.5] 7.1 [24.3] 








2 Pre-1-24-48-72 0.3 [1.1] 0.2 [0.9] 0.3 [1.2] 0.3 [1.1] 0.3 [1.4] 0.2 [1.0] 
3 Pre-1-24-48-96 1.0 [3.1] 0.8 [2.6] 1.0 [3.2] 0.9 [2.9] 1.0 [3.7] 0.7 [2.4] 
4 Pre-1-24-72-96 3.0 [8.4] 2.7 [7.3] 3.1 [8.7] 3.1 [8.8] 3.0 [8.2] 2.0 [5.4] 
5 Pre-1-48-72-96 5.7 [18.2] 5.5 [17.3] 5.9 [18.2] 5.8 [18.2] 5.7 [18.0] 4.0 [13.8] 
6 Pre-1-72-96 13.0 [36.4] 11.3 [34.9] 13.0 [37.5] 12.8 [37.3] 12.7 [35.9] 6.1 [18.8] 
7 Pre-1-48-96 6.2 [18.3] 5.9 [18.0] 6.4 [18.6] 6.3 [18.4] 6.3 [18.1] 4.3 [14.1] 
8 Pre-1-24-96 3.6 [10.8] 3.1 [8.9] 3.6 [10.5] 3.5 [10.4] 3.8 [11.2] 2.4 [6.8] 
9 Pre-1-48-72 5.8 [18.3] 5.5 [17.4] 5.9 [18.1] 5.9 [18.3] 5.9 [18.0] 4.1 [13.8] 
10 Pre-1-24-72 3.1 [9.0] 2.7 [7.2] 3.2 [9.0] 3.1 [8.9] 3.1 [8.8] 2.1 [5.5] 
11 Pre-1-24-48 1.0 [3.5] 0.9 [2.8] 1.1 [3.5] 1.0 [3.1] 1.1 [4.3] 0.7 [2.6] 
12 Pre-1-24 3.8 [11.8] 3.2 [8.9] 3.8 [11.7] 3.7 [10.5] 4.1 [12.7] 2.4 [6.9] 
13 Pre-1-48 6.2 [18.2] 5.9 [17.9] 6.5 [18.6] 6.4 [18.5] 6.4 [18.1] 4.4 [14.2] 
14 Pre-1-72 13.2 [35.5] 11.5 [35.3] 13.1 [37.9] 12.9 [38.5] 13.0 [36.6] 6.2 [18.7] 
15 Pre-1-96 16.5 [42.1] 13.0 [37.5] 16.9 [42.3] 16.0 [41.2] 17.0 [43.3] 6.7 [18.2] 
16 Pre-1 16.9 [39.3] 13.1 [35.6] 16.8 [40.7] 16.3 [40.3] 17.9 [42.5] 6.8 [18.2] 
17 1-24 3.8 [10.8] 3.8 [11.7] 3.8 [11.3] 3.8 [11.4] 4.1 [11.8] 4.3 [12.8] 
18 1-48 6.3 [18.2] 6.3 [18.2] 6.5 [18.6] 6.5 [18.6] 6.4 [18.4] 6.5 [18.3] 
19 1-72 13.2 [35.7] 13.2 [35.4] 13.1 [37.9] 13.0 [37.8] 13.0 [36.7] 12.7 [35.8] 
20 1-96 16.5 [42.1] 16.3 [41.1] 16.9 [42.4] 16.9 [42.0] 16.8 [43.4] 16.5 [41.7] 




Table S8. Absolute error (%, as median [95th percentile]) on C72 estimates, for all permutations 
of study day and predose handling for each age group. To assist with interpretation, a gradient 




TH M W 






2 Pre-1-24-48-72 5.4 [14.3] 3.9 [9.6] 5.7 [14.2] 3.7 [8.6]         
3 Pre-1-24-48-96 5.4 [13.9] 3.7 [9.2] 5.7 [15.0] 4 [10.8]         
4 Pre-1-24-72-96 4 [12.0] 3 [8.4] 4 [11.3] 3.2 [9.5]         
5 Pre-1-48-72-96 1.9 [5.5] 1.5 [4.0] 1.9 [5.2] 1.7 [4.7]         
6 Pre-1-72-96 5.3 [15.3] 3.8 [10.2] 5 [13.6] 4.1 [10.8]         
7 Pre-1-48-96 6.2 [17.2] 4.3 [10.8] 6.6 [18.4] 4.8 [13.2]         
8 Pre-1-24-96 8.8 [25.9] 5.5 [15.2] 9.3 [26.5] 6.6 [21.3]         
9 Pre-1-48-72 6.2 [15.1] 4.4 [10.2] 6.5 [15.7] 4.4 [10.2]         
10 Pre-1-24-72  8.4 [20.8] 5.8 [14.3] 8.9 [21.9] 5.9 [14.8]         
11 Pre-1-24-48 12.6 [30.5] 7.1 [18.0] 11.9 [29.7] 6.5 [16.0]         
12 Pre-1-24 26.3 [64.2] 10.1 [25.4] 24.3 [59.5] 10.5 [29.1]         
13 Pre-1-48 14.2 [35.0] 7.7 [19.3] 14 [34.6] 7.4 [17.7]         
14 Pre-1-72  9.8 [24.1] 6.6 [15.9] 10.4 [25.3] 6.9 [17.0]         
15 Pre-1-96 12.8 [38.4] 6.7 [19.1] 13.3 [38.1] 8.9 [25.5]         
16 Pre-1 73.9 [279.6] 11.6 [29.5] 76.3 [276.1] 14.3 [41.1]         
17 1-24 26.2 [66.7] 25.3 [60.7] 23.9 [59.7] 23.9 [58.7]         
18 1-48 14 [35.3] 14.5 [36.1] 13.9 [34.2] 14.9 [37.5]         
19 1-72 9.9 [24.1] 10.4 [26.8] 10.4 [25.4] 11.5 [27.5]         
20 1-96 13 [38.3] 13.8 [40.9] 13.4 [38.3] 14.7 [39.0]         









2 Pre-1-24-48-72 3.9 [10.8] 2.8 [7.7] 3.9 [10.9] 3 [7.8] 4.1 [11.9] 3.3 [9.8] 
3 Pre-1-24-48-96 6.2 [15.8] 4.3 [10.8] 6.3 [16.3] 5.2 [13.6] 5.9 [15.9] 4.4 [12.2] 
4 Pre-1-24-72-96 6.9 [21.5] 5 [15.8] 7 [20.1] 6.1 [18.7] 6.6 [19.5] 4.3 [11.8] 
5 Pre-1-48-72-96 3.5 [11.2] 2.8 [9.3] 3.5 [10.7] 3.2 [10.7] 3.4 [11.4] 2.4 [7.2] 
6 Pre-1-72-96 11.5 [40.1] 8.1 [26.8] 11.6 [40.9] 10.6 [38.4] 11.2 [38.5] 5.7 [16.0] 
7 Pre-1-48-96 8.2 [20.9] 5.8 [15.3] 8.4 [21.9] 7 [20.1] 8 [20.4] 5.7 [14.3] 
8 Pre-1-24-96 13.4 [36.3] 8.1 [21.9] 13.5 [37.3] 10.6 [31.2] 12.4 [36.3] 7.7 [19.3] 
9 Pre-1-48-72 6.2 [15.5] 4.6 [12.2] 6.1 [15.4] 5.1 [12.8] 6.1 [15.0] 4.5 [11.5] 
10 Pre-1-24-72  9.6 [24.2] 6.6 [17.3] 9.4 [24.1] 7.7 [20.9] 9.5 [24.2] 6.3 [15.6] 
11 Pre-1-24-48 9.4 [25.4] 5.9 [14.8] 9.8 [25.9] 7.2 [19.0] 10 [26.2] 6.9 [18.9] 
12 Pre-1-24 21.9 [53.9] 10.5 [25.1] 22 [55.4] 13.8 [37.6] 23.3 [55.7] 11.4 [28.7] 
13 Pre-1-48 12.3 [29.7] 7.7 [18.3] 12.6 [30.4] 9.2 [24.0] 12.5 [30.7] 8.2 [21.7] 
14 Pre-1-72  15 [41.5] 10 [28.1] 14.7 [42.6] 12.6 [39.7] 14.2 [41.6] 7.7 [19.1] 
15 Pre-1-96 29.1 [117.7] 12.7 [38.2] 28.6 [104.5] 22.6 [86.5] 28.2 [115.7] 9.5 [24.4] 
16 Pre-1 72.2 [242.9] 16.1 [43.6] 71 [242.3] 30.8 [118.4] 77.4 [279.1] 14 [34.5] 
17 1-24 22 [55.9] 21.6 [53.5] 21.9 [56.9] 21.9 [53.8] 23.7 [61.2] 22.1 [52.9] 
18 1-48 12.3 [29.8] 12.8 [30.5] 12.5 [30.5] 12.9 [31.4] 12.3 [30.7] 12.9 [32.0] 
19 1-72 15 [41.5] 15.6 [42.5] 14.7 [42.7] 15.2 [42.5] 14.2 [41.7] 14.8 [42.1] 
20 1-96 29.1 [117.4] 29.6 [118.8] 28.7 [104.5] 29.2 [105.2] 28.1 [115.8] 28 [103.8] 








2 Pre-1-24-48-72 0.7 [2.9] 0.6 [2.4] 0.7 [3.1] 0.7 [3.0] 0.8 [3.8] 0.6 [2.5] 
3 Pre-1-24-48-96 2.3 [8.3] 2 [7.2] 2.3 [8.5] 2.2 [7.7] 2.5 [9.7] 1.7 [6.4] 
4 Pre-1-24-72-96 6.5 [20.3] 5.7 [17.3] 6.7 [21.8] 6.6 [21.5] 6.3 [19.9] 4.3 [13.4] 
5 Pre-1-48-72-96 9 [23.8] 8.6 [22.2] 9.3 [24.6] 9.3 [24.6] 9.1 [24.3] 6.3 [15.6] 
6 Pre-1-72-96 24.6 [69.6] 20.7 [60.9] 24.5 [69.2] 24.2 [69.1] 23.9 [67.4] 10.2 [26.9] 
7 Pre-1-48-96 10.1 [25.2] 9.4 [24.3] 10.7 [27.1] 10.5 [26.7] 10.3 [25.7] 6.9 [16.8] 
8 Pre-1-24-96 7.9 [27.7] 6.8 [21.7] 7.9 [26.8] 7.7 [25.8] 8.5 [27.6] 5.2 [17.7] 
9 Pre-1-48-72 9.2 [23.5] 8.7 [22.1] 9.5 [24.7] 9.4 [24.6] 9.3 [24.2] 6.4 [15.9] 
10 Pre-1-24-72  6.7 [21.6] 5.8 [17.8] 6.9 [21.9] 6.8 [21.4] 6.6 [20.8] 4.4 [13.8] 
11 Pre-1-24-48 2.4 [9.3] 2.1 [7.6] 2.5 [9.3] 2.4 [8.6] 2.6 [11.3] 1.8 [7.1] 
12 Pre-1-24 8.4 [29.1] 6.9 [21.7] 8.3 [28.2] 8 [26.8] 8.9 [30.8] 5.3 [17.2] 
13 Pre-1-48 10.3 [25.5] 9.6 [24.2] 10.9 [27.4] 10.7 [26.7] 10.5 [25.9] 7 [16.9] 
14 Pre-1-72  25.2 [70.1] 21.1 [58.7] 24.7 [70.1] 24.5 [67.8] 24.7 [73.8] 10.4 [27.2] 
15 Pre-1-96 33.2 [69.2] 24.9 [70.2] 34.2 [79.1] 32.2 [78.6] 34.5 [77.5] 11.6 [29.8] 
16 Pre-1 31 [69.1] 25.4 [67.8] 30.7 [69.7] 32.7 [73.3] 33.1 [74.3] 11.8 [30.7] 
17 1-24 8.3 [28.1] 8.5 [29.0] 8.3 [28.1] 8.3 [28.2] 9.1 [29.7] 9.6 [30.6] 
18 1-48 10.3 [25.4] 10.6 [26.0] 10.9 [27.4] 11 [27.7] 10.5 [26.0] 11.2 [28.8] 
19 1-72 25.2 [70.1] 25.3 [71.6] 24.7 [70.1] 24.6 [70.5] 24.7 [73.8] 24.8 [75.4] 
20 1-96 33.1 [69.2] 33.1 [69.8] 34.2 [79.1] 34.2 [79.3] 34.4 [77.3] 34.4 [81.7] 






Table S9. Absolute error (%, as median [95th percentile]) on C96 estimates, for all permutations 
of study day and predose handling for each age group. To assist with interpretation, a gradient 




TH M W 






2 Pre-1-24-48-72 7 [18.5] 5.1 [12.8] 7.3 [18.9] 4.7 [11.2]         3 Pre-1-24-48-96 6.4 [16.1] 4.4 [10.8] 6.8 [17.7] 4.6 [12.5]         
4 Pre-1-24-72-96 4.3 [12.3] 3.1 [8.4] 4.3 [11.7] 3.2 [8.7]         
5 Pre-1-48-72-96 1.6 [4.7] 1.1 [3.3] 1.6 [4.4] 1.3 [3.7]         
6 Pre-1-72-96 5.2 [14.9] 3.6 [10.0] 4.9 [13.5] 3.7 [10.7]         
7 Pre-1-48-96 7.1 [18.1] 4.8 [11.8] 7.5 [19.8] 5.2 [13.5]         
8 Pre-1-24-96 10 [28.1] 6.2 [16.4] 10.5 [28.4] 7.1 [20.7]         
9 Pre-1-48-72 7.6 [19.3] 5.4 [13.1] 8 [19.8] 5.1 [11.8]         
10 Pre-1-24-72  10.1 [24.9] 7 [16.9] 10.7 [26.4] 6.8 [16.4]         
11 Pre-1-24-48 15.8 [38.6] 8.9 [23.5] 14.9 [37.2] 8 [19.5]         
12 Pre-1-24 32 [77.3] 12.2 [30.2] 29.3 [69.6] 12.2 [30.8]         
13 Pre-1-48 17.3 [42.2] 9.4 [23.5] 17 [42.6] 8.7 [20.9]         
14 Pre-1-72  11.2 [28.2] 7.5 [18.4] 11.8 [28.4] 7.5 [18.4]         
15 Pre-1-96 13.1 [40.5] 7 [19.2] 13.6 [38.6] 8.7 [26.5]         
16 Pre-1 88.3 [339.2] 13.4 [33.4] 90.2 [366.0] 15 [41.9]         
17 1-24 32.6 [85.9] 30.4 [72.2] 28.9 [71.2] 28.6 [67.7]         
18 1-48 17.3 [43.5] 17.4 [42.7] 16.8 [42.7] 18 [45.1]         
19 1-72 11.3 [27.6] 11.8 [29.3] 11.8 [29.1] 13.2 [31.9]         
20 1-96 13.1 [40.6] 14.4 [41.9] 13.6 [38.6] 15.4 [40.0]         









2 Pre-1-24-48-72 4.5 [13.8] 3.2 [9.8] 4.5 [13.8] 3.4 [9.4] 4.9 [15.0] 3.9 [12.4] 
3 Pre-1-24-48-96 6.4 [16.4] 4.4 [11.0] 6.6 [16.9] 5.2 [14.0] 6.1 [17.3] 4.7 [13.6] 
4 Pre-1-24-72-96 6.1 [16.1] 4.3 [12.0] 6.2 [16.0] 5.2 [14.6] 5.7 [15.6] 3.9 [9.8] 
5 Pre-1-48-72-96 2.6 [7.2] 1.9 [5.5] 2.6 [7.1] 2.3 [6.6] 2.5 [7.1] 1.8 [4.6] 
6 Pre-1-72-96 8.5 [25.5] 5.9 [16.5] 8.7 [25.5] 7.5 [23.8] 8.4 [24.5] 4.9 [12.7] 
7 Pre-1-48-96 7.7 [20.1] 5.2 [13.2] 8 [20.0] 6.4 [17.8] 7.6 [19.7] 5.6 [14.4] 
8 Pre-1-24-96 12.7 [35.1] 7.5 [19.1] 13 [34.9] 9.8 [27.0] 11.8 [33.0] 7.7 [19.9] 
9 Pre-1-48-72 6 [15.7] 4.3 [11.1] 6 [15.5] 4.7 [11.4] 6.1 [16.8] 4.6 [13.5] 
10 Pre-1-24-72  9.4 [23.7] 6.3 [15.6] 9.2 [23.2] 7.2 [18.2] 9.3 [22.8] 6.5 [17.1] 
11 Pre-1-24-48 10.4 [30.3] 6.5 [16.6] 10.7 [30.4] 7.6 [21.3] 11.2 [31.1] 7.9 [22.8] 
12 Pre-1-24 22.8 [58.8] 10.4 [25.9] 22.9 [61.3] 13.4 [36.5] 24.4 [64.7] 12.3 [34.1] 
13 Pre-1-48 12.7 [34.0] 7.6 [18.8] 13 [34.5] 9 [23.9] 13 [35.8] 8.7 [25.8] 
14 Pre-1-72  12.5 [30.0] 8.1 [19.5] 12.3 [30.4] 9.8 [25.9] 12 [30.2] 7.4 [18.9] 
15 Pre-1-96 22.2 [68.9] 10 [26.5] 22.1 [65.3] 16.4 [56.7] 21.7 [61.6] 9.1 [24.6] 
16 Pre-1 62.9 [180.0] 13.8 [32.8] 61.8 [175.4] 23.9 [71.4] 67.9 [197.4] 14.5 [38.5] 
17 1-24 23.2 [61.2] 22.3 [57.7] 22.9 [62.9] 22.7 [60.6] 26 [72.6] 22.9 [59.8] 
18 1-48 12.7 [33.6] 13.1 [34.9] 12.9 [34.9] 13.2 [35.1] 13.2 [35.7] 13 [34.6] 
19 1-72 12.5 [30.2] 13.1 [31.6] 12.3 [30.3] 13 [31.8] 12.1 [30.4] 12.5 [32.2] 
20 1-96 22.2 [69.0] 22.9 [68.0] 22.1 [65.3] 22.8 [67.4] 21.7 [61.8] 21.5 [59.0] 








2 Pre-1-24-48-72 0.5 [2.4] 0.4 [2.0] 0.6 [2.7] 0.5 [2.7] 0.6 [3.4] 0.5 [2.3] 
3 Pre-1-24-48-96 1.5 [6.5] 1.2 [5.4] 1.5 [7.0] 1.4 [6.4] 1.7 [7.9] 1.1 [5.3] 
4 Pre-1-24-72-96 3.4 [12.6] 2.9 [10.2] 3.5 [13.9] 3.5 [13.2] 3.4 [12.2] 2.2 [8.2] 
5 Pre-1-48-72-96 3.4 [9.3] 3.2 [8.5] 3.5 [9.5] 3.5 [9.4] 3.5 [9.6] 2.4 [6.3] 
6 Pre-1-72-96 9.8 [28.7] 8 [23.1] 9.8 [28.1] 9.7 [27.3] 9.6 [29.4] 4.2 [12.8] 
7 Pre-1-48-96 4.2 [11.7] 3.8 [10.2] 4.5 [13.2] 4.3 [12.8] 4.3 [12.3] 2.8 [7.9] 
8 Pre-1-24-96 4.6 [19.9] 3.7 [14.5] 4.5 [18.7] 4.3 [16.7] 5.1 [22.1] 3 [11.8] 
9 Pre-1-48-72 3.6 [9.8] 3.3 [8.7] 3.7 [10.1] 3.6 [9.9] 3.7 [10.6] 2.5 [6.7] 
10 Pre-1-24-72  3.6 [14.6] 3 [10.9] 3.7 [14.4] 3.6 [14.4] 3.6 [14.2] 2.3 [9.1] 
11 Pre-1-24-48 1.6 [7.0] 1.3 [6.0] 1.7 [7.5] 1.5 [6.6] 1.9 [9.8] 1.3 [6.0] 
12 Pre-1-24 5 [23.2] 3.8 [14.8] 4.8 [21.6] 4.6 [18.4] 5.5 [24.5] 3.1 [12.2] 
13 Pre-1-48 4.4 [12.7] 3.9 [10.9] 4.7 [13.7] 4.5 [13.0] 4.6 [14.0] 3 [8.3] 
14 Pre-1-72  10.2 [30.0] 8.3 [23.7] 10 [29.7] 10 [28.6] 10.1 [30.6] 4.4 [13.7] 
15 Pre-1-96 14.7 [46.1] 10.3 [31.4] 15.4 [50.2] 13.9 [44.0] 15.5 [50.8] 5.2 [17.2] 
16 Pre-1 14.3 [49.1] 10.7 [31.9] 14.1 [50.1] 14.6 [44.6] 15.8 [55.0] 5.4 [17.5] 
17 1-24 4.9 [22.3] 5.1 [23.5] 4.8 [21.6] 4.8 [21.1] 5.7 [23.6] 5.7 [24.2] 
18 1-48 4.4 [12.6] 4.6 [14.4] 4.7 [13.8] 4.8 [14.5] 4.6 [13.9] 5 [15.6] 
19 1-72 10.2 [30.1] 10.3 [29.8] 10 [29.7] 10 [29.4] 10.1 [30.5] 10.3 [30.4] 
20 1-96 14.7 [45.9] 14.7 [44.8] 15.4 [50.2] 15.4 [50.5] 15.5 [50.6] 15.6 [50.8] 






Table S10. IDAR72 and IDAR96 for all permutations of study day and predose handling for each 
age group. To assist with interpretation, a gradient has been applied, with IDAR increasing from 




TH M W TH M W 






2 Pre-1-24-48-72 0.0% 0.1% 0.1% 0.0%     0.8% 0.5% 0.7% 0.9%     3 Pre-1-24-48-96 0.1% 0.0% 0.3% 0.3%     2.1% 1.6% 2.4% 1.7%     
4 Pre-1-24-72-96 0.4% 0.4% 0.3% 0.4%     1.0% 0.7% 1.6% 1.1%     
5 Pre-1-48-72-96 0.0% 0.2% 0.0% 0.3%     0.4% 0.2% 0.4% 0.4%     
6 Pre-1-72-96 0.9% 0.7% 0.3% 0.6%     0.9% 0.8% 1.8% 1.4%     
7 Pre-1-48-96 0.2% 0.2% 0.3% 0.4%     2.9% 1.5% 3.0% 2.4%     
8 Pre-1-24-96 0.5% 0.2% 0.7% 1.0%     3.4% 1.5% 3.7% 2.7%     
9 Pre-1-48-72 0.0% 0.2% 0.1% 0.4%     1.0% 0.6% 1.0% 1.3%     
10 Pre-1-24-72  0.6% 0.6% 0.4% 0.2%     1.6% 1.4% 2.6% 1.7%     
11 Pre-1-24-48 0.1% 0.1% 0.3% 0.3%     2.9% 2.3% 3.1% 2.1%     
12 Pre-1-24 0.7% 0.3% 1.2% 0.9%     6.6% 2.9% 7.2% 4.2%     
13 Pre-1-48 0.2% 0.2% 0.3% 0.6%     4.1% 2.5% 3.5% 2.7%     
14 Pre-1-72  0.8% 0.7% 0.7% 0.8%     1.6% 1.2% 3.1% 1.8%     
15 Pre-1-96 1.5% 0.8% 1.8% 1.9%     4.4% 2.6% 4.9% 3.9%     
16 Pre-1 1.5% 0.9% 1.8% 2.0%     13.1% 3.7% 13.8% 5.2%     
17 1-24 0.5% 0.8% 1.3% 1.1%     6.5% 6.3% 7.1% 7.0%     
18 1-48 0.2% 0.1% 0.4% 0.5%     4.0% 4.1% 3.4% 3.6%     
19 1-72 0.8% 0.9% 0.7% 0.8%     1.7% 2.2% 3.1% 3.3%     
20 1-96 1.5% 1.6% 1.8% 2.0%     4.4% 4.5% 4.9% 5.1%     









2 Pre-1-24-48-72 0.3% 0.5% 0.2% 0.5% 0.7% 0.2% 2.1% 1.4% 1.8% 1.7% 2.1% 1.7% 
3 Pre-1-24-48-96 1.7% 1.5% 1.9% 1.9% 1.5% 0.7% 3.7% 3.1% 3.5% 2.9% 4.0% 3.1% 
4 Pre-1-24-72-96 3.8% 3.1% 1.9% 2.4% 2.3% 1.4% 3.3% 2.0% 2.4% 1.6% 2.3% 1.0% 
5 Pre-1-48-72-96 0.9% 1.1% 1.4% 1.4% 1.4% 0.8% 1.1% 1.2% 1.0% 0.8% 1.1% 0.6% 
6 Pre-1-72-96 5.5% 4.3% 4.8% 5.1% 4.7% 1.8% 3.7% 2.5% 2.5% 1.9% 2.8% 1.9% 
7 Pre-1-48-96 2.6% 1.9% 3.6% 3.1% 2.6% 1.3% 4.5% 3.5% 4.1% 3.3% 3.8% 4.0% 
8 Pre-1-24-96 5.9% 4.0% 4.6% 4.6% 4.3% 1.4% 7.5% 4.4% 8.0% 5.1% 5.5% 4.2% 
9 Pre-1-48-72 1.1% 1.0% 1.5% 1.3% 2.0% 0.7% 2.9% 2.2% 2.3% 1.9% 2.2% 2.0% 
10 Pre-1-24-72  4.6% 3.8% 2.4% 2.3% 2.5% 1.7% 5.0% 2.9% 3.3% 3.4% 3.5% 2.0% 
11 Pre-1-24-48 1.8% 1.4% 1.7% 1.8% 1.9% 0.8% 5.8% 3.6% 5.2% 4.5% 5.2% 4.4% 
12 Pre-1-24 6.8% 4.6% 4.9% 4.7% 5.4% 1.8% 14.2% 4.5% 13.6% 6.6% 13.0% 5.8% 
13 Pre-1-48 2.4% 1.8% 3.9% 2.6% 2.9% 1.6% 6.6% 4.6% 7.3% 6.0% 5.6% 4.2% 
14 Pre-1-72  6.7% 4.2% 4.7% 4.8% 5.5% 1.9% 6.1% 3.4% 4.7% 4.3% 3.6% 2.5% 
15 Pre-1-96 12.6% 6.0% 12.8% 11.8% 13.2% 2.4% 8.1% 4.8% 10.8% 6.2% 7.6% 4.3% 
16 Pre-1 16.1% 6.1% 15.1% 13.1% 16.1% 2.8% 34.5% 5.9% 34.8% 10.0% 34.0% 6.7% 
17 1-24 6.6% 6.3% 5.0% 5.4% 5.5% 5.0% 13.0% 13.4% 13.6% 13.9% 10.7% 11.6% 
18 1-48 2.6% 2.9% 3.9% 3.5% 2.9% 3.2% 6.8% 7.2% 7.2% 7.5% 5.5% 6.2% 
19 1-72 6.7% 6.8% 4.7% 4.7% 5.5% 5.6% 5.7% 6.4% 4.6% 4.8% 3.6% 4.3% 
20 1-96 12.6% 12.6% 12.8% 13.1% 13.2% 12.2% 8.2% 9.0% 10.8% 10.0% 7.6% 7.6% 








2 Pre-1-24-48-72 0.4% 0.6% 0.5% 0.4% 0.5% 0.3% 0.1% 0.1% 0.1% 0.0% 0.6% 0.2% 
3 Pre-1-24-48-96 1.2% 0.8% 1.3% 1.2% 1.5% 1.2% 0.2% 0.2% 0.2% 0.3% 0.7% 0.6% 
4 Pre-1-24-72-96 2.2% 2.1% 2.6% 2.3% 2.1% 1.5% 0.0% 0.0% 0.3% 0.3% 0.4% 0.2% 
5 Pre-1-48-72-96 1.5% 0.8% 1.1% 0.8% 1.4% 1.0% 0.3% 0.1% 0.2% 0.1% 0.3% 0.3% 
6 Pre-1-72-96 3.4% 2.8% 3.7% 3.4% 3.5% 2.4% 0.3% 0.2% 0.3% 0.4% 0.5% 0.2% 
7 Pre-1-48-96 2.2% 1.5% 1.9% 1.6% 2.5% 2.0% 0.5% 0.3% 0.3% 0.2% 0.4% 0.6% 
8 Pre-1-24-96 3.6% 3.0% 4.0% 3.2% 3.4% 2.1% 0.4% 0.2% 0.4% 0.3% 0.9% 0.8% 
9 Pre-1-48-72 1.8% 1.1% 1.1% 0.8% 1.4% 1.2% 0.3% 0.1% 0.2% 0.1% 0.5% 0.5% 
10 Pre-1-24-72  2.4% 2.1% 2.9% 2.4% 2.0% 1.3% 0.2% 0.1% 0.3% 0.5% 0.5% 0.4% 
11 Pre-1-24-48 1.1% 1.0% 1.2% 1.1% 1.7% 1.3% 0.3% 0.2% 0.1% 0.3% 1.0% 0.7% 
12 Pre-1-24 4.4% 3.2% 4.0% 3.5% 4.1% 2.1% 0.6% 0.3% 0.7% 0.4% 1.5% 0.9% 
13 Pre-1-48 2.3% 1.5% 2.1% 1.7% 2.7% 1.7% 0.7% 0.3% 0.2% 0.2% 0.6% 1.0% 
14 Pre-1-72  3.8% 3.3% 4.2% 3.8% 4.7% 2.5% 0.4% 0.1% 0.4% 0.4% 0.7% 0.6% 
15 Pre-1-96 6.8% 3.8% 8.9% 6.5% 9.6% 3.7% 0.7% 0.3% 0.6% 0.3% 1.0% 1.1% 
16 Pre-1 9.2% 4.5% 9.3% 8.1% 12.1% 4.3% 0.9% 0.5% 0.7% 0.4% 1.7% 1.0% 
17 1-24 4.5% 5.0% 3.9% 4.3% 3.3% 3.3% 0.4% 0.6% 0.7% 0.9% 1.3% 1.7% 
18 1-48 2.4% 2.2% 2.0% 2.0% 2.4% 2.4% 0.5% 0.7% 0.2% 0.2% 0.9% 0.8% 
19 1-72 3.8% 4.2% 4.2% 4.1% 4.7% 5.3% 0.3% 0.3% 0.4% 0.2% 0.7% 0.7% 
20 1-96 6.8% 7.3% 8.9% 8.6% 9.6% 9.6% 0.7% 0.7% 0.6% 0.6% 1.0% 1.2% 








Figure S1. Scatter plots of η-values versus age following the inclusion of fat-free mass on CL, 










Figure S3. Histograms of parameter estimates of variability from bootstrap analysis 
 
Figure S4. Histograms of prediction errors on half-life, time to 2% activity, clearance, and 











Figure S6.  Correlation plots for all body size metrics used in simulations for the normal BMI 
subgroup. Diagonal elements contain histograms. 
 
 
Figure S7. Correlation plots for all body size metrics used in simulations for the 
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Gent University Hospital, Gent, Belgium 
Gulf States Hemophilia, Houston, United States 
Haematology and Haemophilia Centre Catelfranco Veneto, Catelfranco Veneto, Italy 
Haemophilia Centre Copenhagen, Copenhagen, Denmark 
Haemophilia Centre of Perugia, Perugia, Italy 
Haemophilia Comprehensive Care Ljubljana, Ljubljana, Slovenia 
Hamilton Health Sciences, Hamilton, Canada 
Hämophilie-Zentrum Rhein Main GmbH, Frankfurt, Germany 
Heim Pál Gyermekkórház, Budapest, Hungary 
Helsinki University Hospital, Helsinki, Finland 
Hematologia y oncologia del oriente SAS, Bogota, Colombia 
Hematology and Oncology Department, CHU Nord, St. Etienne, France 
Hemocentro Unicamp, São Paulo, Brazil 
Hemofiliecentrum, UZ Leuven, Leuven, Belgium 
Hemophilia Center of Western New York, Buffalo, United States 
Hemophilia Center of Western Pennsylvania, Pittsburgh, United States 
Hemophilia Comprehensive Care Team, Jakarta, Indonesia 
Hemophilia Treatment Center of Central PA, Hershey, United States 
Hemostasis and Thrombosis Center of Nevada, Las Vegas, United States 
Hemostasis and Thrombosis Center Rhode Island, Rhode Island, United States 
Hôpital de l'Enfant-Jésus, Quebec City, Canada 
Hôpital Trousseau, CHRU de Tours, Tours, France 
Hôpital Universitaire des Enfants Reine Fabiola, Huderf, Belgium 
Hôpitaux Universitaires de Genève, Geneva, Switzerland 
Hospital Alvaro Cunqueiro, Vigo, Spain 
Hospital Clinico Universitario de Santiago, Santiago, Spain 
Hospital de la Santa Creu i Sant Pau, Barcelona, Spain 




Hospital General Universitario de Alicante, Alicante, Spain 
Hospital Humberto Notti, Mendoza, Argentina 
Hospital Miguel Servet, Zaragoza, Spain 
Hospital Posadas, Buenos Aires, Argentina 
Hospital Regional Universitario de Málaga, Málaga, Spain 
Hospital Roberto del Río, Santiago, Chile 
Hospital Sant Joan de Déu, Barcelona, Spain 
Hospital Teresa Herrera Materno Infantil, Coruna, Spain 
Hospital Universitario Dr José Eleuterio Gonzalez, Monterrey, Mexico 
Hospital Universitario La Paz, Madrid, Spain 
Hospital Universitario Virgen de la Arrixaca, Murcia, Spain 
Hospital University and Politechnic La Fe, Valencia, Spain 
Hospital Vall d'Hebron, Barcelona, Spain 
Hospital Virgen de las Nieves, Granada, Spain 
Hull and East Yorkshire Hospitals NHS Trust, Hull, United Kingdom 
Indiana Hemophilia and Thrombosis Center, Indianapolis, United States 
Institute of Hematology and Blood Diseases Hospital Chinese Academy of Medical Science, Tianjin,  
     China 
Instituto Guatemalteco de Seguridad Social, Guatemala City, Guatemala 
Intergral Solutions SD S.A.S, Bogota, Colombia 
IPS Especializada, Bogota, Colombia 
IWK Health Centre, Halifax, Canada 
Johns Hopkins All Children's Hospital, St. Petersburg, United States 
Kaohsiung Medical University Hospital, Kaohsiung, Taiwan 
King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia 
Kingston General Hospital, Kingston, Canada 
Klinik für Kinder- und JugendmedizinUniversitätsklinikum Jena, Jena, Germany 
Korea Hemophilia Foundation Seoul Clinic, Seoul, South Korea 
Kuopio University Hospital, Kuopio, Finland 
Kyung Hee University Hospital at Gangdong, Seoul, South Korea 
Laiko General Hospital of Athens, Athens, Greece 
L'hemostase de Strasbourg, Strasbourg, France 
London Health Sciences Center, London, Canada 
Luzerner Kantonsspital, Lucerne, Switzerland 
Manitoba Health Sciences Centre, Winnipeg, Canada 
Massachusetts General Hospital, Boston, United States 
Maxima Medisch Centrum, Veldhoven, Netherlands 
Mohács Hospital, Mohács, Hungary 
Montreal Children's Hospital, Montreal, Canada 
Nagoya University Hospital, Nagoya, Japan 
Nanfang Hospital, Guangzhou, China 
National Haemophilia Center Budapest, Budapest, Hungary 




Nemours Children's Specialty Care, Jacksonville, United States 
North Dakota Hemostasis and Thrombosis Treatment Center, Fargo, United States 
North Estonia Medical Center, Tallinn, Estonia 
Northern Alberta Bleeding and Rare Blood Disorders Clinic - Kaye Edmonton Clinic, Edmonton, Canada 
Northwest Ohio Hemophilia Treatment Center, Toledo, United States 
Ogikubo Hospital, Tokyo, Japan 
Oklahoma Center for Bleeding and Clotting Disorders, Oklahoma City, United States 
ONCOORIENTE SAS, Villavicencio, Colombia 
Oregon Health and Science University, Portland, United States 
Orthopaedic Hemophilia Treatment Center, Los Angeles, United States 
Ospedale S. Bortolo, Vicenza, Italy 
Oulu University Hospital, Oulu, Finland 
Palmetto Health Richland, Columbia, United States 
Pediatric Hemophilia Center of Turin, Italy 
Peking Union Medical College Hospital, Beijing , China 
Phoenix Children's Hospital, Phoenix, Unites States 
Policlinico di Palermo, Palermo, Italy 
Policlinico Umberto I - "Sapienza" Università di Roma, Rome, Italy 
Pontificia Universidad Católica de Chile, Santiago, Chile 
Rady Children's Hospital, San Diego, United States 
Riley Children's Health, Indianapolis, United States 
Royal Adelaide Hospital, Adelaide, Australia 
Royal Brisbane and Women's Hospital, Brisbane, Australia 
Royal Free Hospital, London, United Kingdom 
Royal London, London, United Kingdom 
Ruan Rehacer IPS, Bogota, Colombia 
Rush University Medical Center, Chicago, United States 
Sahlgrenska University Hospital, Gothenburg, Sweden 
Saskatchewan Bleeding Disorders Program, Saskatoon, Canada 
Sheffield Children's Hospital, Sheffield, United Kingdom 
SickKids Hospital, Toronto, Canada 
Skåne University Hospital, Malmö, Sweden 
South Texas Hemophilia Treatment Center, San Antonio, United States 
St. George's University Hospital, London, United Kingdom 
St. Joseph's Hospital - Center for Bleeding and Clotting Disorders, Tampa, United States 
St. Jude Affiliate Clinic at NH Hemby Children's Hospital, Charlotte, United States 
St. Jude Children's Research Hospital, Memphis, United States 
St. Michael's Hospital, Toronto, Canada 
St. Paul's Hospital, Vancouver, Canada 
St-Luc University Hospital, Brussels, Belgium 
Stollery Children's Hospital, Edmonton, Canada 
Taichung Veterans General Hospital, Taichung, Taiwan 




Tampere University Hospital, Tampere, Finland 
The Alfred Hospital, Melbourne, Australia 
The Bleeding and Clotting Disorders Institute, Peoria, United States 
The Children's Hospital at Montefiore, New York, United States 
The Children's Hospital of Philadelphia, Philadelphia, United States 
The Children's Hospital, Zhengjiang University School of Medicine, Hangzhou, China 
The Maine Hemophilia and Thrombosis Center, Scarborough, United States 
The Royal Children's Hospital, Melbourne, Australia 
The Women's and Childrens Hospital, Adelaide, Australia 
Turku University Hospital, Turku, Finland 
U.O. Pediatria Generale e Specialistica "B. Trambusti", Bari, Italy 
UHHS Cleveland. University Hospitals Health System, Cleveland, United States 
Universitaets - Kinderklinik Wien, Vienna, Austria 
Universitätsklinikum Bonn, Bonn, Germany 
University Children's Hospital Berne, Berne, Switzerland 
University Children's Hospital Zurich, Zurich, Switzerland 
University Hospital Bristol, Bristol, United Kingdom 
University Hospital Brno, Brno, Czech Republic 
University Hospital Coventry and Warwickshire, Coventry, United Kingdom 
University Hospital Magdeburg, Magdeburg, Germany 
University Hospital Southampton, Southampton, United Kingdom 
University Hospitals of Leicester, Leicester, United Kingdom 
University Medical Center Utrecht, Utrecht, Netherlands 
University Medical Centre Ljubljana, Ljubljana, Slovenia 
University of California San Francisco Pediatric Hemophilia Treatment Center, San Francisco, United    
     States 
University of Debrecen, Debrecen, Hungary 
University of Florida Hemophilia Treatment Cente, Gainsville, United States 
University of Helsinki and Children's Hospital, Helsinki, Finland 
University of Iowa Children's Hospital, Iowa City, United States 
University of Kentucky Hemophilia Treatment Center, Lexington, United States 
University of Louisville, Louisville, United States 
University of Miami Hemophilia Treatment Center, Miami, United States 
University of North Carolina, Chapel Hill, United States 
University of Szeged, Szeged, Hungary 
University of Virginia Health System, Charlottesville, United States 
University of Wisconsin Comprehensive Program for Bleeding Disorders, Madison, United States 
Valley Children's Healthcare, Madera, United States 
Vanderbilt University Medical Center, Nashville, United States 
Vivantes Clinic in Friedrichshain, Berlin, Germany 
Wake Forest University, Winston-Salem, United States 
Weill Cornell Medical College, New York, United States 
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